Development of Physiologically Realistic In Vitro Models of the Gastrointestinal Tract by McAuliffe, Gretchen
  
 
DEVELOPMENT OF PHYSIOLOGICALLY REALISTIC IN VITRO MODELS OF 
THE GASTROINTESTINAL TRACT 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
by 
Gretchen Jennifer McAuliffe 
May 2008
  
 
 
 
 
 
 
 
 
 
 
 
© 2008 Gretchen Jennifer McAuliffe
 DEVELOPMENT OF PHYSIOLOGICALLY REALISTIC IN VITRO MODELS OF 
THE GASTROINTESTINAL TRACT 
 
Gretchen Jennifer McAuliffe, Ph. D. 
Cornell University 2008 
 
The gastrointestinal (GI) tract is the largest surface exposed to the environment 
in the human body. Intestinal absorption is the entry route for most essential nutrients 
and the preferred method for pharmaceutical administration. Understanding how 
compounds interact with and are absorbed through the small intestinal epithelium, and 
how they go on to affect the rest of the body, is crucial for nutritional and 
toxicological evaluation. Our group has developed an in vitro cell culture model of the 
gastrointestinal tract that includes digestion and physiologically realistic cell 
populations with a mucus layer. The applications of this model include predicting iron 
bioavailability, studying the effects of oral exposure to nanoparticles, and measuring 
the metabolism and toxicity of ingested chemicals or drugs. 
  Co-cultures of absorptive and mucus-producing cells were incorporated into an 
existing in vitro digestion/cell culture model used to assess iron bioavailability. At 
physiologically relevant ratios of Caco-2 absorptive cells to HT29-MTX mucus-
producing cells, a mucus layer completely covered the cell monolayer and the in vitro 
digestion model was nearly as responsive to changes in sample iron bioavailability as 
pure Caco-2 cultures. The existing in vitro digestion/Caco-2 cell culture model 
correlates well with human iron bioavailability studies, but, as mucus appears to play a 
role in iron absorption, the addition of a physiologically realistic mucus layer and 
goblet-type cells to this model may give more accurate iron bioavailability predictions. 
An in vitro cell culture model of the intestinal epithelium with absorptive, 
 goblet, and M cells was used to study the effects of nanoparticle exposure on iron 
uptake and transport. Polystyrene 50 nm and 200 nm particles were found to interfere 
with cellular iron uptake and transport, indicating that oral exposure to nanoparticles 
could potentially have an effect on the normal physiological functions of intestinal 
epithelial cells. These preliminary results suggest that nanoparticle size, concentration, 
and charge can influence the uptake and transport of iron. 
Microscale cell culture analogs (μCCAs) are used to study the metabolism and 
toxicity of a chemical or drug. These in vitro devices are physical replicas of 
physiologically based pharmacokinetic models that combine microfabrication and cell 
culture. A GI tract μCCA, together with a multi-chamber silicon chip μCCA, has been 
used to recreate the toxic effects of acetaminophen. Proof of concept experiments 
show that acetaminophen passes through the in vitro intestinal epithelium and is 
metabolized by liver cells, resulting in liver cell toxicity.  
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CHAPTER 1 
 
INTRODUCTION TO IN VITRO MODELS OF THE GASTROINTESTINAL 
TRACT 
 
1.1. Motivation 
The lining of the gastrointestinal (GI) tract is the largest surface exposed to the 
external environment in the human body [1]. One of the main functions of the small 
intestine is absorption, and intestinal absorption is the route used by most essential 
nutrients and many pharmaceuticals to enter the body [2]. Understanding the effects of 
digestion, how compounds interact with and are absorbed through the small intestinal 
epithelium, and how these compounds go on to affect the rest of the body is therefore 
critical for nutritional and toxicological evaluation. The goal of this project is to create 
physiologically realistic in vitro models of the human GI tract that provide rapid, 
inexpensive, and accurate predictions of the digestion, absorption, cellular response to, 
and interactions between ingested compounds.  
1.2. Relevant GI tract anatomy and physiology 
Soon after food enters the stomach it is mixed with gastric juice to form a 
viscous, acidic mixture called chyme. The main components of gastric juice are 
hydrochloric acid (HCl), which is secreted by parietal cells, pepsin, which is secreted 
by chief cells as the inactive proenzyme pepsinogen, and gastric lipase [2]. The acidic 
environment created by HCl kills many of the microbes present, partially denatures 
proteins and inactivates most enzymes in the food, helps to break down the connective 
tissue in meat and plant cell walls, and converts pepsinogen into pepsin [2]. The 
protein-digesting enzyme pepsin, which is most effective at pH 2 and inactivated at 
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higher pH, digests peptide chains in chyme into smaller peptide fragments [3]. Gastric 
lipase digests triglyciderides into fatty acids and monoglycerides [3].    
 Acidic chyme entering the duodenum stimulates duodenal enteroendocrine 
cells to release secretin, which promotes the secretion of bile and buffering 
bicarbonate (HCO3-) ions by the liver and pancreas [2]. Amino acids from partially 
digested proteins and fatty acids from partially digested triglycerides trigger the 
release of cholecystokinin (CCK) by enteroendocrine cells [3]. CCK activates both the 
secretion of pancreatic juice, which is rich in digestive enzymes, and the ejection of 
bile, which aids in the emulsification, digestion, and absorption of fats [3].   
Almost all absorption and chemical digestion occur in the small intestine, and 
its structure is specifically adapted for these functions. The small intestine is 
approximately 600 cm long, 2.5 to 4 cm in diameter, and divided into three unequal 
sections: the duodenum, the jejunum, and the ileum [2]. The duodenum receives 
chyme from the stomach and is ~25 cm long, the jejunum follows the duodenum and 
is ~250 cm long, and the ~350 cm long ileum is the last section [4]. The surface area 
in the small intestine available for digestion and absorption is ~2x106 cm2 due to 
circular folds (10 mm high ridges) and villi (0.5-1 mm high fingerlike projections) 
along the intestinal wall and microvilli on the apical cell membrane of absorptive 
enterocytes, although most absorption occurs in the duodenum and proximal jejunum 
[4, 5]. The apical surface of the intestinal epithelium faces the intestinal lumen, while 
the basolateral surface faces the body cavity and is responsible for the exchange of 
molecules between the intestine and the rest of the body. Segmentation (annular 
contraction of smooth muscle) and peristalsis (successive waves of smooth muscle 
contraction) within the intestine mix chyme with digestive juices, bring food into 
contact with the intestinal epithelium for absorption, and propel chyme through the 
small intestine [5].    
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The membrane lining the small intestine is composed of more than 8 different 
cell types that are joined together by tight junctions, which are proteins that 
interconnect epithelial cells to reduce passive diffusion between the cells [6]. 
Absorptive enterocytes make up about 90% of the cell population in the upper 
intestine and are covered with 1 μm long, tightly packed microvilli that contain 
digestive enzymes; the metabolizing microvilli form a brush border [7]. Absorptive 
cells allow the passage of small molecules by one or more of four different routes: 
passive transcellular (through the cell), passive paracellular (between cells), active 
(energy-dependent) carrier-mediated, and transcytosis (transport across the epithelium 
with uptake into coated vesicles) [8]. Goblet cells are the second most common cell 
type in the human small intestine, with the ratio of goblet cells ranging from 10% in 
the small intestine to 24% in the distal colon [9]. Goblet cells secrete mucus, which is 
largely composed of heavily glycosylated proteins, providing a barrier that prevents 
viruses, bacteria, and large molecules from reaching the membrane surface [10]. The 
mucus also lubricates the epithelial surface, protects the epithelial cells from 
mechanical damage by solid food, protects the cells from chemical damage due to the 
influx of acid from the stomach, and aids in the digestion process by immobilizing 
enzymes near the epithelium surface, which allows for better nutrient hydrolysis and 
absorption [10, 11]  
The connective tissue layer (lamina propria) of the intestinal membrane 
contains B and T lymphocytes, which are the cells that produce antibodies and destroy 
infected cells, respectively [7]. Clusters of B and T cells in the connective tissue are 
called aggregated lymphatic follicles, or Peyer’s patches, and overlying the Peyer’s 
patches are M cells [7]. Human M cells have small folds over their luminal surface 
instead of microvilli, produce almost no digestive enzymes, and are located near very 
few mucus producing cells [12]. These features allow microorganism and 
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macromolecule approach and adherence to the M cell surface. M cells also contain 
only a few lysosomes, which permits the transcytosis of attached macromolecules and 
microorganisms in almost un-degraded form. After M cell transport across the 
intestinal epithelium the antigens are taken up and processed by macrophages and 
presented to T lymphocytes, which stimulate B lymphocytes to produce antibodies 
[12].  
M cells and the immune-associated cells in the lamina propria form the gut-
associated lymphoid tissue or GALT. The lining of the gastrointestinal tract is the 
largest vulnerable surface facing the external environment and it must defend the body 
against many potentially toxic substances in food or produced by bacteria [1]. The 
GALT is the defense mechanism the small and large intestines have developed for 
defending the epithelial membrane. Overall, 70-80% of the immune cells of the body 
are in the gut [13].  
1.3. In vitro models of the GI tract 
1.3.1. In vitro digestion model 
 
 
Figure 1.1. Schematic of the in vitro digestion/Caco-2 cell culture model used for 
evaluating iron bioavailability developed by Glahn et al. [14].  
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An in vitro digestion/Caco-2 cell culture model has been developed by Glahn 
et al. for studying iron bioavailability from food (Figure 1.1) [14]. The food of interest 
is cooked and freeze dried before it is subjected to an hour-long digestion at 37oC and 
pH 2 with porcine pepsin. The pepsin is then deactivated by raising the pH to 5.5-6.5 
with sodium bicarbonate, a porcine pancreatin-bile solution is added to the mixture, 
the pH is readjusted to 7.0 with sodium bicarbonate, and the chyme mimic is placed 
into 15,000 molecular weight cut-off (MWCO) dialysis membrane inserts above a 
Caco-2 human colon carcinoma cell monolayer. The 15,000 MWCO membrane on the 
insert prevents large particles from reaching the cells and protects the cells from 
digestive enzymes in the mixture. After 2 hours, the insert and food mixture are 
removed from the cells, and after another 22 hours the cells are harvested, lysed, and 
cell protein content and ferritin assays are performed.  
1.3.2. In vitro models of the intestinal epithelium 
Figure 1.2. Diagram of intestinal epithelial cells grown in a Transwell insert. The 
top or apical chamber represents the intestinal lumen, and the bottom or 
basolateral chamber corresponds to the capillary network surrounding the small 
intestine.   
The most common in vitro model for the intestinal epithelium involves 
culturing intestinal epithelial cell lines on semi-permeable membrane inserts that 
divide the wells of the culture plate into apical (top) and basolateral (bottom) 
chambers separated by the confluent monolayer of epithelial cells grown on the 
membrane (Figure 1.2). When seeded onto Type I collagen-coated plates or 
polycarbonate membranes under normal culture conditions, Caco-2 cells differentiate 
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into a polarized, absorptive enterocyte-like epithelial barrier that is morphologically 
and biochemically very similar to the small intestinal epithelium [15]. Type I collagen 
is used to model the epithelial basement membrane because it has been found to best 
stimulate proliferation, cell spreading, and differentiation in static Caco-2 cultures 
[16]. After a growth period of two to three weeks, the Caco-2 monolayers express 
tightly packed microvilli, tight junctions, and are capable of paracellular, transcellular, 
active, and transcytotic transport [8, 17]. Any material that is absorbed in the intestine 
must first diffuse across the mucus layer, the epithelial cells lining the intestine, the 
lamina propria, and the endothelial cells that line the capillaries [3]. The epithelial cell 
layer, however, has been shown to be the rate-limiting step and, therefore, the use of 
Caco-2 cells is appropriate for nutrient and drug absorption studies [18].  
Goblet cells can be mimicked in vitro using mucus secreting cell lines such as 
HT29-MTX. HT29-MTX are a subpopulation of HT29 human colonic 
adenocarcinoma cells, which, after a slow adaptation to methotraxate (MTX), consist 
exclusively of differentiated, gastric-like mucus secreting, goblet-type cells that retain 
their differentiated phenotype after reversion to MTX-free medium [19, 20]. Co-
cultures of Caco-2 and HT29-MTX represent the two major cell types (absorptive and 
goblet) found in the small intestinal epithelium.  
The co-culture of Caco-2 cells with the Raji B-cell lymphoma cell line has 
been shown to induce the differentiation of Caco-2 epithelial cells into cells with an M 
cell-like morphology, including up-regulated Sialyl Lewis A antigen, β1 integrin 
localization on the apical pole of the cells, loss of microvilli, and increased particle 
transport (Figure 1.3A and 1.3C) [21, 22]. Using an inverted in vitro M cell model 
(Raji cells were cultured on top of Caco-2 monolayers instead of in the basolateral 
Transwell chamber, Figure 1.3B) it was found that between 15 and 30% of the Caco-2 
cells differentiated into M cells [23]. 
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Figure 1.3. In vitro M cell models. (A) Caco-2 cells are cultured on a Transwell 
insert and M cell differentiation is induced by culturing the Raji B cell line in the 
basolateral chamber. The M cell culture discussed in Chapter 3 was performed in 
this orientation. (B) The inverted in vitro M cell model developed by des Rieux et 
al. [23]. A silicone holder allows the Raji cells to be cultured on top of the 
basolateral side of the Caco-2 monolayer. (C) Particle transport studies are 
performed with the Caco-2 monolayer in the upright position. 
A frequently used method for evaluating epithelial monolayer integrity and 
tight junction functionality is measuring the transepithelial electrical resistance or 
TER. TER is a measurement of ion permeability across the cell monolayer, and is 
assessed by passing a current across monolayers grown on permeable membrane 
inserts and measuring the resulting voltage across the cells. The resistance is then 
calculated using Ohm’s law, which states that resistance = voltage/current. The TER 
across Caco-2 monolayers generally increases with culture time and reaches a 
maximum after approximately 9 days. TER values of Caco-2 monolayers depend on 
the surface area of the Transwell inserts, filter support material, culture conditions, and 
especially passage number of the cells, and have been reported to range between 150 
and >1400 Ω/cm2 [24].  
1.4. Iron absorption across the intestinal epithelium 
1.4.1. Iron absorption in vivo 
Iron is an essential nutrient in the body that is absorbed from food through the 
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intestinal epithelium, but there is a delicate balance between iron absorption, 
utilization, and loss [25]. An excess of systemic iron exceeds the capacity of the 
proteins that sequester it and catalyzes the formation of free radicals [26]. Free 
radicals go on to attack cell membranes, proteins, and DNA, causing tissue damage. A 
lack of iron, on the other hand, results in anemia, which is characterized by not having 
enough hemoglobin to adequately oxygenate tissues [26]. Because the body has no 
significant mechanism for eliminating excess iron, iron balance is dependent on tightly 
linking body iron requirements with intestinal iron absorption from food.  
The percentage of iron absorbed from a meal (i.e. bioavailability) partly 
depends on dietary composition. Meat, poultry, and fish all contain heme iron, which 
is two to three times more absorbable than the nonheme iron found in plant-based and 
iron fortified foods [27]. The bioavailability of nonheme iron is affected by other 
foods ingested in the meal. Nonheme iron absorption enhancers include heme iron 
from meat and vitamin C or ascorbic acid, which has the ability to chelate iron and 
promotes nonheme iron reduction [27-29]. Inhibitors of iron absorption include the 
polyphenols found in some vegetables, tannins in tea, phytates in bran, and calcium 
[30, 31]. 
Most iron absorption takes place in the proximal small intestine, near the 
gastro-duodenal interface [32]. There are currently heme, ferrous, and ferric iron 
absorption pathways that have been identified in the intestinal epithelium. Heme iron 
is transported into enterocytes intact through the heme carrier 1 (HCP1) protein [33]. 
Inorganic, nonheme iron, which is mostly in the Fe3+ form, is reduced to the ferrous 
state by the ferrireductase duodenal cytochrome B (Dcytb) [34]. Fe2+ is transported 
into the cell by divalent metal iron transporter 1 (DMT1) [35]. In the IMP or integrin-
mobileferrin pathway, ferric iron is transported across the apical surface of intestinal 
cells by β3-integrin and mobilferrin before cytosolic reduction by paraferritin [36, 37]. 
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Once inside the cell, some iron is stored within ferritin and some is exported as Fe2+ 
across the basolateral membrane through the basolateral iron transport protein 
ferroportin 1 (FPN1) [38].  Fe2+ must be oxidized to Fe3+ by hephaestin (Heph) and 
ceruloplasmin (Cp) in order to bind transferrin, the blood iron carrier protein [39, 40]. 
Figure 1.4 is a diagram of the major iron uptake, storage, transport, and carrier 
proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Iron uptake, storage, transport, and carrier proteins in the small 
intestinal epithelium.  
Understanding of the molecular mechanisms involved in iron absorption by 
duodenal enterocytes has increased dramatically, but the mechanism by which iron is 
transported from the apical pole of enterocytes to the basolateral membrane is only 
beginning to become clear. There is evidence for an endocytic/exocytic cycling 
mechanism involving apotransferrin, or transferrin that does not contain bound iron, 
which stimulates transepithelial iron transport in a dose-dependent manner when 
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added to the basolateral surface of Caco-2 monolayers [41-43]. The apotransferrin 
containing endosomes are routed towards the apical pole of the cell where they co-
localise with DMT1 that has endocytosed from the apical surface [44]. It has been 
proposed that during the endosome co-localization, Fe2+ bound by DMT1 is oxidized 
to Fe3+ by Heph and transferred to apotransferrin [45]. The newly formed 
holotransferrin, or iron saturated transferrin, then cycles out to the blood. Experiments 
using a combination of biochemical inhibitors to disrupt the vesicular network in 
Caco-2 cells have shown that this pathway may account for as much as 50% of the 
transepithelial iron transport [45, 46]. 
The mucus layer covering the intestinal epithelium is also thought to play a 
role in iron absorption. Some ingested metals remain soluble throughout the 1-8 pH 
range of the GI tract (Na, Mg, and Ca), but others (Al, Cu, Fe, Mn, and Zn) are 
susceptible to hydroxy-polymerization, which is the formation of insoluble metal 
hydroxides that cannot be absorbed [47]. Hydroxy-polymerization occurs when, in the 
absence of soluble ligands, acid soluble Al, Cu, Fe, and Zn form hydroxide 
precipitates as the intestinal lumen pH increases. Work by Conrad et al. has shown 
that mucins, which are the heavily glycosylated proteins secreted by goblet cells, bind 
iron at an acidic pH when iron is soluble and prevent iron precipitation as the pH in 
the small intestine increases [48]. These findings, along with the ability of mucin to 
accept iron from ascorbate, fructose, and histidine chelates at neutral pH, suggest that 
mucin presents iron to the intestinal mucosa in an acceptable form for absorption [49]. 
More recently two main iron transport proteins, DMT1 and mobilferrin,  were found to 
be concentrated in mucin vesicles near the luminal surface, strengthening the role of 
mucin in iron uptake [50]. All of these attributes illustrate that mucus plays an 
essential role in human nutrition and health. The concentration of mobilferrin and 
DMT1 found in mucin and the ability of mucin to stabilize soluble iron as the luminal 
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pH rises and to accept iron from chelates, however, also indicate that mucus influences 
iron bioavailability. 
1.4.2. In vitro iron absorption models 
Halleux and Schneider were the first to propose the use of Caco-2 cells 
cultured on permeable membranes for iron absorption studies [51]. Alvarez-
Hernandez et al. found that there was significantly more 59Fe2+ uptake and transport by 
Caco-2 monolayers when compared with 59Fe3+ [52]. Iron deficient cells also took up 
and transported more iron than cells grown in iron-rich medium, which agreed with 
results in humans and animals [52]. Later experiments showed that Caco-2 cells 
express Dcytb, DMT1, ferritin, FPN-1, Heph, and synthesize and secrete transferrin, 
which are all of the major iron uptake, storage, transport, and carrier proteins [51, 53].  
Models that combine Caco-2 cells and in vitro digestion measure iron 
bioavailability from food due to both iron solubility and iron uptake by a living 
component. Gangloff et al. developed an in vitro digestion/Caco-2 cell culture model 
for predicting iron bioavailability from food that demonstrated the enhancing effect of 
ascorbic acid and beef on Caco-2 cell 59Fe uptake, which is in agreement with in vivo 
observations. Glahn et al. showed that 59Fe uptake by Caco-2 cells from extrinsically 
labeled foods in an in vitro digestion/Caco-2 model corresponded with in vivo studies 
[54, 55]. Glahn et al. later eliminated the need for extrinsic food labeling by showing 
Caco-2 ferritin formation accurately predicts iron bioavailability from food [14]. 
1.5. Nanoparticle transport across the intestinal epithelium 
1.5.1. Nanoparticle absorption in vivo  
In animal studies, orally delivered particles are taken up by both M cells and 
absorptive enterocytes in vivo [56]. Oral administration of nanoparticles to rats has 
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shown that differences in particle uptake and distribution are due to hydrophobicity, 
particle shape, particle size, and surface chemistry [57, 58]. Water soluble, ultrafine 
(<0.1 μm) 192Iridium and C60 fullerene nanoparticles were not significantly absorbed 
through the rat GI tract [59-61]. Water insoluble titanium dioxide (TiO2) particles in 
the 150-500 nm range, however, were absorbed into the blood stream and found in rat 
liver, spleen, lung, and peritoneal tissue [62]. The water insoluble, lipophilic particles 
most likely passively diffuse via the transcellular route. Pontefract et al. found 0.2-2 
μm long asbestos fibers in the air and city drinking water [58]. After finding a 23.55 
μm long fiber in a rat’s blood stream, Pontefract et al. concluded that smaller fibers 
pass through the intestinal wall by pinocytosis, while larger fibers pierce the 
epithelium like a needle [58]. The uptake of orally delivered polystyrene nanoparticles 
in rats showed a size and surface charge dependent trend. In experiments with non-
ionized particles, 6.6% of 50 nm particles, 5.8% of 100 nm particles, 0.8% of 1 μm 
particles, and 0% of 3 μm particles were taken up into rat liver, spleen, blood, and 
bone marrow [63]. Carboxylated polystyrene particles were less well absorbed than 
non-ionized particles of the same size [64]. The gastrointestinal tract epithelial cells 
carry a negative charge on their surface due to the presence of negatively charged 
protein residues and selective active ion pumps in the cell membranes [65]. The mucus 
that covers the intestinal epithelial surface also has a negative charge, and the charge 
of the epithelial cell membrane and mucus could contribute to the increased absorption 
of non-ionized or positively charged particles when compared with negatively charged 
particles.  
Fine (1.0-0.1 μm) and ultrafine (<0.1 μm) particles primarily composed of 
TiO2 and aluminosilicates are food additives that account for the ingestion of 1012-1014 
particles per day for the average person in a developed country [66]. These particles 
are resistant to gastrointestinal degradation and are taken up by M cells and passed on 
  13
to underlying macrophages [67]. The inorganic microparticles are also resistant to 
macrophage degradation, therefore human intestinal lymphoid aggregates often appear 
pigmented due to particle accumulation [68, 69].   
1.5.2. In vitro nanoparticle uptake and transport studies 
The use of in vitro cell culture models of the intestinal epithelium for studying 
orally delivered nanoparticle uptake and transport is widespread. A study by Behrens 
et al., however, showed that including mucus in the in vitro intestinal epithelial models 
is critical when evaluating the uptake and transport of hydrophobic particles [70]. 
Behrens et al. studied the effects of a mucus layer on particle transport in Caco-2 
absorptive and MTX-E12 goblet-like intestinal cell models [70]. It was found that the 
presence of mucus decreased the association of non-ionized, 200 nm polystyrene 
nanoparticles with cell cultures by 60%, suggesting that mucus provides a barrier to 
hydrophobic particle absorption.  
des Rieux et al. used an in vitro model of Caco-2 monolayers containing M 
cells to study polystyrene nanoparticle transport [71]. Smaller size and positive charge 
were both shown to increase the transport of nanoparticles through monolayers with M 
cells, which agrees with in vivo observations. A later study by des Rieux at al. 
determined that the transport of polystyrene particles by M cells occurred by non-
specific absorptive endocytosis through a non-clatherin dependent route that was most 
likely macropinocytosis [23].  
1.5.3. Nanoparticle toxicity after oral exposure  
There have been few studies on the acute toxicity or chronic effects related to 
oral exposure to nanoparticles. Chen et al. found that orally delivered copper 
nanoparticles, but not copper microparticles, were toxic to mice [72]. The kidney, 
liver, and spleen were found to be target organs of the copper nanoparticles. Gerhart et 
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al. observed that chronic administration of 125 μm coal particles to fat-head minnows 
(Pimephales-promelas) resulted in increased mucus secretion from goblet cells, which 
is consistent with the idea that mucus secretion is a mechanism for protecting the 
intestinal lumen from abrasion [73]. Jani et al. showed that orally administered 50 nm 
polystyrene nanoparticles translocated to rat liver, spleen, and bone marrow and later 
showed that 500 nm TiO2 particles reached to the liver, spleen, and lungs [62, 64].  
Humans in developed nations regularly ingest TiO2, silicates, and 
aluminosilicates nanoparticles, and these particles accumulate at the base of Peyer’s 
Patches [67]. The ingestion of these particles has been hypothesized to promote the 
development of Crohn’s disease, which is characterized by transmural inflammation of 
the GI tract that first appears over Peyer’s patches [66]. This link is uncertain because 
there was no difference in microparticle consumption found between healthy patients 
and those with Crohn’s disease, and limiting the amount of microparticles in the diet 
of Crohn’s disease patients resulted in no improvement in their symptoms [74, 75]. A 
recent study, however, showed that dietary microparticles that interact with 
macrophages may increase the antigenic response toward bacterial antigens in the GI 
tract [76]. 
1.6. Drug transport across the intestinal epithelium 
1.6.1. Oral drug transport in vivo 
The majority of cells in the duodenum and proximal jejunum, which is where 
most absorption takes place, are absorptive enterocytes, and these cells are responsible 
for most drug absorption (Figure 1.5) [7]. The intestinal epithelium provides both a 
physical and biochemical barrier to orally administered drugs. The tight junctions 
formed between cells and hydrophobicity of the cell membranes provide a physical 
barrier, while the digestive and metabolizing enzymes expressed by enterocytes form a 
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biochemical barrier. Human absorptive enterocytes express digestive enzymes such as 
peptidases, esterases, and lipases; phase I cytochrome P450 (CYP) metabolizing 
enzymes; and phase II metabolizing enzymes such as UDP-glucuronyltransferase, N-
acetyltransferase, sulfotransferase, and glutathione-S-transferase [77, 78]. Enzymes in 
the CYP superfamily oxidize compounds, especially chemicals or drugs that are 
hydrophobic and relatively insoluble, to form a reactive intermediate [79]. The 
reactive intermediate is then susceptible to conjugation by phase II enzymes [80]. 
 
Figure 1.5. Drug absorption pathways through absorptive enterocytes in the 
small intestinal epithelium. (A) passive transcellular, (B) passive paracellular, (C) 
active carrier-mediated, (D) apical efflux, and (E) transcytosis. 
Absorption of small lipophilic molecules occurs mainly by passive 
transcellular diffusion, and these drugs are rapidly and completely absorbed [8]. Small 
hydrophilic drugs and peptides partition poorly into cell membranes and this type of 
drug is most likely transported through the water filled pores of the paracellular 
pathway [8]. Some nutrients, vitamins, and their structural analogs are transported 
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across the epithelium by active, carrier-mediated transport [8]. Two families of apical 
efflux transporters, multidrug resistance (MDR) and multidrug resistance-associated 
protein (MRP), export drugs out of enterocytes and back into the intestinal lumen  [81, 
82]. P-glycoprotein (P-gp), which is the product of the MDR1 gene and one of the 
most studied apical efflux transporters, has been shown to limit the absorption of 
many drugs [77]. Macromolecular drugs can be transported by enterocytes via 
transcytosis across the intestinal epithelium, but low transport capacity and proteolytic 
enzymes within vesicles make this route less attractive for oral drug delivery [83]. 
Transcytosis of macromolecules is more effective in M cells, as this cell type has 
lower vesicle proteolytic activity and a higher transport capacity [12]. The low number 
of M cells in the human intestinal epithelium (<10%), however, makes this pathway 
viable only for highly potent drugs such as peptide antigens [8, 84].      
Blood that reaches the liver from the portal vein is derived from splanchnic 
circulation, which includes blood flow from the stomach, small intestine, large 
intestine, pancreas, and spleen [85]. Once a drug has absorbed across the small 
intestine and reached the blood within the surrounding capillary network, it is 
immediately delivered to the liver, which is a phenomenon called first pass 
metabolism. The result of first pass metabolism can be an extensively reduced 
concentration of bioavailable, active drug due to phase I and phase II liver 
metabolism.  
1.6.2. In vitro orally administered drug transport studies 
Caco-2 cells have been found to express a number of phase I drug 
metabolizing genes including CYP1A1, CYP1A2, CYP2C8-19, CYP2D6, CYP2E1, 
and CYP3A5 [86]. Expression of CYP3A4 and CYP2B6/7, however, was below the 
detection limit. Caco-2 cells were also found to have measurable UDP-
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glucuronyltransferase, N-acetyltransferase, sulfotransferase and glutathione-S-
transferase activity [78, 87]. The gene expression in Caco-2 cells was found to be 
closer to that of cells in the human duodenum after 16 days in culture when compared 
with Caco-2 cells cultured for only 4 days [88].  
Lennernäs et al. compared drug transport rates in Caco-2 monolayers with 
those obtained in the human jejunum in vivo [89]. Caco-2 cells were found to be an 
excellent model for the passive, trancellular pathway. The permeability of rapidly and 
completely absorbed compounds transported by the transcellular route in Caco-2 cells 
differed only 2 to 4-fold from in vivo results. The permeability of slowly or 
incompletely absorbed drugs in Caco-2 monolayers agreed with the permeability in 
vivo qualitatively, but not quantitatively; the permeability values found with Caco-2 
cells were 30 to 80-fold lower than those in the human jejunum in vivo. This 
discrepancy is most likely related to the larger amount of absorptive surface area in 
vivo and possibly because the human jejunum has a leakier paracellular pathway. The 
transepithelial resistance in the human jejunum is approximately 25-50 Ω/cm2, while 
the TER in Caco-2 monolayers ranges between 150 and >1400 Ω/cm2 [24, 90]. The 
carrier-mediated drug transport rates were also found to be lower in Caco-2 
monolayers when compared with the human jejunum because Caco-2 cells express 
lower levels of most transporters. A study by Sun et al. showed a 2 to 595-fold 
difference in the expression of transporters, channels, and metabolizing enzymes 
between the human duodenum and Caco-2 cells [88].  
One approach used to increase paracellular permeability and make the in vitro 
model more physiologically realistic was the co-culture of Caco-2 and mucus 
secreting, goblet-like cell lines. The paracellular permeability of HT29-H mucus 
secreting cell monolayers was found to be 50-fold higher than the permeability of 
Caco-2 monolayers, and the mucus layer formed by HT29-H cells was shown to be a 
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barrier to lipophilic drug absorption [91]. Co-cultures of Caco-2 and HT29-H mucus 
secreting cells were first characterized by Wilkman-Larhead and Artursson for in vitro 
drug and peptide absorption studies [92]. For co-cultures with ~50% HT29-H cells, 
the TER decreased by 1.5 fold and the mannitol permeability increased by 2.6 fold. 
Co-cultures of 50% Caco-2 and 50% HT29-MTX were used by Walter et al. to 
generate human and rat in vivo-in vitro drug permeability correlations; passively 
diffused, well absorbed drugs were found to correlate best with fractions absorbed in 
humans [93]. Hilgendorf et al. studied different seeding ratios of Caco-2 and HT29-
MTX for in vitro drug absorption and intestinal permeability applications [93, 94]. It 
was shown that varying the ratio of Caco-2 and HT29-MTX cells allows for the 
modification of monolayer paracellular resistance and secretory transport via P-gp. All 
of the previously mentioned studies showed that when Caco-2 and goblet-like cells are 
grown together they form monolayers with tight junctions between the two cell 
populations. The co-cultures were also found to have a higher permeability to ions, 
hydrophilic molecules, and peptides than Caco-2 only cultures.  
There have been several in vitro models developed that mimic first pass 
metabolism. Choi et al. cultured Caco-2 cells on a permeable Transwell membrane 
and cultured the HepG2 liver cell line on the bottom of the same well [95]. 
Benzo[a]pyrene (B[a]P), a chemical that is metabolized by CYP1A1/2 into toxic 
metabolites, was added to the apical chamber as a model compound. HepG2 and 
Caco-2 cells were found to actively metabolize B[a]P, and Caco-2 cells were shown to 
protect the HepG2 cells from B[a]P toxicity by transporting toxic metabolites back to 
the apical chamber, which agrees with rat in vivo data. Lau et al. developed a similar 
system to predict orally administered drug bioavailability [96]. Caco-2 cells were 
cultured on permeable Transwell membranes and immediately before experiments 
primary human hepatocytes were added to the basolateral chamber. Drugs of interest 
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were added to the apical compartment and samples from the basolateral compartment 
were analyzed with mass spectrometry. The oral bioavailability predicted from these 
in vitro experiments correlated with human data for 22 of the 24 compounds studied. 
Brand et al. developed an in vitro diffusion/perifusion system which studied  
peroxovanadium (a drug with insulin-like properties) transport across Caco-2 cells 
cultured on a semi-permeable membrane and downstream response by HepG2 liver 
cells in a separate cell culture compartment [97]. Peroxovanadium was found to 
passively diffuse across the Caco-2 monolayer, flow downstream to the liver cell 
compartment, and cause increased glucose consumption by HepG2 cells. This system 
required two syringe pumps and computer control, ran at a flow rate of 4 mL/hr 
without recirculation, and only one experiment could be performed at a time. Choi et 
al. developed a physiologically based, multi-compartment, in vitro perfusion system 
with recirculation that could be used to study intestinal B[a]P absorption and first pass 
metabolism by the liver [98]. The bioreactor consisted of three compartments which 
included Caco-2 cells cultured on a semi-permeable membrane with an apical and 
basolateral chamber, HepG2 liver cells cultured in cellulose-based microcarrier beads, 
and a third empty compartment that represented the fluid distribution in other tissues. 
B[a]P was introduced to the system on the apical side of the Caco-2 monolayer, and 
total of 28 mL of culture medium was re-circulated between the intestinal basolateral, 
liver, and other tissues compartments. It was found that CYP1A1/2 activity was 
significantly increased in co-culture systems, but this increase was also seen in static 
Transwell co-culture systems. The large volume of culture medium used in this system 
prevents physiologically realistic residence times, in vivo-like liquid:cell ratios, and 
requires a large amount of the compound being studied.  
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1.7. Physiologically based pharmacokinetic models and cell culture analogs  
A physiologically based pharmacokinetic (PBPK) mathematical model 
describes an organism as a set of interconnected compartments based on vasculature 
structure, and is designed to describe the time-dependent distribution of a chemical or 
drug in various tissues [85]. This type of model is based on known physiological 
parameters such as blood flow rates, tissue volumes, and chemical characteristics such 
as partition coefficients and metabolic rates [85]. A PBPK model can be useful for 
cross-species extrapolation and as a human surrogate for estimating risks associated 
with chemical or drug exposure [99]. 
 
Figure 1.6. A schematic of a physiologically based pharmacokinetic (PBPK) 
model and a photograph of silicon, chip microscale cell culture analog (μCCA). A 
PBPK model includes tissues of interest (e.g. the liver) explicitly, but other tissues 
known to have minimal interaction with the compound being studied can be 
combined into either well perfused tissues (e.g. the lungs) or slowly perfused 
tissues (e.g. the muscle) to help maintain an accurate description of chemical 
dilution in the body. A μCCA is a physical replica of a PBPK model. 
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A cell culture analog (CCA) is a physical representation of a PBPK model 
(Figure 1.6). The CCA devices consist of channels and chambers arranged and sized to 
mimic the residence time and flow distribution of the corresponding PBPK model. 
Where the PBPK model mathematically specifies an organ or tissue compartment the 
CCA has an actual chamber holding a cell type that mimics the organ or tissue, while 
recirculating culture medium represents the circulatory system. The goal of a CCA is 
to create an in vitro system that can replicate some of the cell-cell interactions (i.e. 
interactions through soluble proteins and metabolites) in humans or animals not easily 
studied in vivo or in silico and to apply these observations to toxicology studies. 
Results obtained with CCA devices can also help to refine the corresponding PBPK 
models. 
A three chamber (lung, liver, and other tissues) microscale cell culture analog 
(μCCA) was developed using tools from the semiconductor industry [100]. The μCCA 
was a 2.5 cm x 2.5 cm silicon chip etched to contain cell compartments connected by 
channels. Culture medium was recirculated through the chip using a peristaltic pump. 
A four chamber (lung, liver, fat, and other tissues) proof of concept μCCA was used to 
demonstrate the effects of naphthalene exposure and metabolism on various tissues 
[101]. Two chambers (lung and liver) contained living cells; the other tissue and fat 
compartments had no cells, but mimicked the distribution of fluid in rapidly and 
slowly perfused tissues. Naphthalene added directly to the circulating culture medium 
was converted to reactive metabolites by CYP1A1/2 in the liver compartment. When 
these metabolites circulated to the lung compartment the concentration of glutathione, 
a protective compound, was reduced in the lung cells, resulting in lung cell death.  In 
control experiments without liver cells, however, there was no lung cell death. Later 
experiments using adipocyte-like cells in the fat chamber showed how fat could 
modify the response [102]. These experiments show that the system can recreate the 
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known effects of a toxic chemical. The microscale size of the device allows for near in 
vivo organ residence times, fluid to tissue ratios, and cellular shear stress values. The 
small size decreases manufacturing costs, reagent amounts, and space needed; and 
multiple μCCAs can be run simultaneously.  
1.8. Summary 
 This thesis will describe the development of in vitro models of the GI tract for 
studying iron bioavailability, nanoparticle toxicity, and the absorption, distribution, 
metabolism, elimination, and toxicity (ADMET) of orally administered 
pharmaceuticals. Chapter 2 will describe the incorporation of mucus producing, 
goblet-like cells into an existing in vitro digestion/cell culture model used for 
predicting iron bioavailability from food. Mucus has increasingly been shown to affect 
iron bioavailability in vivo, and including mucus in this in vitro model may help to 
make better iron bioavailability predictions. Chapter 3 will discuss the use of static co-
cultures of Caco-2 and HT29-MTX and tri-cultures of Caco-2, HT29-MTX, and Raji 
to determine the effects of nanoparticle exposure on iron absorption. Iron is an 
essential nutrient transported across the intestinal epithelium by complex mechanisms, 
and little work has been done to characterize the more subtle effects of chronic 
exposure to nanoparticles. The development of a GI tract μCCA using acetaminophen 
as a model drug is discussed in Chapter 4. Previous work with chip μCCAs has been 
useful for characterizing the ADMET of intravenously administered compounds, but 
the addition of an independent GI tract μCCA, which includes digestion and a mucus 
layer, offers an improved in vitro method for studying oral drug administration. 
Chapter 5 will summarize the conclusions made from this work and recommendations 
for future work with this system. 
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CHAPTER 2 
 
CHARACTERIZATION OF CACO-2 AND HT29-MTX CO-CULTURES IN AN IN 
VITRO DIGESTION/CELL CULTURE MODEL USED TO PREDICT IRON 
BIOAVAILABILITY1 
 
2.1. Introduction 
Iron deficiency is one of the most prevalent nutritional problems in the world 
[1]. There are many factors that contribute to iron deficiency, but low dietary iron 
bioavailability is the primary cause [1]. Dietary interventions to help control iron 
deficiency include consuming a diverse diet that includes meat and green leafy 
vegetables, supplementation, fortifying staple foods with iron, and biofortification, 
which is breeding crops that are rich in bioavailable iron [2]. All of these strategies, 
however, require iron bioavailability validation for numerous factors, compounds, 
conditions, and potential food interactions. Human studies are lengthy and expensive, 
and animal response may differ from that of humans [3]. The in vitro digestion/Caco-2 
cell culture model developed by Glahn et al. offers a rapid, low cost method to screen 
foods and food combinations for iron bioavailability before more definitive human 
trials [4]. 
Iron bioavailability results from the in vitro digestion/Caco-2 cell culture 
model have been well correlated, qualitatively, with human data. The effects of meat 
and ascorbic acid on iron absorption, both known to enhance iron availability in vivo, 
have been reproduced in this system [4, 5]. Factors that inhibit iron uptake, such as 
                                                 
1 Portions of this chapter have been published previously. 
Copyright 2008 from “Characterization of Caco-2 and HT29-MTX Co-cultures in an In Vitro 
Digestion/Cell Culture Model Used to Predict Iron Bioavailability” by Gretchen J. McAuliffe, Michael 
L. Shuler, and Raymond P. Glahn. Reproduced with the permission of Elsevier B.V.  
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phytic and tannic acid, have also been replicated [6]. The in vitro iron bioavailability 
of iron supplements (a polysaccharide-iron complex and an FeSO4 preparation) agreed 
with results from a closely matched human study [7, 8].  
Results from quantitative studies comparing in vivo human to in vitro Caco-2 
iron uptake results for semisynthetic meals have shown that human and Caco-2 data 
generally agree [9-11]. Yun et al. determined that the Caco-2 model can be used to 
estimate human iron bioavailability from complex meals if the results can be 
compared as absorption ratios, which are the iron absorption at a given level of 
promoter or inhibitor divided by the iron absorption without the promoter or inhibitor 
present [10]. This was the first study to provide an actual conversion factor for 
transforming Caco-2 cell observations into a prediction for human iron absorption. A 
study performed by Beiseigel et al. confirmed that absorption ratios from Caco-2 cell 
data accurately predicted human iron absorption from maize meals extrinsically 
isotope labeled for nonheme iron, but not for extrinsically labeled great northern and 
pinto bean meals [11]. Recent work by Jin et al., however, has shown that there is poor 
equilibration between extrinsic and intrinsic iron in the bean samples, which questions 
the reliability of extrinsic isotope labeling of plant foods for iron absorption studies 
[12]. Although human and Caco-2 iron absorption data generally agree and the current 
Caco-2 to human conversion factor is relatively simple and easy to apply, one missing 
factor in the Caco-2 model that may alter the conversion factor and improve the 
correlation between in vitro and human data is the presence of a mucus layer.  
The mucus layer covering the intestinal epithelium is thought to play a role in 
iron absorption. Mucus, which is largely composed of heavily glycosylated proteins 
(mucins), is secreted by goblet cells in the intestinal epithelium. [13]. Some ingested 
metals remain soluble throughout the 1-8 pH range of the GI tract (Na, Mg, and Ca), 
but others (Al, Cu, Fe, Mn, and Zn) are susceptible to hydroxy-polymerization, which 
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is the formation of insoluble metal hydroxides that cannot be absorbed [14]. Hydroxy-
polymerization occurs when, in the absence of soluble ligands, acid soluble Al, Cu, 
Fe, and Zn form hydroxide precipitates as the intestinal lumen pH increases. Work by 
Conrad et al. has shown that mucins bind iron at an acidic pH when iron is soluble and 
these mucin-iron complexes prevent iron precipitation as the pH in the small intestine 
increases to near neutral values [15]. These findings, along with the ability of mucin to 
accept iron from ascorbate, fructose, and histidine chelates at neutral pH, suggest that 
mucin presents iron to the intestinal mucosa in an acceptable form for absorption [16]. 
More recently two main iron transport proteins, divalent metal transporter-1 (DMT-1) 
and mobilferrin,  were found to be concentrated in mucin vesicles near the luminal 
surface, strengthening the role of mucin in iron uptake [17].  
Goblet cells can be mimicked in vitro using mucus secreting cell lines such as 
HT29-MTX. HT29-MTX are a subpopulation of HT29 human colonic 
adenocarcinoma cells selected for resistance to methotrexate (MTX) [18]. After a slow 
adaptation to MTX, the HT29-MTX cell population consists exclusively of 
differentiated, gastric-like mucus secreting, goblet-type cells that retain their 
differentiated phenotype after reversion to MTX-free medium [19]. Co-cultures of 
Caco-2 and HT29-MTX represent the two major cell types (absorptive and goblet) 
found in the small intestinal epithelium. Wilkman-Larhead and Artursson first 
characterized co-cultures of Caco-2 and goblet-like HT29-H cells for in vitro drug and 
peptide absorption studies [20]. Walter et al. used Caco-2 and HT29-MTX co-cultures 
to generate human and rat in vivo-in vitro drug permeability correlations, and 
Hilgendorf et al. studied different seeding ratios of Caco-2 and HT29-MTX for in 
vitro drug absorption and intestinal permeability applications [21, 22]. All of these 
studies showed that when Caco-2 and goblet-like cells are grown together they form 
monolayers with tight junctions between the two cell populations. This work is the 
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first to use co-cultures of Caco-2 and HT29-MTX for iron bioavailability studies.  
The goal of this study was to incorporate HT29-MTX mucus producing cells 
into an in vitro digestion/cell culture model used to predict iron bioavailability. Ferric 
chloride (FeCl3), ferric chloride plus ascorbic acid (FeCl3 + AA), horse spleen ferritin 
(HSF), horse spleen ferritin plus ascorbic acid (HSF + AA), white bean, red bean, 
soybean, cooked beef, and cooked fish plus ferric chloride (fish + Fe) were subjected 
to in vitro digestion and placed into 15,000 molecular weight cut-off (MWCO) 
dialysis membrane inserts or 74 μm mesh Netwell® inserts above Caco-2 cells, Caco-2 
cells overlaid with porcine mucin (Caco-2 + mucin), HT29-MTX cells, or co-cultures 
Caco-2 and HT29-MTX cells at varying ratios. Iron bioavailability from the digests 
was evaluated by cell ferritin formation.  
2.2. Materials and Methods 
2.2.1. Chemicals, enzymes, and hormones 
All chemicals, enzymes, and hormones were purchased from Sigma Chemical 
Company (St. Louis, MO) unless otherwise stated. All glassware used in sample 
preparation and analysis was washed, soaked in 10% hydrochloric acid (HCl) and 10% 
nitric acid overnight, and rinsed with 18 MΩ water to avoid iron contamination.  
2.2.2. Cell culture  
The human colon carcinoma Caco-2 cell line was obtained from the American 
Type Culture Collection (Manassas, VA) at passage 17 and used in experiments at 
passage 30-35. The HT29-MTX cell line was kindly provided by Dr. Thécla 
Lesuffleur of INSERM U560 in Lille, France at passage 11 and used in experiments at 
passage 14-19. Caco-2 cells were grown in Dulbecco's Modified Eagle Medium 
(DMEM, Invitrogen, Grand Island, NY) containing 4.5 g/L glucose, 25 mM HEPES 
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buffer, and 10% fetal bovine serum (Invitrogen). HT29-MTX and Caco-2 co-cultured 
with HT29-MTX were grown in DMEM containing 4 mM Glutamax, 4.5 g/L glucose, 
and 10% heat inactivated fetal bovine serum (Co-culture medium, Invitrogen). The 
cells were maintained at 37°C in 5% CO2 and culture medium was changed every 
2 days. For experimental studies Caco-2 and HT29-MTX were stained with trypan 
blue, counted with a hemocytometer, and re-suspended at ratios of 100:0 (Caco-
2:HT29-MTX), 90:10, 75:25, 50:50, 25:75, and 0:100. Caco-2, Caco-2 and HT29-
MTX, or HT29-MTX were seeded at a density of 50,000 cells/cm2 onto 6 well plates 
(Corning Life Sciences, Acton, MA) coated with rat tail Type I collagen (BD 
Biosciences, San Jose, CA) at 8 μg/cm2. Experiments were performed 16 days post 
seeding. On the day before the in vitro digestion experiment, DMEM was removed 
and the monolayers were washed with and cultured overnight in very low iron (<8 
μg/L) minimal essential medium (MEM, Invitrogen) supplemented with 10 mM 
PIPES (piperazine-N,N'-bis-[2-ethanesulfonic acid]), 4 mg/L hydrocortisone, 5 mg/L 
insulin, 5 μg/L selenium, 34 μg/L triiodothyronine, 1% antibiotic-antimycotic 
solution, and 20 μg/L epidermal growth factor at pH 7.0 [4]. Under these conditions, 
baseline cell ferritin levels were approximately 3 ng ferritin/mg cell protein.  
2.2.3. Mucus layer characterization 
A method developed by Kerss et al. and Sandzen et al. and modified by 
Wikman et al. was used to determine mucus layer coverage [23-25]. HT29-MTX and 
co-cultures of Caco-2 and HT29-MTX were seeded onto polycarbonate, 0.4 μm pore 
size, Type I collagen coated, 24 mm Transwell® inserts (Corning Life Sciences) at a 
density of 50,000 cells/cm2. After 16 days, strips of the monolayer on the 
polycarbonate membrane were cut using a tool made from two razor blades glued onto 
each side of a microscope slide. The strips were stained for 1 minute in 0.25% 
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toluidine blue in PBS and held transversely in co-culture medium with silicone holders 
placed on a microscope slide. The weakly stained mucus layer was discernable from 
the more darkly stained cell monolayer.  
Periodic acid Schiff (PAS, stains hexose and sialic acid-containing 
mucosubstances pink) staining was used to visualize the mucus layer thickness. HT29-
MTX and co-cultures of Caco-2 and HT29-MTX were seeded onto polycarbonate, 0.4 
μm pore size, Type I collagen coated, 24 mm Transwell inserts at a density of 50,000 
cells/cm2. After 16 days, the cells were washed with Dulbecco's Phosphate Buffered 
Saline (DPBS, Invitrogen), fixed with 6% formaldehyde in 0.27 M CaCl2, pH 4.0 at 
4oC for 1 hour, and washed again with DPBS. HistoGelTM (Richard-Allan Scientific, 
Kalamazoo, MI) was liquefied by heating to 60oC and approximately 1 mL was added 
to the apical and basolateral sides of the polycarbonate membrane. After the HistoGel 
cooled and solidified, the membranes were removed with a razor blade and embedded 
in paraffin. Thin sections were cut transversely and stained with PAS. 
Co-cultures of Caco-2 and HT29-MTX at varying ratios were seeded onto 6-
well plates for histochemical evaluation of HT29-MTX cell location. After 16 days in 
culture, cells were washed with DPBS, fixed with 6% formaldehyde in 0.27 M CaCl2, 
pH 4.0 at 4oC for 1 hour, and washed again with DPBS. Cells were stained with alcian 
blue (pH 2.5) to visualize acid mucosubstances firmly attached to HT29-MTX cells.     
2.2.4. Sample preparation 
All samples were prepared in 50 mL conical centrifuge tubes and adjusted to 
contain a final concentration of 50 μM Fe (FeCl3, FeCl3 + AA, HSF, HSF + AA, and 
fish + Fe) with a 1:20 molar ratio of Fe:AA for the + AA samples, 1.0 g of food (white 
bean, red bean, and soybean), and/or 0.5 g of food (beef and fish + Fe) in 15 mL of 
digest. All samples containing FeCl3 were prepared by adding 42 μL of a 1000 μg 
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Fe/mL in 2% HCl stock solution (High Purity Standards, Charleston, SC) to each 50 
mL tube. A 100 μL aliquot of a freshly prepared 100 mM AA solution (~1:20 Fe:AA 
molar ratio) was added to the FeCl3 + AA samples and allowed to react for 15 minutes 
at room temperature before further manipulations were made. FeCl3 stock solution 
was added to 0.5 g fish to make the fish + Fe samples. A 2 μL aliquot of HSF stock 
solution (91 mg ferritin/mL) was used for each HSF and HSF + AA sample; 100 uL of 
100 mM AA solution was added to the HSF + AA samples and allowed to react for 15 
minutes before further manipulation. All food samples were obtained from a local 
grocery store. White bean (Goya Great Northern Beans, 70.71 μg Fe/g), red bean 
(Goya Red Kidney Beans, 53.59 μg Fe/g), beef (81.17 μg Fe/g), and fish (haddock, 
0.12 μg Fe/g) food samples were cooked, autoclaved, lyophilized, ground, and stored 
at -20oC until use. Soybeans (Arrowhead Mills Soybeans, 64.01 μg Fe/g) were ground 
and used in experiments uncooked.  
2.2.5. Mucin preparation 
Mucin preparation and characterization was previously described in detail [26]. 
Porcine stomach mucin was prepared at a concentration of 25 mg/mL in 140 mM 
NaCl, 5 mM KCl, pH 2.0; mixed with chelating resin to remove iron (Chelex-100, 
Bio-Rad Laboratories, Hercules, CA); poured through a glass column (ID = 1.5 cm, 
length = 45 cm) to remove the resin; and stored at -20oC. The iron concentration in the 
resin-treated mucin was 1.4 mg/L. On the day of the in vitro digestion experiment the 
mucin was thawed and added to MEM for a final concentration of 5 mg/mL mucin. A 
1 mL aliquot of the MEM + mucin solution was added to designated monolayers 
immediately before the intestinal digestion.     
2.2.6. In vitro digestion/cell culture technique 
A detailed in vitro digestion method has been described elsewhere [4]. Briefly, 
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the gastric digestion phase was initiated by adding 10 mL of 140 mM NaCl, 5 mL 
KCl, pH 2 solution to each sample and re-adjusting each sample to pH 2 with 1 M 
HCl. An aliquot of 0.5 mL very low iron porcine pepsin solution (25 mg/mL, 800-
2500 units/mg protein) in 0.1 M HCl was added to each tube and the samples were 
rocked at 55 oscillations/min on a rocking platform (Laboratory Instrument Model RP-
50, Rockville, MD) for 1 hour at 37oC. After the 1 hour gastric incubation, the pH of 
the samples was raised to 5.5-6.0 with 1 M NaHCO3 and 2.5 mL of very low iron 
porcine pancreatin/bile solution (2 mg/mL pancreatin, activity 4 × USP specifications; 
11 mg/mL bile, glycine and taurine conjugates of hyodeoxycholic and other bile salts) 
was added. The pH was then adjusted to 7.0 with 1 M NaHCO3 and the volume of 
each tube brought to 15 mL by weight with 140 mM NaCl, 5 mM KCl, pH 6.7. After 
this point, the samples were referred to as digests.  
Immediately before the intestinal digestion period, the MEM was removed 
from each culture well and replaced with a fresh 1.0 mL aliquot of MEM (or MEM 
containing 5 mg/mL mucin for Caco-2 + mucin treatments). Transwell insert rings 
fitted with 15,000 MWCO dialysis membrane and sterilized with 0.5 M HCl were also 
inserted into each well, creating a two-chamber system. The intestinal digestion period 
was initiated by adding a 1.5 mL aliquot of digest into the modified Transwell insert. 
The plates were then incubated at 37oC on a rocking shaker at 6 oscillations/min for 2 
hours. The intestinal digestion was terminated by removing the insert ring and digest. 
The solution in the bottom chamber was allowed to remain on the cell monolayers and 
an additional 1 mL of MEM was added to each well. The cell culture plate was 
returned to the incubator and the cells were harvested after an additional 22 hours. 
Cells were harvested by removing the MEM; washing the monolayers twice with 2 
mL 130 mM NaCl, 5 mM, and 5 mM PIPES, pH 7.0; adding 2 mL of 18 MΩ water to 
each well; and sonicating the cells (Elma Transsonic Digital sonicator, Lab-Line 
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Instruments) for 15 minutes at  4oC. After sonication the cell solutions were aspirated 
and stored at –20°C. 
2.2.7. Removal of mucus layer 
To study the effects of the mucus layer on iron absorption in HT29-MTX cells, 
the mucus layer was removed using a protocol described by Behrens et al. [27]. 
Immediately before the intestinal digestion, MEM was removed from HT29-MTX 
cells cultured for 16 days and replaced with 2.0 mL of 10 mM N-acetylcysteine in 
DPBS. The plates were then incubated at 37oC under agitation (135 rpm, Labnet 
International, Edison, NJ) for 1 hour. Subsequently, the cells were washed twice with 
DPBS and 1.0 mL of MEM was added to each well. Mucus removal was verified by 
alcian blue staining after the washing procedure.   
2.2.8. Assays  
Cell protein was measured using a Bio-Rad DC protein assay kit, which is a 
commercial semimicro adaptation of the Lowry assay (Bio-Rad Laboratories), on 
samples that had been solubilized in 0.5 M NaOH. A one stage, two site 
immunoradiometric assay was used to measure cell ferritin content (FER-IRON II 
Serum Ferritin Assay, RAMCO Laboratories, Stafford, TX). A 10 μL sample of the 
cell solutions was used for each ferritin measurement and gamma radiation was 
counted in an automatic gamma counter (Packard Auto-Gamma Model 5530, 
PerkinElmer Life and Analytical Sciences, Wellesley, MA). The iron content of the 
food samples and porcine mucin was evaluated using an inductively coupled argon 
plasma emission spectrometer (ICAP Model 61E Trace Analyzer, Thermo Jarrell Ash 
Corporation, Franklin, MA). 
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2.2.9. Statistical analysis 
Results are expressed as mean ± standard error. Data was analyzed with the 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA). A 
one-way ANOVA with Tukey’s post test was used to compare differences between 
means and data was transformed when necessary to obtain equal sample variances. 
Differences between means were considered significant at p < 0.05.  
2.3. Results 
2.3.1. Mucus layer visualization and characterization 
 
Figure 2.1. (A) Caco-2, (B) 90:10, (C) 75:25, and (D) HT29-MTX viable cells after 
16 days in culture, ratios are Caco-2:HT29-MTX. Toluidine blue stained the cell 
monolayer dark and weakly stained the mucus layer. These images show that the 
mucus layer completely covered the cell monolayer, even in co-cultures with low 
ratios of HT29-MTX cells. (E) Co-culture of 90% Caco-2 and 10% HT29-MTX 
grown for 16 days on a Transwell insert and stained with periodic acid Schiff 
(PAS, stains acidic mucosubstances pink). This figure shows that the mucus layer 
thickness was irregular, but at the lowest ratio of HT29-MTX cells used (90:10 
Caco-2:HT29-MTX) the mucus was approximately 2-10 μm thick. Similar results 
were found for other Caco-2:HT29-MTX seeding ratios. Scale bar = 10 μm. 
HT29-MTX and co-cultures of Caco-2 and HT29-MTX cells grown for 16 
days on a permeable membrane developed a mucus layer that completely covered the 
monolayer and was approximately 2-10 μm thick (Figure 2.1). The porcine gastric 
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mucin did not form a visible coating. The mucus layer over HT29-MTX cells was 
more firmly attached than the layer over Caco-2 cells and could withstand the multiple 
washing steps involved in histochemical preparation. Figure 2.2 shows that at lower 
HT29-MTX ratios there are clusters of HT29-MTX cells surrounded by Caco-2 cells 
and at higher HT29-MTX ratios there are clusters of Caco-2 cells surrounded by 
HT29-MTX cells, but that, overall, the number of HT29-MTX cells in the 16 day-old 
cultures increased with increasing initial HT29-MTX seeding ratios.   
 
Figure 2.2. Co-cultures of Caco-2 and HT29-MTX stained with alcian blue (pH 
2.5, stains acid mucosubstances blue) after 16 days in culture, ratios are Caco-
2:HT29-MTX. The mucus stained more intensely above HT29-MTX cells, and 
this figure shows that the number of HT29-MTX cells after 16 days in culture 
increased as the initial seeding ratio of HT29-MTX cells increased. (A) Caco-2 
(100:0), (B) 90:10, (C) 75:25, (D) 50:50, (E) 25:75, (F) HT29-MTX (0:100). 
2.3.2. Cell protein levels and ferritin formation after direct contact with digest 
  Experiments were performed to determine if the mucus layer generated by the 
HT29-MTX cells could replace the 15,000 MWCO dialysis membranes, which are 
used in the in vitro digestion experiments to protect cell monolayers from the digestive 
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Figure 2.3. Cell ferritin formation of Caco-2 and 90:10 (Caco-2:HT29-MTX) 
cultures for 15,000 MWCO dialysis membrane inserts and 74 μm Netwell mesh 
inserts. Digests with FeCl3 and horse spleen ferritin contained 50 μM iron and 
ascorbic acid, when present, was at a 1:20 (iron:ascorbic acid) molar ratio. 
Values are mean ± SEM, n = 4. 
 
 
 
 
 
 
 
Figure 2.4. 90:10 (Caco-2:HT29-MTX) +74 μm mesh insert cell protein shown as 
a percent of 90:10 +15,000 MWCO dialysis membrane insert control. 
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enzymes. Netwell inserts with a 74 μm mesh were used in these experiments to screen 
out large food particles while still allowing the digest to come in contact with the cell 
monolayer.  Figure 2.3 shows the results of an in vitro digestion experiment where the 
digest was placed into 15,000 MWCO dialysis membrane inserts or 74 μm Netwell 
mesh inserts. The addition of 10% HT29-MTX cells to the monolayer decreased the 
ferritin formation for the 15,000 MWCO and 74 μm mesh inserts when compared with 
the Caco-2 +15,000 MWCO membrane control. For the FeCl3, HSF, white bean, and 
cooked beef treatments it appears that the co-cultures with 74 μm mesh inserts are 
more sensitive to iron in the digests because the cells formed more ferritin than the co-
cultures with a 15,000 MWCO insert. Figure 2.4, however, shows that the co-culture 
cell protein is lower (50% - 75% of the control) when the 74 μm mesh inserts are used. 
The cell protein is lowest for the treatments without food to act as a buffer (FeCl3, 
FeCl3 + AA, HSF, and HSF + AA) and for the uncooked soybeans. The cell protein 
levels are also higher than the control for the cooked beef digest. This is most likely 
due to animal protein from the cooked beef sample that remained on the monolayer 
after the washing steps. These low cell protein levels indicate substantial cell loss and 
damage, which invalidate the ferritin formation results.   
  Increasing the ratio of HT29-MTX cells in the monolayers and diluting the 
digests with culture medium were both attempted to remedy the cell death and damage 
caused by contact with the digestive enzymes in the experimental digests. Two 
treatments (FeCl3 and FeCl3 + AA) with highly bioavailable iron that were shown in 
previous experiments to damage cells were used. Digests were diluted with MEM after 
2 hours of contact with the cell monolayer. Figure 2.5 shows the results of these co-
culture dilution experiments. These results show that increasing the amount of culture 
medium in the culture well does not alter the baseline ferritin formation (MEM only  
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Figure 2.5. Cell ferritin formation of Caco-2, 90:10, and 75:25 (Caco-2:HT29-
MTX) cultures with 74 μm Netwell mesh inserts and digest dilution with MEM. 
Dilution by a factor of ~4 or ~5.5 resulted in cell survival after 24 hours. Dilution 
factor is the total fluid in each culture well, which includes 1.5 mL digest and 
MEM. Treatments without bars had no viable cells. Digests with FeCl3 and horse 
spleen ferritin contained 50 μM iron and ascorbic acid, when present, was at a 
1:20 (iron:ascorbic acid) molar ratio. Values are mean ± SEM, n = 4. 
treatments). The results also show that increasing the ratio of HT29-MTX cells does 
not increase resistance to the digestive enzymes, but diluting the digest by a factor of 
~4 or ~5.5 (8 mL or 10 mL total fluid in the well, respectively) results in cell survival 
after 24 hours. 
  Figure 2.6 is the results from an experiment where Caco-2 and co-cultures of 
Caco-2 and HT29-MTX (90:10 ratio) were exposed to digests in 15,000 MWCO 
membrane or 74 μm mesh inserts. The digests in wells with 74 μm mesh inserts were 
diluted by a factor of ~5.5 with MEM (total fluid in well was brought up to 10 mL 
with MEM) after two hours in contact with the cell monolayers. These results show 
that direct contact with the digest decreases the cell ferritin formation for Caco-2 and 
90:10 cultures; this decrease was most dramatic for Caco-2 cultures in contact with  
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Figure 2.6. Cell ferritin formation of Caco-2 and 90:10 (Caco-2:HT29-MTX) 
cultures with 15,000 MWCO membrane or 74 μm mesh inserts. Digests in 
cultures with 74 μm mesh inserts were diluted by a factor of ~5.5 with MEM (10 
mL total fluid in each well) after 2 hours in contact with the cell monolayer. 
Digests with FeCl3 and horse spleen ferritin contained 50 μM iron and ascorbic 
acid, when present, was at a 1:20 (iron:ascorbic acid) molar ratio. Values are 
mean ± SEM, n = 3. 
 
 
 
 
 
 
 
Figure 2.7. Caco-2 and 90:10 (Caco-2:HT29-MTX) +74 μm mesh insert, factor of 
~5.5 digest dilution (10 mL total fluid in each well) cell protein shown as a 
percent of +15,000 MWCO dialysis membrane insert control. 
  48
highly available iron digests. Figure 2.7 shows the Caco-2 and 90:10 protein levels 
after direct contact with the digests. These results show that, excluding the uncooked 
soybean sample, diluting the digests allowed the cells to better withstand the digestive 
enzymes for a variety of different food samples. For the cooked beef and fish samples, 
however, cell protein was most likely overestimated due to interaction of sample 
animal protein with the cell protein assay.  
2.3.3. Cell ferritin formation for varying ratios of Caco-2 to HT29-MTX cells 
 
 
Figure 2.8. Cell ferritin formation in response to high available iron digests in 
15,000 MWCO membrane inserts. Caco-2, Caco-2 overlaid with porcine mucin, 
co-cultures of Caco-2 and HT29-MTX (ratios are Caco-2:HT29-MTX), and 
HT29-MTX were used in experiments. Digests with FeCl3 and horse spleen 
ferritin contained 50 μM iron and ascorbic acid, when present, was at a 1:20 
(iron:ascorbic acid) molar ratio. Values are mean ± SEM, n = 9. Bars with no 
letters in common are significantly different (p < 0.05).  
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Table 2.1. Average cell ferritin formation (ng ferritin/mg cell protein) for similar 
forms of highly available iron as a percent of Caco-2 control (Caco-2 cells 
without porcine mucin). Ratios are Caco-2:HT29-MTX, n = 9. 
 
Figure 2.9. Cell ferritin formation in response to low available iron digests. Caco-
2, Caco-2 overlaid with porcine mucin, co-cultures of Caco-2 and HT29-MTX 
(ratios are Caco-2:HT29-MTX), and HT29-MTX were used in experiments. 
Values are mean ± SEM, n = 9. Bars with no letters in common are significantly 
different (p < 0.05). 
For experiments where all cultures were exposed to digests in 15,000 MWCO 
membranes, the addition of HT29-MTX mucus producing cells generally reduced the  
amount of ferritin formed, and as the ratio of HT29-MTX cells increased the ferritin 
formation in the cultures decreased. The decrease in ferritin formation due to added 
HT29-MTX cells was most significant for digests with highly available iron (FeCl3, 
FeCl3 + AA, HSF, HSF + AA, cooked fish + FeCl3, cooked beef, Figure 2.8). Caco-2 
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cells and co-cultures presented iron in similar forms (heme iron, iron plus promoter) 
responded in a very consistent, reproducible manner (Table 2.1). Digests with less 
bioavailable iron (MEM control, red bean, white bean, and soybean) showed fewer 
statistically significant differences in ferritin formation between different cell 
preparations (Figure 2.9). The porcine mucin preparation used in this study had an 
original iron content of 274 mg iron/L, which after treatment with a chelating resin 
was reduced to 1.4 mg/L. The remaining iron in the mucin is most likely responsible 
for the significantly larger ferritin formation in Caco-2 + mucin cultures exposed to 
only MEM (Figure 2.9).  
2.3.4. Effects of mucus layer removal and culture medium 
 
 
 
 
 
 
 
 
 
Figure 2.10. HT29-MTX cell ferritin formation with and without a mucus layer. 
Digests with FeCl3 and horse spleen ferritin (HSF) contained 50 μM iron and 
ascorbic acid (AA), when present, was at a 1:20 (iron:ascorbic acid) molar ratio. 
Values are mean ± SEM, n = 3, p < 0.05. 
Iron bioavailability experiments were performed with HT29-MTX cells with a 
mucus layer and with the mucus layer removed (Figure 2.10). These results show that 
removing the mucus layer over the HT29-MTX cells did not increase the ferritin 
formation by the cells. HT29-MTX protein levels were unchanged after mucus 
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removal, which indicated that there was little cell death and detachment due to the 
mucus removal process. Experiments were also performed with Caco-2 cells only in 
DMEM or in co-culture medium to determine the effects of culture medium on iron 
bioavailability (Figure 2.11). On day 15 in culture, cells grown in DMEM or in co-
culture medium were rinsed once in MEM and cultured overnight in MEM. There was 
no statistically significant difference in ferritin formation between Caco-2 cells grown 
for 15 days in DMEM or co-culture medium. 
 
 
 
 
 
 
 
Figure 2.11. Caco-2 cell ferritin formation in DMEM and co-culture medium. 
DMEM contained 4.5 g/L glucose, 25 mM HEPES buffer, and 10% fetal bovine 
serum. Co-culture medium was DMEM containing 4 mM Glutamax, 4.5 g/L 
glucose, and 10% heat inactivated fetal bovine serum. Digests with FeCl3 and 
horse spleen ferritin (HSF) contained 50 μM iron and ascorbic acid (AA), when 
present, was at a 1:20 (iron:ascorbic acid) molar ratio. Values are mean ± SEM, n 
= 3, p < 0.05. 
2.4. Discussion 
Iron is primarily available from food in two forms: nonheme iron from foods 
like vegetables or cereals, and heme iron in the form of hemoglobin or myoglobin 
from animal sources [28]. There are currently heme, ferrous, and ferric iron absorption 
pathways that have been identified in the intestinal epithelium [29]. Heme iron is more 
efficiently absorbed than inorganic iron from the diet because heme iron is soluble at 
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the pH of the small intestine, and a recently discovered importer, HCP1, mediates 
dietary heme iron uptake [29, 30]. Most inorganic, nonheme iron in the diet is present 
as the Fe3+ form. Ferric iron precipitates in solutions with pH 3 or higher, and must be 
bound by dietary components or intestinal mucins to stay in solution when it enters the 
less acidic duodenum [29]. The ferrireductase duodenal cytochrome B (Dcytb) reduces 
ferric iron to its ferrous form, which allows iron to be transported into intestinal 
epithelial cells by the divalent metal transporter DMT1 [28]. In the IMP, or integrin-
mobleferrin pathway, ferric iron is transported across the apical surface of intestinal 
cells by β3-integrin and mobilferrin before cytosolic reduction by parraferritin [31, 
32].   
In the small intestine, goblet cells secrete mucus that forms a coating over the 
epithelial layer. There is a loosely adherent layer and a layer that is firmly attached to 
the mucosa. The thickness of the loosely and firmly adherent mucus has been 
measured in rats from stomach to colon; in the human duodenum, where most iron 
absorption takes place, the firmly adherent mucus layer is approximately 15 μM thick 
[33, 34]. The main functions of mucus include protecting the epithelium from 
mechanical damage, acidic gastric secretions, and digestive enzymes [35]. Mucus 
binds pathogenic viruses and bacteria to help prevent infection and aids in the 
digestion process by immobilizing enzymes near the epithelium surface, allowing for 
better nutrient hydrolysis and absorption [35]. The mucus also forms a semi-
permeable barrier that allows ions and small molecules (MW < 1000) to pass, but is 
impermeable to larger molecules (MW > 17,000) [36]. All of these attributes illustrate 
that mucus plays an essential role in human nutrition and health. Additionally, the 
concentration of mobilferrin and DMT1 found in mucin and the ability of mucin to 
stabilize soluble iron as the luminal pH rises and to accept iron from chelates also 
indicate that mucus influences iron bioavailability. 
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Staining of the co-cultured Caco-2 and HT29-MTX monolayers showed that 
the mucus layer formed is about 2/3 of the thickness (2-10 μm) of the duodenal firmly 
adherent mucus layer in humans (15 μm), and that the mucus layer is continuous over 
the Caco-2 and HT29-MTX cells even at lower ratios of HT29-MTX cells (Figure 
2.1). The mucus layer was more firmly adherent over the HT29-MTX cells and could 
withstand multiple washing steps. Since the acid mucosubstances stained with alcian 
blue stained more intensely above HT29-MTX cells, Figure 2.2 shows that as the 
initial seeding ratio of HT29-MTX cells increased there was a higher ratio of HT29-
MTX cells present after 16 days in culture. Visual examinations of the cell monolayers 
over the 16 days in culture suggest that there is no observable change in the cell ratios.  
Experiments characterizing the in vitro digestion/co-culture culture model 
without 15,000 MWCO dialysis membrane inserts were performed in an effort to 
make model conditions closer to those in vivo. The 15,000 MWCO dialysis 
membranes are used to protect the cell monolayers from digestive enzymes in 
samples, but also add an artificial barrier to iron absorption. Figure 2.3 shows that the 
90:10 monolayers exposed directly to digest were more sensitive than 90:10 
monolayers with a 15,000 MWCO membrane for FeCl3, HSF, white bean, and cooked 
beef samples, but the 90:10 + 74 μm insert cell protein loss (Figure 2.4) prevents these 
results from being reliable.  
Methods tested to reduce cell protein loss after a 24 hour exposure to digest 
included increasing the proportion of HT29-MTX cells and diluting digests with MEM 
by a factor of approximately 3, 4, or 5.5 after 2 hours in contact with the monolayer 
(Figure 2.5). Increasing the proportion of HT29-MTX cells did not protect the 
monolayers from damage, but dilution by a factor of 4 or 5.5 did improve cell 
viability. Digests were diluted by a factor of 5.5 for Caco-2 and 90:10 monolayers 
exposed directly to a range of food samples (Figure 2.6). The digest dilution prevented 
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major cell loss (Figure 2.7), but significantly decreased the ferritin formation by both 
Caco-2 and 90:10 cultures. The ferritin formation by Caco-2 and 90:10 cultures 
exposed directly to digest was statistically the same for nearly all samples, therefore 
the decrease in ferritin formation was most likely due to cell damage and not 
interaction of the sample with the mucus layer. Studies after this point were performed 
with 15,000 MWCO membrane inserts to determine if the mucus layer formed by 
HT29-MTX cells was interacting with samples without the confounding factor of cell 
damage caused by direct contact with digestive enzymes.  
The results of experiments with Caco-2, Caco-2 + mucin, Caco-2 and HT29-
MTX co-cultures, and HT29-MTX with 15,000 MWCO membrane inserts show that 
including goblet-like cells in the in vitro digestion model has significant effects on 
iron bioavailability predictions. In the presence of high bioavailable iron digests, co-
cultures of Caco-2 and HT29-MTX had significantly lower cell ferritin formation 
(Figure 2.8). The high available iron digests presented iron to the cells as ferrous iron 
with and without a promoter (FeCl3 and FeCl3 + AA), as a whole ferritin molecule 
with and without promoter (HSF and HSF + AA), as heme iron (cooked beef), and as 
a low iron meat supplemented with iron to display the meat factor effect (cooked fish 
+ Fe). There are three possibilities for why the addition of goblet-like cells and a 
mucus layer to this model decreases ferritin formation.  First, the mucus layer in co-
cultures could act as a barrier to and reduce the speed of iron absorption. Experiments 
with HT29-MTX cells with and without a mucus layer (Figure 2.10), however, 
showed that removing the mucus layer over the cells does not increase the cell ferritin 
formation; indicating that the more substantial mucus layer present as the HT29-MTX 
cell ratio increases is not interacting with the digests. Second, in conditions where iron 
is easily absorbed it is possible that the HT29-MTX cells themselves and not 
interactions between the digests and the mucus layer causes a decrease in cell ferritin 
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formation. The HT29-MTX cells, in a characteristic that is true to the goblet cells they 
are mimicking, absorb less iron and produce less ferritin than the absorptive cell 
analog Caco-2 cells, and the decrease in ferritin formation would be due to Caco-2 cell 
dilution. The third possibility is that a combination of the mucus layer and goblet cells 
influences cell ferritin formation.  
In the human small intestine, the ratio of goblet cells ranges from 10% the 
small intestine to 24% in the distal colon [37]. At ratios of 90:10 and 75:25 (Caco-
2:HT29-MTX), the co-culture ferritin formation was generally lower than the Caco-2 
cultures, but this difference was statistically significant only for the cooked fish +Fe 
and cooked beef digests. These results suggest that at the 90:10 and 75:25 ratios there 
is a Caco-2 cell dilution effect that results in decreased ferritin formation, but the 
model still remains responsive to changes in iron bioavailability.      
In digests with low available iron there was very little difference in cell ferritin 
formation between Caco-2 cells and co-cultures (Figure 2.9). The low available iron 
digests were the MEM control and iron presented in mostly ferric form from plant 
sources (red bean, white bean, and uncooked soybean). The minor differences between 
Caco-2 and co-cultures in low iron bioavailability conditions could mean that the cells 
present absorb all available iron or that the mucus layer in the co-cultures aids in iron 
absorption and helps to compensate for the lack of Caco-2 cells. Experiments in the 
future studying the effects of co-cultures in the presence of iron absorption inhibitors 
such as tannic acid could help to determine if the mucus layer aids in iron absorption 
from low available iron digests.  
Experiments by Jin et al. showed that the application of porcine mucin to 
Caco-2 monolayers before placing digests in an 8 μm pore size, polycarbonate 
Transwell insert above the monolayers significantly increased iron bioavailability 
from digests containing heme and large molecules such as ferritin, but decreased the 
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iron bioavailability from white beans [26]. The experiments performed for this study 
were slightly different in that a 15,000 MWCO dialysis membrane was used for Caco-
2 + mucin treatments instead of an 8 μm pore size, polycarbonate membrane. This 
difference could explain the fact that in this work the porcine mucin did not increase 
ferritin formation for heme iron or large molecule digests or significantly decrease 
iron bioavailability in white beans. As noted by Jin, the mucin conditions are difficult 
to reproduce and this may have also been a factor in the discrepancy between the two 
studies [26]. The use of reconstituted porcine mucin for this study was only for 
comparison purposes, as this product bears little resemblance to the natural product of 
goblet cells [38]. In general, the co-cultures outperformed the mucin analog by 
maintaining their original seeding ratios and forming ferritin from digests in a fairly 
consistent manner from experiment to experiment. The different ratios of Caco-2 to 
HT29-MTX also responded consistently to similar forms of iron such as heme iron or 
iron with a promoter (Table 2.1).     
In conclusion, co-cultures of Caco-2 and HT29-MTX represent the two major 
cell types found in the human intestinal epithelium. HT29-MTX cells form a more 
physiologically realistic mucus layer that may interact with food digests and influence 
iron bioavailability predictions. In preliminary studies, increasing ratios of HT29-
MTX cells decreased the amount of ferritin formation in high available iron digests 
such as those containing ferrous iron, heme iron, and whole ferritin molecules. For 
low available iron digests, which present iron to the cells in mostly ferric form, 
increasing the ratio of HT29-MTX cells had no effect on ferritin formation. The 
physiologically realistic ratios of 90:10 and 75:25 (Caco-2:HT29-MTX) offer the best 
compromise between model response and the presence of a mucus layer. These ratios 
are recommended for future work with the in vitro digestion/cell culture model, as the 
addition of goblet-type cells may give more accurate iron bioavailability predictions 
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and further enhance this rapid, low cost tool to assess iron bioavailability from 
different foods and food combinations. 
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CHAPTER 3 
 
AN IN VITRO INTESTINAL EPITHELIUM MODEL REVEALS INTERACTIONS 
BETWEEN NANOPARTICLE ABSORPTION AND IRON UPTAKE AND 
TRANSPORT 
 
3.1. Introduction 
Oral delivery is the preferred route of pharmaceutical administration due to the 
comparatively low medical costs and relatively high patient comfort, compliance and 
convenience [1]. The oral delivery of peptide (greater than three or four residues) and 
protein therapeutics, however, is difficult due to the harsh gastric and intestinal 
environments. There have been many studies that focused on improving the 
bioavailability of peptide and protein therapeutics, and the encapsulation of peptides 
or proteins within polymeric nanoparticles is one strategy that has resulted in some 
success [2].  
There are several advantages to the use of polymeric nanoparticles for drug 
delivery including the ability to manipulate the polymer’s physiochemical 
characteristics, drug release profile, and biological behavior [3]. Polymeric 
nanoparticle carriers are also more stable than other colloidal carriers in the 
gastrointestinal tract, and their size to surface area ratio favors absorption through the 
intestinal epithelium when compared with larger carriers [2]. Many potential peptide 
and protein therapeutics, such as insulin, would be administered at least daily, and 
very little is know about the chronic effects of nanoparticle ingestion.  
While we are primarily concerned with emerging classes of engineered 
nanoparticles, many traditional particles enter the body through the intestines. It is 
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estimated that the average person in a developed country consumes 1012-1014 
manmade fine (0.1-1 μm diameter) to ultrafine (<100 nm diameter) particles per day 
[4]. The sources of these dietary particles are mainly TiO2, silicates, and 
aluminosilicates. These micro and nanoparticles have negatively charged surfaces, are 
able to bind biomolecules in the gut lumen, absorb across the GI tract, and accumulate 
at the base of Peyer’s Patches (i.e. concentrations of M cells) [4]. The ingestion of 
these particles has been hypothesized to promote the development of Crohn’s disease, 
which is characterized by transmural inflammation of the GI tract that first appears 
over Peyer’s patches [4]. The link is uncertain as there was no difference in 
microparticle consumption found between healthy patients and those with Crohn’s 
disease, and limiting the amount of microparticles in the diet of Crohn’s disease 
patients resulted in no improvement in their symptoms [5, 6]. A recent study, however, 
showed that dietary microparticles that interact with macrophages may increase the 
antigenic response toward bacterial antigens in the GI tract [7]. Interestingly, patients 
with Crohn’s disease are also prone to iron deficiency, suggesting a possible link 
between nanoparticles and iron transport [8].  
The goal of this work is to investigate the effects of oral nanoparticle exposure 
on the absorption of iron, an essential nutrient that is transported across the intestinal 
epithelium via complex, highly regulated, protein-assisted vesicular and nonvesicular 
mechanisms [9]. A physiologically realistic in vitro model of the intestinal epithelium 
was used to better understand if oral exposure to nanoparticles affects the normal 
function of the intestinal epithelium. Such a model of the intestinal epithelium requires 
at least three cell types: absorptive enterocytes, mucus-producing goblet cells, and M 
cells that are responsible for particle transport. Caco-2 and HT29-MTX cells were 
used to mimic the absorptive enterocyte and mucus-secreting goblet cells, 
respectively. After a growth period of two weeks, Caco-2 cells differentiate into a 
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polarized, enterocyte-like epithelial barrier; express microvilli and tight junctions;  and 
are capable of paracellular, transcellular, active, and transcytotic transport [10, 11]. 
Caco-2 cells also express ferrireductase duodenal cytochrome b (Dcytb), the apical 
iron transporter divalent metal transporter 1 (DMT1), ferritin, the basolateral iron 
transporter ferroportin 1 (FPN1), the ferroxidase hephaestin (Heph), and transferrin; 
which are all of the major iron uptake, storage, transport, and carrier proteins [12, 13]. 
HT29-MTX cells are a subpopulation of HT29 human colonic adenocarcinoma cells 
selected for resistance to methotrexate (MTX) that consist exclusively of 
differentiated, mucus-secreting, goblet-like cells that retain their differentiated 
phenotype after reversion to MTX-free medium [14]. Cultures of Caco-2, HT29-MTX, 
and Raji mimicked the absorptive, goblet, and M cells present in the intestinal 
epithelium. The co-culture of Caco-2 cells with the Raji B cell lymphoma cell line has 
been shown to induce the transformation of Caco-2 epithelial cells into cells with an 
M cell-like morphology, including up-regulated Sialyl Lewis A antigen, β1 integrin 
localization on the apical pole of the cells and increased particle transport [15, 16]. 
The interaction of 50 nm and 200 nm carboxylated nanoparticles with Caco-
2/HT29-MTX and +M cell (Caco-2/HT29-MTX/Raji B) monolayers was evaluated by 
examining the amount of particles transported by the cells. The effect of nanoparticles 
on normal cell function was assessed by studying the uptake and transport of iron after 
exposure to different concentrations of 200 nm or 50 nm carboxylated, non-ionized, or 
aminated particles. Overall, these results show that the charge, concentration, and 
transport mechanism of the nanoparticles can have an effect on the normal 
physiological functions of intestinal epithelial cells. 
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3.2. Materials and methods 
3.2.1. Materials 
Dulbecco's Modified Eagle Medium (DMEM); RPMI 1640 medium; Minimal 
Essential Medium (MEM); fetal bovine serum; heat inactivated fetal bovine serum; 
goat serum; trypsin-EDTA (0.25%); phosphate buffered saline (PBS); CellTrackerTM 
CM-DiI cell membrane stain; Alexa Fluor® 488 goat anti-mouse IgG1; ProLong® 
Gold antifade reagent; and FluoSpheres® amine-modified, 200 nm, polystyrene, 
yellow-green particles were obtained from Invitrogen (Carlsbad, CA). The monoclonal 
antibody to CD29 (integrin β1 subunit) was from BioGenex (San Ramon, CA). 
Transwell® polycarbonate inserts (0.33 cm2, 0.4 μm pore size) and solid black, 96 well 
assay plates were purchased from Corning Life Sciences (Corning, NY). Inserts were 
coated with 8 μg/cm2 of Type I collagen from Becton Dickinson (Bedford, MA).  
Fluoresbrite® yellow-green, polystyrene, carboxylated and non-ionized 50 nm and 200 
nm particles were acquired from Polysciences, Inc. (Warrington, Pennsylvania). Blue 
fluorescent, aminated, 50 nm particles were obtained from Sigma Aldrich (St. Louis, 
MO). 59FeCl3 was purchased from PerkinElmer (Wellesley, MA), and FeCl3 in 2% 
HCl stock solution was bought from High Purity Standards (Charleston, SC). Ferritin 
content of the cells was determined with a FER-IRON II one-stage, two-site 
immunoradiometric ferritin assay from RAMCO Laboratories (Houston, TX) and total 
cell protein concentration was determined with a Bio-Rad DC Protein Assay 
(Hercules, CA). All other chemicals, enzymes, and hormones were purchased from 
Sigma Aldrich. All glassware used in sample preparation and analysis was washed, 
soaked in 10% hydrochloric acid and 10% nitric acid overnight, and rinsed with 18 
MΩ water to avoid iron contamination. All reagents were prepared in 18 MΩ water.  
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3.2.2. Cell culture 
The human colon carcinoma Caco-2 cell line and human Burkitt’s lymphoma 
Raji B cell line were obtained from the American Type Culture Collection (Manassas, 
VA). The HT29-MTX cell line was kindly provided by Dr. Thécla Lesuffleur of 
INSERM U560 in Lille, France [14]. Caco-2 cells were received at passage 17 and 
used in experiments at passages 30-35. HT29-MTX cells were received at passage 11 
and used at passages 14-19. Caco-2 and HT29-MTX were grown in DMEM 
containing 4 mM Glutamax, 4.5 g/L glucose, and 10% heat inactivated fetal bovine 
serum. Raji cells were maintained in RPMI 1640 Medium with 2 mM L-glutamine, 
4.5 g/L glucose, 10 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES), 1.0 mM sodium pyruvate, and 10% fetal bovine serum. Nanoparticle and 
iron uptake and transport experiments were performed in serum free, very low iron 
(<8 μg Fe/L) MEM containing 10 mM piperazine-N,N'-bis-[2-ethanesulfonic acid] 
(PIPES), 4 mg/L hydrocortisone, 5 mg/L insulin, 5 μg/L selenium, 34 μg/L 
triiodothyronine, 20 μg/L epidermal growth factor, and 1% antibiotic-antimycotic 
solution [17]. The cells were maintained at 37°C in 5% CO2 and culture medium was 
changed every 2 days. For experimental studies, Caco-2 and HT29-MTX were seeded 
at a density of 100,000 cells/cm2 at a ratio of 3:1 Caco-2:HT29-MTX onto Transwell 
inserts. On day 15 of Caco-2/HT29-MTX culture, 1x106 Raji cells were re-suspended 
in 50:50 DMEM:RPMI 1640 and added to the basolateral chamber of the Caco-
2/HT29-MTX culture wells. The tri-cultures were maintained for 2 days with 100 μL 
of culture medium replaced every day in the basolateral chamber. Caco-2/HT29-MTX 
monolayers were used as controls and were cultured as above except for the addition 
of Raji cells.  
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3.2.3. TER measurements 
Transepithelial resistance (TER) of the cell monolayers was measured every 
three days after seeding and every day following the addition of Raji cells to assess the 
confluency of the monolayers and tight junction functionality. Measurements were 
also made after nanoparticle transport experiments to reassess tight junction 
functionality after exposure to nanoparticles. TER measurements were made using the 
Millicell ERS from Millipore (Billerica, MA) with the Endohm-6 chamber from 
World Precision Instruments (Sarasota, FL). The chamber was sterilized prior to use 
with 70% ethanol for 15 min. After the chamber was equilibrated with 2 mL of PBS 
for 2 hours at room temperature, the Millicell ERS voltage was adjusted to a zero 
reading and the PBS was replaced with 600 μL of fresh measurement medium. The 
measurement medium for TER consisted of serum free DMEM. The culture plates 
were removed from the incubator 5 minutes prior to measurements to allow the culture 
medium to come to room temperature. Three measurements at different insert 
positions were taken per sample. Monolayers with TER values between 200 and 300 
Ω/cm2 were used in nanoparticle and iron uptake and transport experiments. 
3.2.4. Nanoparticle uptake, transport and dose 
Nanoparticle uptake and transport studies were performed 17 days post 
seeding. Cells were rinsed once with MEM and then 600 μL of MEM was placed into 
the basolateral chamber of the Transwells and 100 μL of MEM containing varying 
concentrations of aminated, non-ionized, or carboxylated 50 nm or 200 nm particles 
was placed into the apical chamber. Sodium azide was removed from 200 nm 
aminated particles via dialysis with a 15,000 molecular weight cut-off membrane. 
Cells were incubated at 37oC and 5% CO2 on a rocking shaker (Laboratory Instrument 
Model RP-50, Rockville, MD) at 6 oscillations/minute. A 100 μL sample was taken 
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from the basolateral chamber of each well at 15, 30, 45, 60, 120, 180, and 240 minutes 
and replaced with 100 μL MEM. Samples were placed into solid black, 96 well plates 
and read on a SpectraMax Gemini EM fluorescence microplate reader from Molecular 
Devices (Sunnyvale, CA). The number of particles transported through the cell 
monolayers was determined with a standard curve prepared using dilutions of MEM 
containing 50 nm or 200 nm particles.  
Identical 200 nm and 50 nm particle transport experiments were performed at 
4οC to determine if the particle transport mechanisms were energy dependent. On day 
17 post-seeding, cells were rinsed with MEM, 600 μL MEM was placed into the 
basolateral chamber, and 100 μL MEM with 2x1010 50 nm or 1.25x109 200 nm 
particles was placed into the apical chamber. Cells were incubated at 4oC on a rocking 
shaker at 6 oscillations/minute, and a 100 μL sample was taken from the basolateral 
chamber of each well after 45 minutes. Samples were placed into solid black, 96 well 
plates and read on a fluorescence microplate reader, and a standard curve was used to 
determine the number of particles transported through the cell monolayers. 
3.2.5. 59Fe uptake and transport  
For iron uptake and transport experiments, 59Fe was presented to the cells at a 
concentration of 10 μM iron as Fe(II)-ascorbate in MEM. The radiolabeled iron 
experimental medium was prepared immediately before use by combining 59FeCl3 
(iron-59 in 0.5 M hydrochloric acid), FeCl3 (1000 μg Fe/L FeCl3 standard in 2% HCl) 
and 100 μL of 100 mM ascorbic acid to provide ~7 kBq/mL, an iron concentration of 
10 μM, and an Fe:ascorbic acid molar ratio of  1:20. After allowing the Fe(II)-
ascorbate solution to sit at room temperature and pH 2 for 15 minutes, 167 μL of 1.5 
M  NaCl and 5 mL MEM were added. Immediately after the nanoparticle uptake and 
transport experiments, 100 μL of the radiolabeled iron transport medium was added to 
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the apical chamber. Cells were incubated at 37oC and 5% CO2 on a rocking shaker at 6 
oscillations/minute for 120 minutes. Iron uptake and transport was terminated by 
transferring the apical and basolateral culture medium to scintillation vials for 
quantification of 59Fe with an automatic gamma counter (Packard Auto-Gamma 
Model 5530, PerkinElmer Life and Analytical Sciences, Wellesley, MA). Cells were 
immediately washed twice with 200 μL in the apical chamber and 600 μL in the 
basolateral chamber of stop solution (130 mM NaCl, 5 mM KCl, 5 mM PIPES, pH 
6.7). Removal solution (130 mM NaCl, 5 mM KCl, 5 mM PIPES, 5 mM 
bathophenanthrolinedisulfonic acid, 5 mM sodium dithionite) was then added to the 
monolayers. The removal solution has been shown to remove surface bound iron 
without damaging the cell membrane [18]. After 10 minutes, the removal solution was 
aspirated and the cells were washed twice with stop solution. Cells were lysed by 
adding 200 uL of water to the apical chamber and sonicating (Elma Transsonic Digital 
sonicator, Laboratory-Line Instruments Inc., Melrose, IL) for 15 minutes at 4oC. The 
Transwell membrane was removed with a razor blade and placed into a scintillation 
vial with the corresponding aqueous cell lysate for 59Fe quantification. The cell 
membranes and lysate were stored at -20oC before ferritin and protein assays. Cell 
protein was measured in samples that had been solubilized in 0.5 M NaOH. A 10 μL 
sample of the sonicated cell monolayer, harvested in 200 μL of water, was used for 
each ferritin measurement.  
3.2.6. In vitro digestion 
Nanoparticle transport experiments were also performed after subjecting the 
nanoparticles to an in vitro digestion and using the chyme mimic as the nanoparticle 
transport solution. The in vitro digestion/Caco-2 cell culture model was developed by 
Glahn et al. for studying iron bioavailability from food [17]. The food of interest is 
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cooked and freeze dried before it is subjected to an hour long pepsin digestion at 37oC 
and pH 2. The pepsin is then deactivated by raising the pH to 5.5-6.5 with sodium 
bicarbonate, a pancreatin-bile solution is added to the mixture, the pH is readjusted to 
7.0, and the chyme mimic is placed in an insert over a Caco-2 monolayer. In the in 
vitro digestion/nanoparticle transport experiments 50 nm carboxylated particles were 
digested at a concentration of 2x1011 particles/mL in a blank digest (no food added) or 
a digest with 0.067 gram/mL of freeze dried nishiki rice (2.7 μg Fe/mL). An aliquot of 
100 μL of the chyme mimic was placed directly onto the Caco-2/HT29-MTX or +M 
cell monolayers. All other details of the nanoparticle transport experiment were 
identical to those described above and controls were blank or rice digests with no 
nanoparticles. 
3.2.7. Fluorescent evaluation of nanoparticle interaction with the cell monolayer 
After carboxylated, 50 nm and 200 nm nanoparticle transport experiments, 
monolayers were washed once with PBS and then incubated with 1 μM CellTracker 
CM-DiI cell membrane stain in PBS for 20 minutes at 37oC and for an additional 15 
minutes at 4oC. Cells were then washed with PBS, fixed with 2% paraformaldehyde 
for 20 minutes at 4oC, and washed again with PBS. The membranes were removed 
with a razor blade and mounted on glass slides. After curing for 24 hours at room 
temperature in the dark, the slides were examined with a Leica TCS SP2 laser 
scanning spectral confocal microscope (Exton, PA).  
3.2.8. Localization of β1 integrin 
Cell monolayers cultured for 15 days and then with Raji cells for an additional 
2 days were stained for β1 integrin. Controls were grown without Raji cells. 
Monolayers were washed twice with PBS, fixed in 2% paraformaldehyde for 20 
minutes at 4oC, and washed twice again with PBS. Cells were permeabilized with 
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0.1% Triton X-100 in PBS for 5 minutes at room temperature and then blocked with 
5% bovine serum albumin and 1% goat serum in PBS for 1 hour, shaking at 100 rpm 
(Labnet International, Edison, NJ). The monolayers were then incubated for 2 hours at 
37oC with a 1:50 dilution of an anti-CD29 (β1-subunit) monoclonal antibody in PBS. 
The inserts were washed twice with PBS before being incubated for 1 hour with a 
1:2000 dilution of Alexa Fluor 488 goat anti-mouse IgG1. The monolayers were then 
washed twice with PBS, removed with a razor blade, and mounted on glass slides. 
After curing for 24 hours at room temperature in the dark, the slides were examined 
with a Leica TCS SP2 laser scanning spectral confocal microscope. 
3.2.9. Zeta potential 
Zeta potential of particles was measured by dynamic light scattering with a 
Malvern Zetasizer Nano-ZS (Malvern Instruments Inc, Southborough, MA) at 25oC. 
The zeta potential of 50 nm and 200 nm particles was measured in 18 MΩ water, 
MEM, and blank digest and each nanoparticle dispersion was measured three times.  
3.2.10. Transmission electron microscopy 
A 5 μL aliquot of MEM containing 2x1011 50 nm particles/mL or 1.25x1010 
200 nm particles/mL was placed onto a copper grid coated with ~40 nm of formvar. 
Grids were analyzed with a FEI Tecnai T12 Spirit Twin Transmission Elecron 
Microscope.  
3.2.11. Statistics 
All measurements of nanoparticle transport and iron uptake and transport were 
made at least 6 times for each treatment. Cellular ferritin and total cell protein assays 
were also replicated at least 6 times. Results are expressed as mean ± standard error. 
Data was analyzed with the GraphPad Prism version 4.00 for Windows (GraphPad 
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Software, San Diego, CA). A one-way ANOVA with Tukey’s post test was used to 
compare differences between means and data was transformed when necessary to 
obtain equal sample variances. Differences between means were considered 
significant at p < 0.05.  
3.3. Results 
3.3.1. Nanoparticle dose 
Efforts were made to formulate in vitro doses of nanoparticles that were 
relevant to potential real-life exposure. It is known that the average person in an 
industrialized nation consumes 1012-1014 manmade fine (0.1-1 mm diameter) to 
ultrafine (<100 nm diameter) particles per day [4].  The total surface area of the small 
intestine is 2x106 cm2, meaning that 1014 particles is a dose of 107 particles/cm2 [19]. If 
1012 or 1014 particles are ingested, the dose to the duodenum is approximately 109 or 
1011 particles/cm2, respectively. The duodenum is the first section of the small 
intestine, the site where most iron absorption occurs, and has approximately 900 cm2 
of absorbing surface area [20, 21]. If 0.02 mg/kg of 50 nm polystyrene particles were 
administered to a 70 kg human as a pharmaceutical, the dose to the small intestine 
would be 107 particles/cm2 assuming that the particles are monodisperse and have a 
density of 1.053 g/cm3 [22]. A 2 mg/kg and 200 mg/kg oral administration would 
translate to a 109 and 1011 particles/cm2 dose to the small intestine, respectively.   
The dose of 50 nm particles to the cell cultures used in this study, assuming 
that the presence of microvilli increases the surface area by 20 times [19], was 107, 
109, and 1011 particles/cm2 for the low (2x109 particles/mL), mid (2x1011 
particles/mL), and high (2x1013 particles/mL) experimental concentrations used. The 
200 nm particle dosages (1.25x108 particles/mL, 1.25x1010 particles/mL, and 
1.25x1012 particles/mL) were determined by calculating the total surface area of 
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particles in the 50 nm particle dose and normalizing the 200 nm particle dose by 
surface area. 
3.3.2. Cell monolayer and nanoparticle characterization 
 
Figure 3.1. Confocal images of monolayers stained for β1-integrin. The Caco-
2/HT29-MTX monolayer shows greater β1-integrin expression on the basolateral 
side of the membrane (A and B), while the +M cells monolayer exhibits apical 
expression (C and D). Scale bars are 20 μm (A and C) or 50 μm (B and D). 
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Figure 3.2. (A) + M cells monolayer stained with CellTrackerTM CM-DiI cell 
membrane stain after 4 hours of exposure to 50 nm particles. The green particles 
and red cell membranes overlay, showing that the hydrophobic 50 nm 
polystyrene particles primarily diffuse through hydrophobic cell membranes. (B) 
+M cells monolayer stained with CM-DiI stain after 4 hours of exposure to 200 
nm particles. The green particles and red cell membranes, in general, do not 
overlap and a greater number of vesicles can be seen. Scale bars are 20 μm. 
Figure 3.1 shows the basolateral side of Caco-2/HT29-MTX monolayers 
(Figure 3.1A and 3.1B) and apical side of +M cells monolayers (Figure 3.1C and 
3.1D) after staining for β1-integrins. β1-integrins are located at the apical pole of 
differentiated M cells, while mostly basolateral expression is seen in Caco-2/HT29-
MTX cultures [23]. 
Figure 3.2A shows +M cells monolayers after a 4 hour exposure to 2x1010 50 
nm, carboxylated, yellow-green nanoparticles. Figure 3.2B shows +M cells 
monolayers after a 4 hour exposure to 1.25x109 200 nm, carboxylated, yellow-green 
nanoparticles.  The 50 nm particles are localized to the cell membrane, while the 200 
nm particles appear to be independent of the cell membrane or potentially within cell 
vesicles.  
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Figure 3.3. Transmission electron microscopy images of 50 nm and 200 nm 
particles in MEM.  (A) 50 nm carboxylated, (B) 50 nm non-ionized, (C) 50 nm 
aminated, (D) 200 nm carboxylated, (E) 200 nm non-ionized, (F) 200 nm 
aminated. 
 
Table 3.1. Zeta potential of particles in water, MEM, and blank digest. 
The physical state of the nanoparticles in MEM was investigated using 
Transmission Electron Microscopy (TEM). Carboxylated nanoparticles appeared to 
aggregate the least, while aminated particles showed the most aggregation (Figure 
3.3). The zeta potential of 50 nm and 200 nm carboxylated, non-ionized, and aminated 
nanoparticles in water and MEM and 50 nm carboxylated nanoparticles in blank digest 
is shown in Table 3.1. The increased zeta potential of carboxylated and non-ionized 
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particles in MEM and decreased zeta potential of aminated particles in MEM when 
compared with the zeta potential in water suggests that the particles were binding 
medium proteins. These medium proteins (small black dots) can be seen on the 
particle surfaces in Figure 3.3.     
3.3.3. Nanoparticle transport 
Figure 3.4. Results from 50 nm and 200 nm carboxylated particle transport 
experiments. (A) Caco-2/HT29-MTX cultures (▲) transported 4.55% and +M 
cells cultures (■) transported 4.60% of 50 nm particles after 4 hours. (B) Caco-
2/HT29-MTX cultures (▲) transported 0.42% and +M cells cultures (■) 
transported 0.72% of 200 nm particles after 4 hours Error bars are ±SEM. Mean 
particle transport differences between Caco-2/HT29-MTX and +M cells cultures 
that are significant according to a one-way ANOVA with Tukey’s post test are 
indicated with a * (p < 0.05, n = 9). 
Figure 3.4A shows the results from the 37oC 50 nm, carboxylated particle 
transport experiment. After 4 hours Caco-2/HT29-MTX monolayers transported 
4.55% of 2x1010 particles and +M cells monolayers transported 4.60% of the 
nanoparticles. Figure 3.4B shows results from the 37oC 200 nm particle transport 
experiments. Caco-2/HT29-MTX monolayers transported 0.42% of 1.25x109 200 nm 
particles, and +M cell monolayers transported a significantly greater 0.72% of the 
particles. The results of the in vitro digestion/nanoparticle transport experiments are 
shown in Figure 3.5. Caco-2/HT29-MTX monolayers transported 9.13% of 2x1010 50 
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nm particles in blank digest and 8.96% of 2x1010 50 nm particles in rice digest. +M 
cells monolayers transported 8.96% of the particles in blank digest and 8.88% of the 
particles in rice digest.  
 
 
 
 
 
 
 
 
Figure 3.5. Results from digested nanoparticle transport experiments. Caco-
2/HT29-MTX cultures transported 9.13% of the 50 nm carboxylated particles in 
blank digest and 8.96% of particles in rice digest. +M cells cultures transported 
8.96% of particles in blank digest and 8.88% of particles in rice digest (n = 3). 
Figure 3.6. Results from 4oC 50 nm and 200 nm particle transport experiments. 
Error bars show ±SEM. Mean particle transport differences between Caco-
2/HT29-MTX monolayers at 4oC and 37oC and +M cells monolayers at 4oC and 
37oC that are significant according to a one-way ANOVA with Tukey’s post test 
are indicated with a * (p < 0.05, n = 3). 
Caco-2/HT29-MTX and +M cells monolayers were exposed to 2x1010 50 nm 
particles or 1.25x109 200 nm particles at 4oC or 37oC. After 45 minutes Caco-2/HT29-
MTX cells transported 2.16% of the 50 nm particles at 4oC and 2.31% at 37oC. +M 
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cells monolayers exposed to 50 nm particles transported 2.46% at 4oC and 3.08% at 
37oC (Figure 3.6A). The Caco-2/HT29-MTX cells transported no 200 nm particles at 
4oC and 0.08% at 37oC after 45 minutes. +M cells monolayers transported 0.06% of 
the 200 nm particles at 4oC after 45 minutes and 0.59% at 37oC (Figure 3.6B).  
Figure 3.7. TER percent of control for Caco-2/HT29-MTX (A) and +M cells (B) 
monolayers after a 4 hour exposure to low, mid, or high concentrations of 50 nm 
or 200 nm carboxylated particles. Controls were Caco-2/HT29-MTX or +M cells 
monolayers that were not exposed to nanoparticles. Error bars show ±SEM. 
Differences in TER between +nanoparticle and control monolayers that are 
significant according to a one-way ANOVA with Tukey’s post test are indicated 
with a * (p < 0.05, n = 9). 
After exposure to low (2x109 50 nm particles/mL or 1.25x108 200 nm 
particles/mL) or mid (2x1011 50 nm particles/mL or 1.25x1010 200 nm particles/mL) 
concentrations of carboxylated particles in MEM, the TER of the cell monolayers 
remained intact. For high carboxylated particle concentrations (2x1013 50 nm 
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particles/mL or 1.25x1012 200 nm particles/mL) however, there was a significant 
decrease in the TER of both Caco-2/HT20-MTX and +M cells monolayers (Figure 
3.7). Exposure to mid-level concentrations of non-ionized particles did not affect the 
Caco-2/HT29-MTX or +M cells monolayer integrity, but aminated particles 
significantly decreased the TER of Caco-2/HT29-MTX monolayers (Figure 3.8).  
Figure 3.8. TER percent of control for Caco-2/HT29-MTX (A) and +M cells (B) 
monolayers after a 4 hour exposure to a mid concentration of non-ionized or 
aminated 50 nm or 200 nm particles. Controls were Caco-2/HT29-MTX or +M 
cells monolayers that were not exposed to nanoparticles. Error bars show ±SEM. 
Differences in TER between +nanoparticle and control monolayers that are 
significant according to a one-way ANOVA with Tukey’s post test are indicated 
with a * (p < 0.05, n = 6). 
 3.3.4. Iron uptake and transport after nanoparticle exposure 
The results for the iron uptake and transport after a 4 hour exposure to low 
(2x109 50 nm particles/mL or 1.25x108 200 nm particles/mL), mid (2x1011 50 nm 
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particles/mL or 1.25x1010 200 nm particles/mL) or high (2x1013 50 nm particles/mL or 
1.25x1012 200 nm particles/mL) concentrations of nanoparticles are shown in Figure 
3.9. Iron uptake is quantified by the amount of 59Fe in the cell monolayers and iron 
transport is the amount of 59Fe that crosses the model epithelium. Controls were 
corresponding Caco-2/HT29-MTX or +M cells wells that were not exposed to 50 nm 
or 200 nm particles. Low concentrations of particles had no effect on iron uptake or 
transport for the Caco-2/HT29-MTX or +M cells monolayers. At mid-level 
concentrations of particles, iron uptake was not affected for Caco-2/HT29-MTX or 
+M cell monolayers, but the presence of 50 nm particles in the culture medium 
resulted in a significant decrease in iron transport for Caco-2/HT29-MTX monolayers. 
Exposure to mid-level concentrations of 200 nm particles resulted in a significant 
decrease in iron transport in +M cell monolayers. High 50 nm concentrations 
significantly increased Caco-2/HT29-MTX and +M cells iron uptake and transport. 
High 200 nm concentration significantly decreased +M cells iron uptake, and 
significantly increased iron transport in Caco-2/HT29-MTX and +M cells monolayers.   
The effects of nanoparticle charge on iron uptake and transport are shown in 
Figure 3.10. Mid-level (2x1011 50 nm particles/mL or 1.25x1010 200 nm particles/mL) 
concentrations of particles were used in these experiments. Non-ionized particles had 
no effect on iron uptake or transport for Caco-2/HT29-MTX or +M cells monolayers. 
The 50 nm aminated particles significantly increased Caco-2/HT29-MTX and +M 
cells monolayer iron uptake and Caco-2/HT29-MTX iron transport, while the 200 nm 
particles did not have any effect on iron uptake and transport.  
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Figure 3.9. Iron uptake after exposure to high (A), mid (C), or low (E) and iron 
transport after exposure to high (B), mid (D), or low (F) concentrations of 50 nm 
or 200 nm carboxylated particles. Controls were Caco-2/HT29-MTX or +M cells 
monolayers that were not exposed to nanoparticles. Error bars show ±SEM. 
Differences in iron uptake or transport between +nanoparticle and control 
monolayers that are significant according to a one-way ANOVA with Tukey’s 
post test are indicated with a * (p < 0.05, n = 6 for high and low concentrations, n 
= 9 for mid concentrations). 
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Figure 3.10. Iron uptake after exposure to carboxylated (A), non-ionized (C), or 
aminated (E) and iron transport after exposure to carboxylated (B), non-ionized 
(D), or aminated (F) 50 nm or 200 nm particles at a mid concentration. Controls 
were Caco-2/HT29-MTX or +M cells monolayers that were not exposed to 
nanoparticles. Error bars show ±SEM. Differences in iron uptake or transport 
between +nanoparticle and control monolayers that are significant according to a 
one-way ANOVA with Tukey’s post test are indicated with a * (p < 0.05, n = 6 for 
aminated and non-ionized, n = 9 for carboxylated). 
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Figure 3.11. Iron uptake (A) and transport (B) for Caco-2/HT29-MTX and +M 
cells monolayers after exposure to mid concentrations of digested, 50 nm, 
carboxylated particles. 
The results for the iron transport and uptake experiments in blank and rice 
digest are shown in Figure 3.11. Exposure to 200 nm and 50 nm particles in blank and 
rice digest did not result in a significant difference in iron uptake or transport for 
Caco-2/HT29-MTX or +M cells monolayers. 
Ferritin levels were analyzed in all samples to exclude preexisting differences 
in iron status as a cause for differences in iron transport or uptake. Ferritin levels 
between all +nanoparticle and control cultures were not significantly different (p < 
0.05).  
3.4. Discussion 
Previous rat in vivo studies on orally administered nanoparticles have found 
differences in particle uptake and distribution that were most likely due to particle 
size, shape, surface chemistry and hydrophobicity [24, 25]. Ultrafine 192Iridium and 
C60 fullerene nanoparticles were not significantly absorbed through the rat GI tract 
[26-28]. Within 48 hours 98% of the water-soluble, 14C-labeled C60 fullerenes orally 
delivered to rats were eliminated in feces; while in the same study 90% of the 
intravenously administered fullerenes were retained for at least a week, with >70% 
found in the liver [28]. TiO2 particles in the 150-500 nm range, however, were 
 84 
absorbed into the blood stream and found in the liver, spleen, lung, and peritoneal 
tissue [29]. Pontefract et al. found 0.2-2 μm long asbestos fibers in the air and city 
drinking water [25]. After finding a 23.55 μm long fiber in a rat’s blood stream, 
Pontefract et al. concluded that smaller fibers pass through the intestinal wall by 
pinocytosis, while larger fibers pierce the epithelium like a needle [25]. The uptake of 
orally delivered polystyrene nanoparticles showed a size and surface charge dependent 
trend. In experiments with non-ionized particles 6.6% of 50 nm particles, 5.8% of 100 
nm particles, 0.8% of 1 μm particles, and 0% of  3 μm particles were taken up into the 
liver, spleen, blood, and bone marrow [30]. Carboxylated polystyrene particles were 
less well absorbed than non-ionized particles of the same size [31].   
A recent study by Chen et al. found copper nanoparticles, but not copper 
microparticles, to be toxic to mice after oral exposure [32]. Nano and ionic copper 
particles (25 nm diameter) were class 3 or moderately toxic, and micro-copper 
particles (17 μm diameter) were class 5 or practically nontoxic on the Hodge and 
Sterner Scale. The kidney, liver, and spleen were found to be target organs of the 
copper nanoparticles. Gerhart et al. observed that chronic administration of 125 μm 
coal particles to fat-head minnows (Pimephales-promelas) resulted in increased mucus 
secretion from goblet cells, which is consistent with the idea that mucus secretion is a 
mechanism for protecting the intestinal lumen from abrasion [33]. 
There have been several in vitro studies that explored polystyrene nanoparticle 
uptake and transport through intestinal epithelial models. Behrens et al. studied the 
effects of a mucus layer on particle transport in Caco-2 and MTX-E12 intestinal cell 
models [34]. The Caco-2 cells were a model of absorptive enterocytes and the MTX-
E12 cell line represented mucus-secreting goblet cells. It was found that the presence 
of mucus decreased the association of non-ionized, 200 nm polystyrene nanoparticles 
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with cell cultures by 60%, suggesting that mucus provides a barrier for hydrophobic 
particle absorption.  
des Rieux et al. used an in vitro model of Caco-2 monolayers containing M 
cells to study polystyrene nanoparticle transport [23]. Size and charge were both 
shown to influence the transport of nanoparticles through monolayers with M cells; 
the number of 200 nm polystyrene particles transported was significantly higher than 
the number of 500 nm polystyrene particles transported and cationic groups on the 
surface of 200 nm polystyrene particles enhanced transport through monolayers with 
M cells. A later study by des Rieux at al. further characterized the in vitro M cell 
model  [35]. In an inverted in vitro M cell model (Raji cells were cultured on top of 
Caco-2 monolayers instead of in the bottom Transwell chamber) it was found that 
between 15 and 30% of the Caco-2 cells differentiated into M cells. The inverted M 
cell model transported significantly more 200 nm carboxylated polystyrene particles 
than the traditional M cell model, and it was determined that the transport of particles 
occurred by non-specific absorptive endocytosis through a non-clatherin dependent 
route that was most likely macropinocytosis.  
In this study it was shown that there was Caco-2 cell differentiation into cells 
with an M cell-like morphology as evidenced by increased β1-integrin expression on 
the apical side of +M cell monolayers. There was no quantitation of the number of M 
cells in each monolayer, but, in a separate study by des Rieux et al., an inverted in 
vitro M cell model was found to have between 15 and 30% differentiated cells [35]. In 
the study performed by des Rieux the inverted model transported significantly more 
200 nm carboxylated polystyrene particles than the traditionally cultured M cell 
model, meaning that the traditionally cultured model had fewer differentiated M cells. 
In the work described in this paper the cells were cultured traditionally and the Caco-2 
cells were diluted by HT29-MTX mucus producing cells, most likely resulting in less 
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than 15% differentiated M cells in the monolayer. Fewer differentiated M cells may be 
an advantage, however, as the human small intestinal epithelial membrane is 
composed of less than 10% M cells [36]. This is also the first example to date of an in 
vitro intestinal epithelial model that contains a tri-culture of absorptive, goblet, and M 
cells.  
The transport of 50 nm carboxylated particles through the cell monolayers is 
predominately a paracellular, non-energy dependent process. This can be observed in 
the confocal images (Figure 3.2A), where the 50 nm particles were localized to the 
cell membrane, and by the presence of 50 nm particle transport at 4oC (Figure 3.6A). 
The +M cells monolayers did not transport a significantly larger number of 50 nm 
particles, and this is because paracellular transport would not take advantage of the 
increased transcytosis activity characterized by M cells. +M cell monolayers did 
transport a significantly greater percent of 200 nm particles when compared with 
Caco-2/HT29-MTX monolayers, and the M cells most likely transported the particles 
via macropinocytosis [35]. The confocal images showing 200 nm particles 
independent of the cell membrane (Figure 3.2B), and the decrease in 200 nm particle 
transport at 4oC (Figure 3.6B) further indicate that the 200 nm particles are primarily 
transported via energy-dependent mechanisms as opposed to passive transport through 
the cell membrane.   
Nanoparticles were subjected to a physiologically realistic in vitro digestion 
method and the chyme mimic containing nanoparticles was used for nanoparticle 
transport and iron uptake and transport studies. The chyme mimic was used for 
transport and uptake studies to create in vitro intestinal epithelial model conditions 
that better mimic those in the upper small intestine in vivo. When the particles were 
digested before the nanoparticle transport studies, the Caco-2/HT29-MTX and +M 
cells monolayers transported a great deal more 50 nm particles (~5% in MEM and 
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~9% after digestion, Figure 3.5). Exposure to digested nanoparticles had no effect of 
iron uptake or transport, however (Figure 3.11). It has been shown that fewer 
carboxylated polystyrene particles are absorbed when compared with non-ionized 
particles [31]. The zeta potential of nanoparticles in blank digest was more negative 
than in MEM (Table 3.1), therefore the increased particle transport in blank and rice 
digest was most likely due to cell monolayer damage and weakening of tight junctions 
by digestive enzymes present in the digest. No further studies were performed with 
digested nanoparticles because the cell monolayer damage could confound 
nanoparticle transport and iron uptake and transport studies. 
At mid dosages, the presence of 50 nm carboxylated particles resulted in a 
significant decrease in iron transport for Caco-2/HT29-MTX monolayers (Figure 3.9). 
Exposure to 200 nm carboxylated particles in culture medium resulted in a significant 
decrease in iron transport in +M cell monolayers (Figure 3.9). The proteins associated 
with iron absorption across the apical side of the brush border and exit through the 
basolateral side of the enterocyte are well characterized, but the mechanism by which 
iron passes through the cell is poorly understood. Experiments have suggested that 
there is both vesicular and nonvesicular intracellular iron transport, and that vesicular 
transport may account for as much as 50% of the transepithelial iron transport [9]. M 
cells are characterized by increased vesicle transport, and therefore it is likely that iron 
transport in +M cell cultures is primarily vesicular, or that vesicular iron transport 
compensates for any nonvesicular iron transport interference in +M cell monolayers 
exposed to 50 nm particles. Caco-2/HT29-MTX cultures most likely transport iron 
primarily through nonvesicular mechanisms. Therefore, these iron transport results are 
consistent with the hypothesis that 50 nm particles are primarily passively transported 
and interfere with membrane protein associated iron transport while 200 nm particles 
are transported via vesicles and interfere with vesicular iron transport. The TER and 
 88 
iron uptake were not affected by the presence of mid level concentrations of 
nanoparticles for Caco-2/HT29-MTX or +M cell monolayers (Figures 3.7 and 3.9). 
TER is a measurement of tight junction functionality and iron uptake would be 
affected if there was damage to the apical cell membrane, therefore the mid dosage of 
carboxylated nanoparticles did not damage tight junctions or the apical cell membrane.  
Low doses of carboxylated 50 nm and 200 nm particles did not have an effect 
on the TER, iron uptake, or iron transport of Caco-2/HT29-MTX or +M cells 
monolayers (Figures 3.7 and 3.9). High dosages of carboxylated nanoparticles 
significantly decreased the TER of Caco-2/HT29-MTX and +M cells monolayers, 
indicating that the high concentration of carboxylated nanoparticles affected tight 
junctions (Figure 3.7). The significant increase in iron uptake for Caco-2/HT29-MTX 
and +M cells monolayers exposed to high concentrations of 50 nm particles suggests 
apical cell membrane damage from particle exposure (Figure 3.9). The high dose of 
200 nm particles did not affect the iron uptake of Caco-2/HT29-MTX monolayers, but 
did significantly decrease the iron uptake for +M cells monolayers, most likely by 
overwhelming the cellular vesicular transport pathways normally used for iron 
transport (Figure 3.9). Iron transport was significantly increased by 50 nm and 200 nm 
particles in both Caco-2/HT29-MTX and +M cells monolayers. The significant 
decrease in TER for the cell monolayers exposed to high carboxylated nanoparticle 
concentrations indicates that the increase in iron transport was due to an increase in 
paracellular transport because of weakened tight junctions.  
Mid doses of non-ionized particles and 200 nm aminated particles had no 
effect on monolayer TER, iron uptake, or iron transport (Figures 3.8 and 3.10). Mid 
doses of aminated 50 nm particles significantly decreased the TER, increased the iron 
uptake, and increased the iron transport of Caco-2/HT29-MTX monolayers, indicating 
damage to the apical cell membrane and tight junctions of the cell monolayer. The +M 
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cells monolayers also took up significantly more iron after exposure to 50 nm 
aminated particles, which indicates apical membrane damage, but TER and iron 
transport were not affected. Positively charged polymeric nanoparticles have been 
shown to increase the bioavailability of poorly absorbed compounds when compared 
with neutral or negatively charged particles [37]. This behavior has been attributed to 
mucoadhesion mediated by electrostatic interaction between the positively charged 
polymeric particles and the negatively charged mucin on the epithelial surface [37]. 
The results found in this paper, however, suggest that the positive charge may also 
disrupt the apical cell membrane and tight junction integrity. 
The intestinal epithelial layer represents the initial gate that nanoparticles must 
enter to have an acute or chronic toxic effect in the body. The polystyrene particles 
used in these experiments are generally considered non-toxic, but their interaction 
with a normal physiological process suggests a potential mechanism for a chronic, 
harmful, but subtle response. This model provides a new tool to assess nanoparticle 
toxicity following ingestion, new metrics for measuring sublethal effects, and new 
data on the relationship between physicochemical properties of nanoparticles and their 
ability to disrupt cellular behavior. Similar disruptions in nutrient absorption could be 
possible with other inorganic elements such as calcium, copper, and zinc that require 
passive or active transport systems to be absorbed through the intestinal epithelium. 
Fat-soluble vitamins such as vitamins A, D, E, and K are absorbed only after 
micellization by pancreatic lipase [38]. The micelles, due to their small size and 
hydrophilic surface, are able to gain proximity to the brush border and facilitate the 
diffusion of their contents into the phospholipid membrane of the epithelial layer. 
Hydrophobic, charged nanoparticles could potentially disrupt the formation of 
micelles, micelle interactions with the epithelial layer, and nutrient diffusion through 
the phospholipids layer.  
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In conclusion, this work has used a physiologically realistic, cell culture model 
of the intestinal epithelium to study the sublethal effects of oral nanoparticle exposure. 
Iron, which is an essential nutrient that is transported across the intestinal epithelium 
via complex, highly regulated, protein-assisted vesicular and nonvesicular 
mechanisms, was chosen as a model compound. These preliminary results suggest that 
polystyrene nanoparticle size, concentration, and charge can influence iron uptake and 
transport at doses that represent potential human exposure. 
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CHAPTER 4 
 
DEVELOPMENT OF A GASTROINTESTINAL TRACT MICROSCALE CELL 
CULTURE ANALOG TO PREDICT DRUG TRANSPORT 
 
4.1. Introduction 
The cost of developing a new drug was recently estimated to be 1.9 billion 
dollars [1]. With the majority of drug candidates failing in expensive phase III clinical 
trials, there is a significant economic need for a method that accurately assesses the 
ADMET (absorption, distribution, metabolism, elimination, and toxicity) of drug 
candidates early in the development process [2]. In vitro cell cultures and animal 
models are the two most common methods used to determine toxicological and 
pharmacological profiles of potential drugs, but both methods have disadvantages. The 
largest problem with single cell type, monolayer cell cultures is that the effects of drug 
metabolites and systemic changes caused by the compound of interest cannot be 
studied [3]. Animal experiments can take months to complete, cost millions of dollars, 
and the majority of drugs shown to be safe in animals fail in human clinical trials [3].  
This work describes an in vitro system that may be able to better predict 
animal or human response to oral drug exposure. A cell culture analog (CCA) can be 
defined as a physical representation of a physiologically based pharmacokinetic 
(PBPK) model. A PBPK mathematical model describes an organism as a set of 
interconnected compartments that is based on vasculature structure, and is designed to 
describe the time-dependent distribution of a chemical or drug in various tissues [4]. 
The CCA devices consist of channels and chambers arranged and sized to mimic the 
residence time and flow distribution of the corresponding PBPK model. In addition, 
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where the PBPK model mathematically specifies an organ or tissue compartment, the 
CCA has an actual chamber holding a cell type that mimics the organ or tissue. Re-
circulating culture medium represents the circulatory system. The goal of a CCA is to 
create an in vitro system that can replicate some of the cell-cell interactions (i.e. 
interactions through soluble proteins and metabolites) in humans or animals not easily 
studied in vivo or in silico and to apply these observations to toxicology studies. 
A three-chamber (lung, liver, and other tissues) microscale cell culture analog 
(μCCA) has been developed using tools from the semiconductor industry [5]. The 
μCCA consists of etched cell compartments connected by channels on a 2.5 cm x 2.5 
cm silicon chip, with culture medium re-circulated through the chip using a peristaltic 
pump. A four-chamber (lung, liver, fat, and other tissues) μCCA was used to 
demonstrate the effects of naphthalene on various tissues [6]. Two chambers (lung and 
liver) contained living cells; the other tissue and fat compartments had no cells, but 
mimicked the distribution of fluid in rapidly and slowly perfused tissues. Naphthalene 
added to the circulating culture medium was converted to reactive metabolites in the 
liver compartment. When these metabolites circulated to the lung compartment the 
concentration of glutathione, a protective compound, was reduced in the lung cells, 
resulting in lung cell death.  In control experiments without liver cells, however, there 
was no lung cell death. Later experiments using adipocyte-like cells in the fat chamber 
showed how fat could modify the response [7]. These experiments show that the 
system can re-create the known effects of a toxic chemical. The microscale size of the 
device allows for near in vivo organ residence times, fluid to tissue ratios, and cellular 
shear stress values. The small size also decreases manufacturing costs, reagent 
amounts, and space needed.   
In the proof of concept, four-chamber chip, test chemicals were added directly 
to the circulating culture medium, which mimics intravenous administration of a 
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compound. The purpose of this work is to connect an independent gastrointestinal (GI) 
tract μCCA to a multichamber “body” chip μCCA, which may provide a superior in 
vitro method for testing the ADMET of orally administered pharmaceuticals. The GI 
tract μCCA consists of two chambers mounted on top of each other and separated by a 
microporous membrane, on which intestinal epithelial cells are cultured. The top or 
apical chamber represents the intestinal lumen, and the bottom or basolateral chamber 
represents the capillary network surrounding the intestinal tract. The separate GI tract 
unit will be referred to as the GI tract μCCA, the silicon “body” chip will be referred 
to as the chip μCCA, and the connected GI tract and chip μCCAs will be referred to as 
the μCCA system. 
Acetaminophen (APAP) was chosen as a model drug for this work. APAP 
toxicity is closely linked to GI and liver cell metabolism of the drug. Therapeutic 
doses are primarily metabolized by phase II conjugation with sulfate and glucuronide 
[8]. Approximately 5-10% of a therapeutic APAP dose is oxidized by cytochrome 
P450 (CYP) 1A2, 2E1, or 3A4 to N-acetyl-p-benzoquinone (NAPQI), a toxic, 
electrophilic metabolite [9, 10]. NAPQI is detoxified by conjugation with glutathione 
via glutathione-S-transferase and excreted in urine or bile [11]. Large doses of APAP 
that overwhelm the sulfation and glucuronidation pathways or the induction of CYP 
enzymes with drugs such as ethanol can result in high levels of NAPQI [8]. High 
levels of NAPQI cause glutathione depletion and eventual NAPQI accumulation; 
NAPQI electrophilically attacks proteins in nearby cells and causes cell death [12]. 
Figure 4.1 illustrates the acetaminophen metabolism pathways.   
In these proof of concept experiments, APAP was used to test the hypothesis 
that drug passes through the intestinal epithelial monolayer in the GI tract μCCA, 
circulates to the liver and other cell type compartments on the chip μCCA, and causes 
glutathione depletion and cell death. In the first generation μCCA system experiments, 
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a four-compartment model was used where lung, liver, and other tissues compartments 
were etched into the silicon chip μCCAs and the GI tract μCCAs were separate 
devices fabricated from plexiglass. Three of the chambers (lung, liver, and GI) 
contained cells, while the other tissues compartment mimicked the distribution of fluid 
in slowly perfused tissues. The GI tract and chip μCCAs were later revised, and in the 
second generation μCCA system experiments a five-compartment model was used. 
Liver, kidney, fat and bone marrow compartments were etched into silicon chip 
μCCAs, and the GI tract μCCAs were separate devices fabricated from plexiglass. 
Two of the chambers (liver and GI) contained cells, while the other compartments 
mimicked the distribution of fluid in well perfused or poorly perfused tissues. 
Figure 4.1. Common pathways of acetaminophen metabolism [8, 13].  
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4.2. Materials and methods 
4.2.1. Materials 
Dulbecco's Modified Eagle Medium (DMEM), Minimum Essential Medium 
(MEM), Dulbecco's Modified Eagle Medium:Nutrient Mix F-12 (DMEM/F12, 1:1), 
fetal bovine serum (FBS), heat inactivated FBS, trypsin-EDTA (0.25%), phosphate 
buffered saline (PBS), calcein, and monochlorobimane (MCB) were obtained from 
Invitrogen (Grand Island, NY). Polycarbonate, 0.4 μm pore size membranes were 
obtained from Whatman Inc. (Florham Park, New Jersey). Polycarbonate, 0.4 mm 
pore size, 12 mm diameter SnapwellTM inserts and clear, 96-well and 6-well assay 
plates were purchased from Corning Life Sciences (Corning, NY). Membranes were 
coated with Type I collagen from Becton Dickinson (Bedford, MA). Human plasma 
fibronectin was acquired from Millipore (Billerica, MA). β-glucuronidase/arylsufatase 
was purchased from Roche Applied Science (Indianapolis, IN). Silicone wafers were 
purchased from Silicon Quest (Santa Clara, CA). P20 primer and Shipley 1813 and 
1027 photoresist were purchased from Shipley Company (Marlborough, MA). MIF 
300 developer was obtained from Claricut (Somerville, NY). Unless otherwise stated, 
all other chemicals were purchased from Sigma Aldrich (St. Louis, MO).  
4.2.2. Cell culture 
The Caco-2 (human colon carcinoma), HepG2/C3A (human hepatocellular 
carcinoma) and L2 (rat lung) cell lines were obtained from the American Type Culture 
Collection (Manassas, VA). The HT29-MTX cell line was kindly provided by Dr. 
Thécla Lesuffleur of INSERM U560 in Lille, France at passage 11 and used in 
experiments at passage 14-19 [14]. Caco-2 cells were received at passage 17 and used 
in experiments at passage 30-35. Caco-2 and HT29-MTX were grown in DMEM 
containing 4 mM Glutamax, 4.5 g/L glucose, and 10% heat inactivated FBS. 
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HepG2/C3A cells were received at an unknown passage and used in experiments at 
passage n+10-n+20. HepG2/C3A cells were maintained in MEM with 1.0 mM sodium 
pyruvate and 10% FBS. L2 cells were cultured in DMEM/F12 with 10% FBS.   
4.2.3. TER measurements 
Transepithelial resistance (TER) of the cell monolayers in Snapwell inserts 
was measured every three days after seeding to assess the confluency of the 
monolayers and tight junction functionality. TER measurements were made using the 
Millicell ERS from Millipore (Billerica, MA) with the Endohm-24 SNAP chamber 
from World Precision Instruments (Sarasota, FL). The chamber was sterilized prior to 
use with 70% ethanol for 15 minutes. After the chamber was equilibrated with 2 mL 
of PBS for 2 hours at room temperature, the Millicell ERS voltage was adjusted to a 
zero reading and the PBS was replaced with 600 μL of serum free DMEM. Culture 
plates were removed from the incubator 5 minutes prior to measurements to allow the 
culture medium to come to room temperature. Three measurements at different 
membrane insert positions were taken per sample. Membranes with TER values 
between 200 and 300 Ω/cm2 were used in second generation μCCA APAP toxicity 
experiments. 
4.2.4. Cytochrome P450 1A and 2E1 measurement  
CYP1A activity was measured using the method described by Donato et al. 
[15]. HepG2/C3A cells were seeded at 250,000 cells/cm2 in clear 96 well plates coated 
with 8 μg/cm2 fibronectin and grown for 48 hours. Caco-2 cells were seeded at 
100,000 cells/cm2 in clear 96 well plates coated with 8 μg/cm2 Type I collagen and 
grown for 16 days. Cells were then washed twice with PBS and 100 μL of assay 
medium, which consisted of phenol red-free DMEM/F12 containing 8 μM 
ethoxyresorufin and 10 μM dicumerol, was added to each well. After a 1 hour 
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incubation at 37oC and 5% CO2, 75 μL of assay medium was taken from each well 
and transferred to a separate 96 well plate; subsequently 15 Fisherman units of β-
glucuronidase and 120 Roy units of arylsulfatase in 25 μL in 0.1 M sodium acetate 
buffer (pH 4.5) were added to each well containing 75 μL assay medium. The 96 well 
plates were then incubated at 37oC for 2 hours, 200 μL of ethanol was added to each 
well, and the plates were centrifuged at 3000 rpm for 10 minutes. The amount of 
resorufin formed and released into the culture medium was quantified at 530 nm 
excitation and 590 nm emission by a SpectraMax Gemini EM fluorescence microplate 
reader from Molecular Devices (Sunnyvale, CA). A standard curve for resorufin was 
prepared in phenol red free DMEM/F12 and processed in the same manner as samples.       
 CYP2E1 activity was assessed using the methods described by Donato et al. 
and Dicker et al. [16, 17]. HepG2/C3A cells were seeded at 250,000 cells/cm2 in clear 
96 well plates coated with 8 μg/cm2 fibronectin and grown for 48 hours. Caco-2 cells 
were seeded at 100,000 cells/cm2 in clear 96 well plates coated with 8 μg/cm2 Type I 
collagen and grown for 16 days. Cells were then washed twice with PBS and 100 μL 
of assay medium, which consisted of phenol red-free DMEM/F12 containing 500 μM 
p-nitrophenol, was added to each well. After a 1 hour incubation at 37oC and 5% CO2, 
75 μL of assay medium was taken from each well and transferred to a separate 96 well 
plate. 15 Fisherman units of β-glucuronidase and 120 Roy units of arylsulfatase in 25 
μL in 0.1 M sodium acetate buffer (pH 4.5) were added to each well containing 75 μL 
assay medium. The 96 well plates were incubated at 37oC for 2 hours and then 10 μL 
of 10 M NaOH was added to each well. The amount of p-nitrophenol hydroxylation to 
p-nitrocatechol was quantified by measuring the sample absorbance at 546 nm with a 
VersaMax™ microplate reader (Molecular Devices). A standard curve for p-
nitrocatechol was prepared in phenol red free DMEM/F12 and processed in the same 
manner as samples.     
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 Following the CYP1A and CYP2E1 assays the total cell protein was measured 
using the Bradford method described by Kautzky et al. [18, 19]. The remaining 25 μL 
of assay medium was removed from the cells and the monolayers were washed twice 
with PBS. The cells were then lysed by adding 50 μL of 0.1 M NaOH to each well and 
incubating for 15 minutes at 37oC. After lysing the cells, 200 μL of Bradford reagent 
was added to each well and absorbance was read at 595 nm with a microplate reader. 
Dilutions of 0 to 1 mg/mL bovine serum albumin (BSA) dissolved in 0.1 M NaOH 
were used as protein standards. 
4.2.5. μCCA fabrication  
4.2.5.1. First generation μCCA fabrication 
 
 
 
 
 
 
 
Figure 4.2. A photograph of the first generation chip μCCA. The dimensions of 
the chambers are as follows (w x l x d): lung (2 mm x 1.6 mm x 40 μm), liver (2 
mm x 6 mm x 40 μm), and other tissues (1 mm x 123 mm x 100 μm). The channels 
connecting compartments were 100 μm deep. The chip was designed so 85% and 
15% of the medium leaving the lung compartment goes to the other tissues and 
liver chambers, respectively, while 100% of medium leaving the basolateral GI 
tract μCCA chamber goes to the liver. 
The chip was fabricated at the Cornell Nanofabrication Facility (CNF) using 
standard photolithography and etching techniques that have been described previously 
[5]. The chip pattern was first designed on CAD (Cadence, Fishkill, NY). The pattern 
was then converted onto a chrome-coated glass mask via the 3600F optical pattern 
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generator (D.W. Mann/GCA Corp., USA). Two masks were required for the two 
layers of fabrication, a 40 μm etch and a 100 μm etch.   
Figure 4.3. (A) Photograph of the apical side of the first generation GI tract 
μCCA. (B) A side-view schematic of the GI tract μCCA. The dimensions of the 
apical and basolateral chambers are as follows (diameter of the top of the 
chamber x height x diameter of the bottom of the chamber): apical chamber (8 
mm x 0.8 mm x 2.8 mm) and basolateral chamber (2.8 mm x 0.8 mm x 0.8 mm). 
The total area of Caco-2 cells exposed to flow was 6.2 mm2. 
A 4.00 inch diameter, 525 μm thick, <100>, silicon wafer was primed with 
P20 primer at 3000 rpm for 30 seconds. Next, the wafer was coated with 1.3 μm of 
Shipley 1813 photoresist at 3000 rpm. The first mask pattern was transferred to the 
wafer with UV light (405 nm) for 2.5 seconds using an AB-M HTG 3HR Contact 
Proximity Aligner (San Jose, CA). The wafer was then developed for 1 minute in MIF 
300 developer, rinsed in DI water, and dried. A deep reactive ion etch (DRIE) process 
with the UNAXIS 770 plasma etcher (Unaxis USA Inc., St. Petersburg, FL) was used 
to etch the wafer at a rate of approximately 2 μm/min to a depth of 40 μm.  
For the second layer of fabrication the wafer was once again primed with P20 
primer before Shipley 1075 photoresist was spun on the wafer at 2000 rpm for 30 
seconds. The second mask pattern was transferred to the wafer with UV light for 30 
seconds using the HTG contact aligner. The wafer was again developed and etched 
with the UNAXIS 770 to a depth of 100 μm. Finally, the wafer was stripped using a 
heated resist bath and the individual chips (7 per wafer) were separated by scoring 
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with a diamond blade and breaking the wafer. Figure 4.2 is a photograph of the chip 
μCCA used for these experiments.  
The first generation GI tract μCCA was fabricated from ½” thick plexiglass 
(McMaster-Carr, New Brunswick, NJ) by Glenn Swann (School of Chemical and 
Biomolecular Engineering, Cornell University). A photograph and side-view 
schematic of the first generation GI tract μCCA are shown in Figure 4.3. The plastic 
was etched so that the top piece contained a chamber that was 8 mm at the top (surface 
where the fluid inlet and outlet are located), 0.8 mm high, and 2.8 mm at the bottom 
(the surface that comes in contact with the cell monolayer). The bottom piece had an 
etched chamber that was 0.8 mm at the bottom (surface where the fluid inlet and outlet 
are located), 0.8 mm high, and 2.8 mm at the top (the surface that comes in contact 
with the cell monolayer). The top and bottom pieces had two-step inlet and outlet 
channels drilled with a diameter of 740 μm (drill size number 69, Small Parts Inc., 
Miami Lakes, FL) for the top half of the channel and 610 μm (drill size number 73, 
Small Parts) for the bottom half of the channel.  
4.2.5.2. Second generation μCCA fabrication 
The chip pattern was first designed on CAD (Cadence), and the pattern was 
converted onto a chrome-coated glass mask via the 3600F optical pattern generator 
(D.W. Mann/GCA Corp.). Two masks were required for the two layers of fabrication, 
a 30 μm etch and a 100 μm etch.   
 In a furnace tube, silicon dioxide layers (93 nm thick) were grown on silicon 
<100> wafers at 1100oC under 8 L/min O2 flow and 0.24 L/min HCl flow. The wafers 
were covered with Shipley 1813 photoresist at a spin speed of 3000 rpm resulting in a 
1.3 μm-thick layer of photoresist. The pattern was transferred to the resist via a 4 
second UV light (405nm) exposure on an HTG contact aligner contact and subsequent  
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Figure 4.4. Photograph of the second generation chip μCCA. The dimensions of 
the chambers are as follows (w x l x d): liver (8.5 mm x 8.25 mm x 30 μm), fat (0.5 
mm x 115 mm x 100 μm), kidney (3.1 mm x 3.1 mm x 30 μm), and bone marrow 
(7.5 mm x 7.5 mm x 30 μm). The channels connecting compartments were 100 μm 
deep. The chip was designed so 41% of the flow went to the liver chamber, 35% 
went to the kidney chamber, 17% went to the bone marrow chamber, and 7% 
went to the fat chamber. The other poorly and well perfused tissues were 
represented by the external debubbler, which was a 200 μL well. 
development for 2 minutes. Residual resist was removed using oxygen plasma for 30 
seconds and the silicon dioxide layer was etched using a CHF3/O2 plasma for 15 
minutes at 40 mTorr, 50 sccm CHF3, 2 sccm O2, and 40% RF power. The channels 
were then etched with a DRIE process with the UNAXIS 770 until the depth measured 
30 μm. The resist and oxide were removed using resist remover 1165 and Buffered 
Oxide Etch 6:1 for 5 minutes, respectively. New silicon dioxide layers were grown 
using dry oxidation as described above. The wafers were then coated with Shipley 
STR 1045 photoresist at 1000 rpm and baked at 95oC, ramped up stepwise from 25oC 
in 8 minutes. The resist thickness was relatively non-uniform owing to the already 
etched channels, but in general measured between 10-12 μm. The second mask pattern 
was transferred to the wafer with UV light for 20 seconds using the HTG contact 
aligner ad developed for 6 minutes. Residual resist was removed using the same 
parameters described above. The second set of channels was etched using the DRIE 
process until the etch depth measured 100 μm. The resist was stripped with 1165 and 
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the channel depth checked again. If needed, the channels were etched for one or two 
more cycles to obtain an exact etch depth. The oxide layer served as an additional 
masking layer, since the resist is non-uniform and measurement of the etch depth with 
resist may vary on the position of measurement. Figure 4.4 shows a photograph of the 
second generation chip μCCA.  
 
Figure 4.5. Second generation GI tract μCCA device and assembly. The 
dimensions of the apical and basolateral chambers are as follows (diameter of the 
top of the chamber x height x diameter of the bottom of the chamber): apical 
chamber (0.8 mm x 0.8 mm x 2.8 mm) and basolateral chamber (2.8 mm x 0.8 
mm x 0.8 mm). The total area of Caco-2/HT29-MTX cells exposed to flow was 6.2 
mm2. 
The second generation GI tract μCCA was also fabricated from ½” thick 
plexiglass (McMaster-Carr) by Glenn Swann (School of Chemical and Biomolecular 
Engineering, Cornell University). The top and bottom pieces were machined to fit a 12 
mm diameter Snapwell insert. Identical chambers were etched into the top and bottom 
pieces on the surface that contacted the membrane holding intestinal epithelial cells. 
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The chambers were 0.8 mm deep, 2.4 mm in diameter on the side facing the cell 
membrane, and 0.8 mm in diameter where the inlet and out let holes were drilled. The 
top and bottom pieces had two-step inlet and outlet channels drilled with a diameter of 
740 μm (drill size number 69, Small Parts) for the top half of the channel and 610 μm 
(drill size number 73, Small Parts) for the bottom half of the channel. Figure 4.5 
shows the second generation GI tract μCCA assembly. 
4.2.6. μCCA toxicity experiments 
4.2.6.1. First generation μCCA toxicity experiments 
The bottom chambers of the GI tract μCCAs were first sterilized by soaking 
for 30 minutes in 70% EtOH and then placed in a 6-well plate. Polycarbonate, 0.4 μm 
pore size membranes were cut to 12 mm in diameter, sterilized by autoclaving in a dry 
cycle for 30 minutes, and placed in the bottom chamber. A sterile, 12 mm outer 
diameter (OD), 10 mm inner diameter (ID), 0.5 mm thick, silicone gasket was placed 
over the membrane (Grace Bio-Labs, Bend, OR, gasket was cut to the correct size 
from a silicone sheet). The membrane and gasket were held in place with a 12 mm 
OD, 10 mm inner diameter (ID) sterile washer. The membranes were coated with 8 
μg/cm2 Type I collagen dissolved in 0.02 M acetic acid for 1 hour and then washed 
with the same volume of PBS. Caco-2 cells were seeded onto the membranes at a 
concentration of 100,000 cells/cm2, allowed to attach for 2 hours at 37oC and 5% CO2, 
and then each well of the 6-well plate was filled with 3 mL DMEM. Caco-2 cells were 
grown on the membrane for 16 days prior to experiments to allow for full coverage of 
the membrane and cell differentiation.  
μCCA chips were cleaned with a solution of 70% sulfuric acid and 30% 
hydrogen peroxide (30% H2O2 solution) for 10 minutes at room temperature and then 
rinsed with DI water. After cleaning, 1 mm thick silicone gaskets (Grace Bio-Labs) 
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with holes cut out over the cell chambers were placed onto the chips to keep coating 
and cell suspensions within the proper compartments. The chips with gaskets over 
then were dried in an oven at 60oC for 30 minutes to seal the two together, and then 
both were autoclaved in a dry cycle for 30 minutes.  
The μCCA chips were first coated with 4 μg/cm2 poly-D-lysine in PBS for 5 
minutes at room temperature. The poly-D-lysine solution was removed from each 
chamber and each chamber was washed with an equal volume of PBS. The chips were 
then coated with 8 μg/cm2 fibronectin in PBS for 1 hour at room temperature. The 
fibronectin solution was removed, L2 cells were seeded into the lung chamber at a 
concentration of 200,000 cells/cm2, and HepG2/C3A cells were seeded into the liver 
chamber at a concentration of 250,000 cells/cm2. The chips were kept at 37oC and 5% 
CO2 for 4 hours to allow the cells to attach and then the Petri dish holding the chips 
was filled with 25 mL of DMEM/F12. Cells were grown for 48 hours before toxicity 
experiments. 
On the day of the toxicity experiments autoclaved, 0.25 mm ID diameter, 
Pharmed peristaltic pump tubing (Cole-Parmer, Vernon Hills, IL) was placed into a 
peristaltic pump (205S, Watson Marlow, Wilmington, MA) and DMEM/F12 was 
pumped at 10 rpm through the tubing to remove air bubbles. Tips from 200 μL gel 
loading tips (Fisher Scientific, Hampton, NH) were inserted into the ends of the 
peristaltic pump tubing and these tips fit securely into the inlet and outlet holes of the 
top and bottom pieces of the GI tract μCCA and plexiglass housing around the chip 
μCCA.  
The GI tract μCCAs were assembled by placing a 0.5 mm thick gasket on the 
outer edge of the bottom piece and screwing the top and bottom pieces together tightly 
with the membrane holding Caco-2 cells in between the two pieces. The pump flow 
rate was decreased to 0.75 rpm or approximately 3.5 μL/min, and tubing from one 
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pump channel was used for the GI tract μCCA apical or top inlet and tubing from a 
second pump channel was used for the basolateral or bottom inlet. Once culture 
medium could be seen exiting the outlet channels on the apical and basolateral sides, 
tubing was also connected to the outlet channels. Medium was pumped through the GI 
tract μCCAs during chip assembly (~1 hour) to rid the devices of air bubbles.  
The silicone gaskets were peeled off the top of the chips and the chips were 
then placed between two pieces of 1/8” thick machined plexiglass that were screwed 
together tightly. The top pieces of plexiglass had two-step inlet and outlet holes (740 
μm for the top half and 610 μm for the bottom half) and were cleaned with 70% EtOH 
and treated with oxygen plasma in an Expanded Plasma Cleaner (Harrick Plasma, 
Ithaca, NY) for 1 minute before assembly to increase surface wettability and sterility 
[20]. The bottom pieces of plexiglass were etched with ~1.5 mm deep squares that 
were slightly larger than the chips. A 1 mm thick piece of silicone gasket (Grace Bio-
Labs) was placed into each of these cavities to allow for a tight seal between the top 
piece of plexiglass, chip, and bottom plexiglass piece. The bottom piece was sterilized 
by soaking in 70% EtOH for 30 minutes prior to assembly. After removing the 
silicone gasket from a chip, it was placed into the bottom plexiglass piece and 200 μL 
of MEM was pipetted on top of the chip. When pipetting MEM onto the chips, care 
was taken to remove any air bubbles in the liquid and to keep the liquid from spilling 
off of the chip and into the plexiglass chamber. The top plexiglass piece was then 
lowered straight down onto the chip, and the top and bottom pieces were screwed 
together.   
 After the chips were assembled, the outlet tubing from the basolateral side of 
the GI tract μCCA was connected to the liver inlet of the chip. Tubing from a third 
pump channel was attached to the lung inlet. 23-gauge, sterile, stainless steel needles 
were inserted into the tubing starts and ends. These needles were inserted into a well 
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from an 8-well strip plate (Corning) sealed with a silicone cover (996050MR, BioTech 
Solutions, Mt. Laurel, NJ), which acted as a 200 μL culture medium reservoir and 
debubbler. The basolateral side of the GI tract μCCA and chip shared one reservoir 
that contained only DMEM/F12. The apical side of the GI tract μCCA had a different 
reservoir that contained DMEM/F12 only (control) or DMEM/F12 +30 mM APAP.  
 The system was operated at 37oC and 5% CO2 for 6 hours. At the end of the 
experiments, cells were stained with calcein, a viability stain, and MCB, a glutathione 
(GSH) stain. DMEM/F12 containing 5 μM calcein and 80 μM MCB was circulated 
through the GI tract and chip μCCAs for 30 minutes at 37oC.  
4.2.6.2. Second generation μCCA toxicity experiments 
Polycarbonate, 0.4 μm pore size, 12 mm diameter Snapwell membranes were 
coated with 8 μg/cm2 Type I collagen dissolved in 0.02 M acetic acid for 1 hour and 
then washed with the same volume of PBS. Caco-2 and HT29-MTX cells at a 3:1 ratio 
(Caco-2:HT29-MTX) were seeded onto the membranes at a concentration of 100,000 
cells/cm2. The cells were grown on the membrane for 16 days prior to experiments to 
allow for full coverage of the membrane and cell differentiation. 
μCCA chips were cleaned with 70% sulfuric acid and 30% hydrogen peroxide 
(30% H2O2 solution) for 10 minutes at room temperature and then rinsed with DI 
water. A 1 mm thick silicone gasket (Grace Bio-Labs) with holes cut out over the 
corresponding cell chambers was placed onto the chips to keep coatings and cell 
suspensions within the proper compartments. The chips covered with gaskets were 
dried in an oven at 60oC for 30 minutes and autoclaved in a dry cycle for 30 minutes.  
The μCCA chips were coated with 4 μg/cm2 poly-D-lysine in PBS for 5 
minutes at room temperature. The poly-D-lysine solution was removed and each 
chamber was washed with an equal volume of PBS. The chips were next coated with 8 
μg/cm2 fibronectin in PBS for 1 hour at room temperature. The fibronectin solution 
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was removed, and HepG2/C3A cells were seeded into the liver chamber at a 
concentration of 250,000 cells/cm2. The chips were kept at 37oC and 5% CO2 for 4 
hours to allow the cells to attach and then the Petri dish holding the chips was filled 
with 25 mL of MEM. Cells were grown for 48 hours before toxicity experiments. 
Prior to toxicity experiments, autoclaved, 0.25 mm ID diameter, Pharmed 
peristaltic pump tubing (Cole-Parmer) was placed into a Watson Marlow 205S 
peristaltic pump and MEM was pumped at 10 rpm through the tubing. Tips from 200 
μL gel loading tips (Fisher Scientific), which fit securely into the inlet and outlet holes 
of the top and bottom pieces of the GI tract μCCA and plexiglass housing around the 
chip μCCA, were inserted into the ends of the peristaltic pump tubing.  
The GI tract μCCAs were assembled by placing first placing a sterile silicone 
gasket into the bottom GI tract μCCA piece. The gasket dimensions were 0.5 mm 
thick, 14 mm diameter, and there was a 4 mm diameter hole in the middle of the 
gasket corresponding in location to the etched chamber in the bottom piece (Grace 
Bio-Labs, gasket was cut to the correct size from a silicone sheet). The Snapwell 
membrane was then detached from the insert that held it suspended in the 6 well plates 
and the membrane was placed into the bottom chamber. A second sterile, silicone 
gasket (0.5 mm thick and 12 mm in diameter with a 4 mm diameter hold in the middle 
corresponding in location to the etched chamber in the top piece) was placed inside of 
the Snapwell membrane on top of the cell monolayer, and a third sterile, silicone 
gasket (1 mm thick, 14 mm ID, 40 mm OD) was placed on the outer edge of the 
bottom GI tract μCCA piece. The top and bottom pieces were then screwed together 
tightly with the membrane holding Caco-2 and HT29-MTX cells in between the two 
pieces. The pump flow rate was decreased to 0.75 rpm or approximately 3.5 μL/min, 
and tubing from one pump channel was used for the GI tract μCCA apical or top inlet 
and tubing from a second pump channel was used for the basolateral or bottom inlet. 
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Once culture medium could be seen exiting the outlet channels on the apical and 
basolateral sides, tubing was also connected to the chip outlet. Medium was pumped 
through the GI tract μCCAs during chip assembly (~1 hour) to rid the devices of air 
bubbles.    
The silicone gaskets were peeled off the top of the chips and the chips were 
then placed between two pieces of 1/8” thick machined plexiglass that were screwed 
together tightly. The top pieces of plexiglass had two-step inlet and outlet holes (740 
μm for the top half and 610 μm for the bottom half) and were cleaned with 70% EtOH 
and treated with oxygen plasma in an Expanded Plasma Cleaner (Harrick Plasma) for 
1 minute before assembly to increase surface wettability and sterility [20]. The bottom 
pieces of plexiglass were etched with ~1.5 mm deep squares that were slightly larger 
than the chips. A 1 mm thick piece of silicone gasket (Grace Bio-Labs) was placed 
into each of these cavities to allow for a tight seal between the top piece of plexiglass, 
chip, and bottom plexiglass piece. The bottom piece was sterilized by soaking in 70% 
EtOH for 30 minutes prior to assembly. After removing the silicone gasket from a 
chip, it was placed into the bottom plexiglass piece and 200 μL of MEM was pipetted 
on top of the chip. When pipetting MEM onto the chips, care was taken to remove any 
air bubbles in the liquid and to keep the liquid from spilling off of the chip and into the 
plexiglass chamber. The top plexiglass piece was then lowered straight down onto the 
chip, and the top and bottom pieces were screwed together.   
 After the chips were assembled, the outlet tubing from the basolateral side of 
the GI tract μCCA was connected to the inlet of the chip and a separate tube was 
connected to the outlet after medium began to pool at the outlet hole. 23-gauge, 
stainless steel needles were inserted into the tubing starts and ends. These needles 
were inserted into a well from an 8-well strip plate (Corning) sealed with a silicone 
cover (BioTech Solutions), which acted as a culture medium reservoir and debubbler. 
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The basolateral side of the GI tract μCCA and chip shared one reservoir that contained 
200 μL of MEM. The apical side of the GI tract μCCA had a different reservoir that 
contained 250 μL of MEM (control) or MEM +30 mM, 10 mM, 3 mM, or 1 mM 
APAP.  
 The system was operated at 37oC and 5% CO2 for 24 hours. At the end of the 
experiments, cells were stained with calcein, a viability stain, and MCB, a glutathione 
(GSH) stain. MEM containing 5 μM calcein and 80 μM MCB was circulated through 
the GI tract and chip μCCAs for 30 minutes at 37oC before imaging.  
4.2.7. In vitro digestion 
Acetaminophen toxicity experiments were also performed after subjecting the 
acetaminophen to an in vitro digestion and using the chyme mimic as the drug 
transport solution. The in vitro digestion/Caco-2 cell culture model was developed by 
Glahn et al. for studying iron bioavailability from food [21]. The compound of interest 
is subjected to an hour long pepsin digestion at 37oC and pH 2. The pepsin is then de-
activated by raising the pH to 5.5-6.5 with sodium bicarbonate, a pancreatin-bile 
solution is added to the mixture, the pH is readjusted to 7.0 with sodium bicarbonate, 
and the chyme mimic is placed in an insert over a Caco-2 monolayer. In the in vitro 
digestion/acetaminophen experiments, 30 mM, 10 mM, 3 mM, and 1 mM APAP were 
digested and a control, drug-free digest was also prepared. A 250 μL aliquot was 
placed into a third reservoir and the chyme mimic was circulated through the apical GI 
chamber for 2 hours. After two hours the apical chamber tubing was moved to a 
reservoir containing MEM with no drug, and 22 hours later cells were stained with 
calcein and MCB and imaged.    
4.2.8. Fluorescence microscopy and image analysis 
Fluorescent images were acquired with a Retiga CCD camera (Qimaging, 
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Burnaby, BC, Canada) mounted to an Olympus BX51 microscope (Olympus America 
Inc., Center Valley, PA) with a 10X objective. The microscope and camera were 
connected to a computer running the Image Pro Plus version 4.6 software package 
(Media Cybernetics Inc., Silver Springs, MD) in 12-bit grayscale format. Fluorescence 
from the calcein stain was collected with an EGFP cube (Ex 470/Em 610, Chroma 
Technology Corp., Rockingham, VT). Fluorescence from the MCB-GSH adduct was 
collected with a DAPI cube (Ex 360/Em 460). Both image types (calcein, MCB-GSH) 
were obtained in the same field of view; 2 images were taken for each lung 
compartment (first generation devices), 6 images were taken from each liver 
compartment (first and second generation devices), and 4 images were taken of the 
Caco-2/HT29-MTX monolayer (first and second generation devices). Images were 
analyzed for total area stained with Image Pro Plus software.      
4.2.9. HPLC analysis 
APAP concentration in experimental culture medium was determined using the 
protocol described by Wang et al. [22]. Briefly, 100 μL samples taken from the culture 
medium reservoirs were extracted with 100 μL of acetonitrile (first generation 
experiments) or 50 μL acetonitrile (second generation experiments) and centrifuged at 
3,000 rpm for 10 minutes. A 100 μL injection (first generation experiments) or 50 μL 
injection (second generation experiments) of the supernatant was used for 
determination of APAP and metabolites by reverse-phase HPLC analysis. 2-
acetamindophenol was used as an internal standard. A Waters 2690 separations 
module and Waters 996 photodiode array detector set at a wavelength of 254 nm were 
used (Waters Corporation, Milford, MA). Chromatogram analysis was performed 
using Millennium software (version 3.0, Waters). Separations were done on a 250 x 
4.6 mm, RP18, 5 μm XTerra® column (Waters, first generation experiments) or 250 x 
4.6 mm, 5 μm SUPELCOSILTM ABZ-Plus column (Supelco, Bellefonte, PA, second 
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generation experiments). APAP was eluted with 7% acetonitrile (v/v in water) with 
0.1% trifluoroacetic acid (v/v) at a flow rate of 1.8 mL/min. Comparison with APAP, 
2-acetamindophenol, acetaminophen glucuronide (APAP-GLUC), or acetaminophen 
sulfate (APAP-SULF) standards was used for APAP, internal standard, and metabolite 
identification and quantification. Figure 4.6 shows the standard elution times of 
APAP, 2-acetamindophenol, APAP-GLUC, and APAP-SULF.  
 
 
 
 
 
 
 
 
 
 
Figure 4.6. APAP, metabolite, and internal standard (IS) peaks. APAP and 
metabolites were eluted with 7% acetonitrile (v/v in water) with 0.1% 
trifluoroacetic acid (v/v) at a flow rate of 1.8 mL/min and a 250 x 4.6 mm, 5 μm 
SUPELCOSILTM ABZ-Plus column. The retention times are as follows: APAP-
GLUC, 3.2 minutes; APAP, 5.6 minutes; APAP-SULF, 7.2 minutes; and 2-
acetamindophenol (IS), 9.8 minutes.   
4.2.10. Physiologically based pharmacokinetic modeling 
 A PBPK model was developed for the distribution and metabolism of APAP in 
the human flow configuration (Figure 4.7A) and the second generation μCCA system 
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flow configuration (Figure 4.7B). The main purpose of this model was to aid in the 
development and design of the second generation μCCA system by validating the flow 
pattern. The organ or tissue volumes used in the simulations were obtained from 
Brown et al. [4]. Partition coefficients were calculated using the method described by 
Poulin and Theil, and the metabolic parameters for conversion of APAP to NAPQI, 
APAP-GLUC, and APAP-SULF in the liver were obtained from Patten et al. and 
Watari et al. [10, 23, 24]. The PBPK ordinary differential equations were solved with 
MATLAB version 7.1 (MathWorks, Natick, MA) using a fourth and fifth order 
Runge-Kutta-Fehlberg integration method. The PBPK code is shown in Appendix C.  
 
Figure 4.7. The physiologically correct, human blood flow pattern (A) and the 
medium flow pattern through the second generation μCCA system (B).  
4.2.11. Statistical analysis 
Results are expressed as mean ± standard error. Data was analyzed with 
GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA). An 
unpaired Students’s t-test or a one-way ANOVA with Tukey’s post test was used to 
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compare differences between means and data was transformed when necessary to 
obtain equal sample variances.  Differences were considered significant at p < 0.05. 
4.3. First generation μCCA results 
4.3.1. Design of the μCCAs  
 
Figure 4.8. Photograph of the first generation chip and GI tract μCCA 
experimental set-up (A) and a PBPK schematic of the flow pattern (B).  
Figure 4.7 shows a photograph of the chip and GI tract μCCA system. Three 
channels were used on the peristaltic pump for the two devices. The first channel 
pumped DMEM/F12 or DMEM/F12 +30 mM APAP through the apical chamber of 
the GI tract μCCA at ~3.5 μL/min. After the medium passed through the apical 
chamber of the GI tract μCCA, it recirculated to a reservoir containing 200 μL of 
DMEM/F12 or DMEM/F12 +30 mM APAP. The second channel pumped 
DMEM/F12 at ~3.5 μL/min into the lung chamber on the chip μCCA. After the 
culture medium passed through the lung chamber, 85% of the liquid went to the other 
tissues chamber and 15% went to the liver chamber. The third pump channel was used 
to pump liquid at ~3.5 μL/min into the basolateral side of the GI tract μCCA. All 
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liquid from the basolateral outlet of the GI tract μCCA then went through a second 
inlet to the liver chamber, mimicking first pass metabolism. The culture medium from 
the liver and other tissues chambers combined at the chip outlet and returned to a 
second reservoir containing 200 μL DMEM/F12 before being re-circulated to the lung 
and basolateral GI tract inlets. Table 4.1 compares the physiological parameter values 
for rat with those of the GI tract and chip μCCAs. The chip chambers and channels 
were designed so that the pressure drop was the same for each, allowing for a passive 
fluid flow split.  
 
Table 4.1. Comparison between rat physiological parameter and μCCA design 
parameter values for the first generation μCCA system. Values for rat body 
weight, regional blood flow distribution, and organ residence times were taken 
from Brown et al. [4]. GI flow rates for the μCCA represent flow through the 
basolateral GI tract μCCA chamber.   
 
 
4.3.2. Cell line selection  
The L2 rat lung cell line was used to imitate the lung, a toxicity target tissue [6, 
25]. L2 cells possess many of the characteristics of primary rat type II lung epithelial 
cells, including glutathione-S-transferase activity [26]. The HepG2/C3A cell line, 
which is a subclone of the HepG2 cell line, was used as a model for the liver. This cell 
line has detectable CYP1A and 2E1, UDP-glucuronyltransferase, sulfotransferase, and 
glutathione-S-transferase activity [27]. The Caco-2 cell line was used to mimic the 
intestinal epithelium. When seeded onto Type I collagen-coated inserts or culture 
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plates under normal culture conditions, Caco-2 cells differentiate into a polarized, 
enterocyte-like epithelial barrier that is morphologically and biochemically very 
similar to the small intestinal epithelium [28]. After a growth period of two to three 
weeks, the Caco-2 monolayers express tightly packed microvilli, tight junctions, and 
are capable of paracellular, transcellular, active, and transcytotic transport [29]. Type I 
collagen is used to model the epithelial basement membrane because it has been found 
to best stimulate proliferation, cell spreading, and differentiation in static Caco-2 
cultures [30]. Caco-2 cells also express CYP1A, 2E1, UDP-glucuronyltransferase, 
sulfotransferase, and glutathione-S-transferase [31-33]. 
4.3.3. CYP1A and CYP2E1 activity 
Figure 4.9. Metabolizing cell line CYP2E1 (A) and CYP1A (B) activity (n = 32). 
 The CYP1A and 2E1 activity of HepG2/C3A and Caco-2 cells was assessed 
using a fluorescent and colorimetric substrate (Figure 4.9). CYP2E1 activity is 
expressed as μM 4-nitrocatechol formation/mg cell protein/hr and CYP1A activity is 
expressed as μM resorufin formation/mg cell protein/hr. Both cell lines have 
detectable CYP1A and CYP2E1 activity under the culture conditions used for these 
experiments, although the values are much lower than those found in humans [27, 32].   
 120 
4.3.4. μCCA acetaminophen toxicity  
Culture medium with 30 mM APAP was pumped through the apical chamber 
of the GI tract μCCA for 6 hours. Culture medium without drug was pumped through 
the basolateral chamber of the GI tract μCCA and chip μCCA, therefore drug had to 
diffuse through the Caco-2 cell monolayer to reach the chip. After the 6-hour 
experiments, cells were stained with calcein and MCB to indicate viable cells and 
glutathione levels, respectively. Control experiments were run simultaneously without 
APAP in the GI tract μCCA apical chamber.  
Figure 4.10. HepG2/C3A and L2 viability (A) and glutathione levels (B) after 
culture medium with 30 mM APAP was pumped through the apical chamber of 
the first generation GI tract μCCA for 6 hours. Controls had only culture 
medium pumped through the apical GI tract μCCA chamber. Values are 
expressed as a percent of control ± SEM. Differences in viability or glutathione 
levels between cells exposed to APAP and controls that are significant according 
to an unpaired Student’s t-test are indicated with a * (p < 0.05, n = 3). 
Figure 4.10A shows the cell viability results as a percent of control. The 
viability of HepG2/C3A cells decreased to 56% of the control and the viability of L2 
cells decreased to 18% of the control. Figure 4.10B shows the cell glutathione levels 
as a percent of control. The HepG2/C3A glutathione levels decreased to 45% of the 
control and the L2 glutathione levels decreased to 10% of the control. Figure 4.11 
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shows the control (Figures 4.11A and 4.11C) and 30 mM APAP treated (Figures 
4.11B and 4.11D) HepG2/C3A and L2 cells on the chip. The Caco-2 images were 
taken through ½” etched plexiglass, which did not allow for images that were of high 
enough quality for analysis. The Caco-2 cells were viable and the monolayers did 
remain intact in controls and after APAP exposure (data not shown).    
 
Figure 4.11. Comparison of control (A) and 30 mM APAP treated (B) 
HepG2/C3A cells and control (C) and 30 mM APAP treated (D) L2 cells on the 
chip μCCA after a 6 hour experiment where culture medium (control) or 30 mM 
APAP was pumped through the apical chamber of the GI tract μCCA. 
 HPLC analysis of the apical and basolateral GI tract μCCA culture medium 
revealed that the concentration of APAP in the basolateral chamber, and, therefore the 
medium circulating through the chip, reached 10 ± 2.6 mM. The APAP concentration 
in culture medium in the apical chamber decreased from 30 mM to 13 ± 3.1 mM after 
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the 6 hour experiment.  
Experiments with only the chip μCCA were run with DMEM/F12 +30 mM 
APAP re-circulating for 6 hours. These experiments were done to determine the 
effects of adding the GI tract μCCA to the system. The result was 100% cell death for 
both HepG2/C3A and L2 cells (data not shown). 
4.4. Second generation μCCA results 
4.4.1. Design of the μCCAs  
 
Figure 4.12. Photograph of the second generation chip and GI tract μCCA 
experimental set-up (A) and a PBPK schematic of the flow pattern (B). 
Figure 4.12 shows a photograph of the connected second generation chip and 
GI tract μCCAs. Two channels were used on the peristaltic pump for the two devices. 
The first channel pumped MEM or MEM +30 mM, 10 mM, 3 mM, or 1 mM APAP 
through the apical chamber of the GI tract μCCA at ~3.5 μL/min. After the medium 
passed through the apical chamber of the GI tract μCCA, it returned to a reservoir 
containing 250 μL of MEM or MEM +APAP. The second channel pumped MEM at 
~3.5 μL/min into the chip inlet. The flow immediately split after entering the chip and 
41% of the flow went to the liver chamber, 35% went to the kidney chamber, 17% 
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went to the bone marrow chamber, and 7% went to the fat chamber. The culture 
medium chambers combined at the chip outlet and returned to a second reservoir 
containing 200 μL MEM before being recirculated to the basolateral GI tract inlet. 
Table 4.2 compares the physiological parameter values for humans with those of the 
μCCA. The chip chambers and channels were designed so that the pressure drop was 
the same for each, allowing for a passive fluid flow split. Design calculations are 
shown in Appendix B. 
 
Table 4.2. Comparison between human physiological parameter and μCCA 
design parameter values for the second generation μCCA system. Values for 
human body weight, regional blood flow distribution, and organ residence times 
were taken from Brown et al. [4]. GI flow rates for the μCCA represent flow 
through the basolateral GI tract μCCA chamber.   
 
The practical design of a μCCA system requires that well perfused and poorly 
perfused tissues or organs not included in the study are lumped together with the 
plasma compartment as shown in Figure 4.7. Organs or tissues should be grouped 
together based on characteristics such as perfusion, drug or chemical partitioning, and 
metabolism, and can then be considered mathematically as a functionally equivalent 
bulk average [34].  Design constraints can also require that the medium flow pattern in 
μCCAs is modified from the physiologically correct blood flow pattern. In the second 
generation device, for example, the need to eliminate multiple inlets and outlets on the 
chip μCCA prevented a design that accurately mimicked first pass metabolism (i.e. all 
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culture medium from the GI tract μCCA flows directly to the liver compartment). The 
impact of lumping and changes to the flow pattern on chemical or drug 
pharmacokinetics can be examined by creating representative PBPK models.  
Figure 4.13. Comparison of PBPK predicted APAP distribution in the liver 
chamber for a human flow configuration and the second generation μCCA 
system flow configuration after a 1mM oral APAP dose. The APAP area under 
the curve (AUC) of the human configuration is 92% of the chip μCCA 
configuration APAP AUC after 24 hours.   
Figure 4.13 shows the results of PBPK predicted APAP distribution to the liver 
compartment after a 1 mM oral dose for a physiologically correct flow structure and 
for the second generation μCCA system flow structure. These results show that for 
both configurations the maximum APAP concentration is reaches after 1 hour. In the 
chip μCCA configuration the APAP concentration rapidly decreases in the liver 
compartment over hours 2-3 and then gradually decreases for the remaining 21 hours, 
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while in the human configuration there is a steady APAP concentration decrease over 
hours 2-24 in the liver compartment. The area under the curve (AUC), which 
corresponds to the total drug exposure, for the human configuration liver compartment 
was 92% of the chip configuration liver compartment AUC after 24 hours. This means 
that both configurations receive approximately the same APAP dose over a 24 hour 
period.    
4.4.2. Cell line selection  
The HepG2/C3A cell line, which has detectable CYP1A and 2E1, UDP-
glucuronyltransferase, sulfotransferase, and glutathione-S-transferase activity, was 
used to model the liver [27]. Co-cultures of the Caco-2 and HT29-MTX cell lines were 
used to mimic the absorptive entrocyte and mucus-secreting goblet cells of the 
intestinal epithelium, respectively. Caco-2 cells differentiate into a polarized, 
absorptive enterocyte-like epithelial barrier that is morphologically and biochemically 
very similar to the small intestinal epithelium [28]. HT29-MTX cells are a 
subpopulation of HT29 human colonic adenocarcinoma cells selected for resistance to 
methotrexate (MTX) that consist exclusively of differentiated, mucus-secreting, 
goblet-like cells that retain their differentiated phenotype after reversion to MTX-free 
medium [14]. Caco-2 cells have been shown to express CYP1A, CYP2E1, UDP-
glucuronyltransferase, sulfotransferase and glutathione-S-transferase [31-33]. 
4.4.3. μCCA acetaminophen toxicity  
Culture medium with APAP was pumped through the apical chamber of the GI 
tract μCCA for 24 hours. Culture medium without drug was pumped through the 
basolateral chamber of the GI tract μCCA and chip μCCA, therefore drug had to 
diffuse through the Caco-2/HT29-MTX cell monolayer to reach the chip. In 
experiments including digested APAP, chyme mimic contained drug was circulated 
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through the apical chamber for two hours, and then MEM with no drug was circulated 
through the apical chamber for the remaining 22 hours. After the 24-hour experiments, 
cells were stained with calcein and MCB to indicate viable cells and glutathione 
levels, respectively. Control experiments were run simultaneously without APAP in 
the GI tract μCCA apical chamber. In experiments including digestion, chyme mimic 
with no drug was circulated through control apical chambers for 2 hours, and MEM 
with no drug was circulated through the apical chamber for the remaining 22 hours. 
Viability and glutathione levels for liver cells are shown below. Glutathione levels are 
shown for the Caco-2/HT29-MTX monolayers. Calcein stain was used in the Caco-
2/HT29-MTX monolayers to visualize monolayer integrity, and results were discarded 
if the monolayers did not remain intact.  
Figure 4.14. HepG2/C3A viability (A) and glutathione levels (B) after culture 
medium with APAP was pumped through the apical chamber of the second 
generation GI tract μCCA for 24 hours. Controls had only culture medium 
pumped through the apical GI tract μCCA chamber. Values are expressed as 
mean ± SEM. Bars with no letter in common are significant according to a one-
way ANOVA with Tukey’s post test (p < 0.05, n = 3). 
The results in Figure 4.14 show that as the concentration of APAP in the apical 
GI chamber increases, the viability and glutathione concentration of the cells in the 
liver compartment decreases. The glutathione levels also decreased with increasing 
APAP concentration in the Caco-2/HT29-MTX membranes (Figure 4.15). Figure 4.16 
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shows representative photographs of HepG2/C3A cells after a 24 hour exposure to 
APAP in GI tract μCCA apical chamber culture medium. 
Figure 4.15. (A) A representative photograph of the Caco-2/HT29-MTX 
monolayer after a 24 hour exposure to APAP and staining with calcein. Calcein 
was used only to determine if the monolayer was intact and not for viability 
analysis. (B) Caco-2/HT29-MTX glutathione levels after culture medium with 
APAP was pumped through the apical chamber of the second generation GI tract 
μCCA for 24 hours. Controls had only culture medium pumped through the 
apical GI tract μCCA chamber. Values are expressed as mean ± SEM. Bars with 
no letter in common are significantly different according to a one-way ANOVA 
with Tukey’s post test (p < 0.05, n = 3). 
 
Figure 4.16. Representative photographs of HepG2/C3A liver cells after a 24 
hour exposure to APAP in the GI tract μCCA apical chamber culture medium. 
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Figure 4.17. (A) APAP, (B) APAP-GLUC, and (C) APAP-SULF concentration 
after 24 hours in the apical GI reservoir (AP) and the basolateral GI/chip 
reservoir (BA). Values are expressed as mean ± SEM. Bars with a * are 
significant according to a one-way ANOVA with Tukey’s post test (p < 0.05, n = 
3). 
Figure 4.17 shows the APAP and APAP metabolite concentration after 24 
hours in the apical GI reservoir and the basolateral GI/chip reservoir. The APAP 
concentration was generally lower in the basolateral/chip reservoir, but this difference 
was statistically significant only for the 1 mM and 3 mM concentrations. The 
formation of APAP-GLUC remained fairly constant for all of the APAP 
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concentrations. This suggests that the UDP-glucuronyltransferase-catalyzed reaction 
was close to saturated even at low APAP exposure. The sulfotransferase activity was 
found to be much higher in these cell lines. The formation of APAP-SULF was 
approximately 13 times greater in the 30 mM apical chamber when compared with 
APAP-GLUC, and APAP-SULF formation generally decreased in the apical and 
basolateral chambers with decreasing APAP concentration, suggesting that at lower 
APAP concentrations this enzyme was not saturated.   
 
Figure 4.18. Results of HPLC analysis for a time course experiment with devices 
exposed to 10 mM APAP. (A) APAP, (B) APAP-GLUC, and (C) APAP-SULF 
concentrations at 2, 6, 12, and 24 hours (n = 1). 
A time course experiment was performed with devices exposed to 10 mM 
APAP. The devices were disassembled at 2, 6, 12, and 24 hours to determine APAP 
and metabolite concentration in the apical and basolateral chambers. These results are 
shown in Figure 4.18. The concentration of APAP in the basolateral/chip reservoir 
gradually increased over the 24 hour period, but never reached equilibrium with the 
apical chamber. The formation of APAP-GLUC reached saturation after 6 hours in the 
basolateral chamber and chip, and decreased in the apical chamber after the first time 
point. APAP-SULF formation increased over the 24 hour period in the apical chamber 
and basolateral chamber/chip.  
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4.4.4. μCCA digested acetaminophen toxicity 
Figure 4.19. HepG2/C3A viability (A) and glutathione levels (B) after digested 
APAP was pumped through the apical chamber of the second generation GI tract 
μCCA for 2 hours followed by culture medium with no drug for 22 hours. 
Controls had chyme mimic with no APAP circulated through the apical GI tract 
μCCA chamber for 2 hours followed by culture medium with no drug for 22 
hours. Values are expressed as mean ± SEM. Bars with no letter in common are 
significant according to a one-way ANOVA with Tukey’s post test (p < 0.05, n = 
3). 
 
 
 
 
 
 
Figure 4.20. Caco-2/HT29-MTX glutathione levels after digested APAP was 
pumped through the apical chamber of the second generation GI tract μCCA for 
2 hours followed by culture medium with no drug for 22 hours. Controls had 
chyme mimic with no APAP circulated through the apical GI tract μCCA 
chamber for 2 hours followed by culture medium with no drug for 22 hours. 
Values are expressed as mean ± SEM. Bars with no letter in common are 
significant according to a one-way ANOVA with Tukey’s post test (p < 0.05, n = 
3). 
Figures 4.19 and 4.20 show the results for experiments with digested APAP. 
As the APAP concentration in the apical chamber increased, the viability of liver cells 
and the glutathione levels of liver cells and Caco-2/HT29-MTX cells decreased 
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significantly. Digestive enzymes in the chyme mimic did affect the viability of the 
liver cells, as the control viability for digestion experiments (Figure 4.19) was lower 
when compared with the control viability for experiments were only culture medium 
was circulated through the devices (Figure 4.14). 
 
Figure 4.21. (A) APAP, (B) APAP-GLUC, and (C) APAP-SULF concentration 
for digested APAP after 24 hours in the apical GI reservoir (AP) and the 
basolateral GI/chip reservoir (BA). Values are expressed as mean ± SEM. 
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Figure 4.21 shows the APAP and APAP metabolite concentration after 24 hour 
experiments with digested APAP. The concentration of APAP in the apical and 
basolateral chambers was lower when compared with previous experiments where 
MEM containing APAP was circulated through the apical chamber for 24 hours. 
When the chyme mimic containing 30 mM APAP was used, for example, the 
concentration of APAP in the apical chamber and basolateral chamber/chip reached 
~3.5 mM after 24 hours. There was no significant difference between the apical 
chambers and basolateral chambers/chips, which means that the APAP concentration 
reached equilibrium between the apical chambers and basolateral chambers/chips after 
24 hours for all concentrations tested. The formation of APAP-GLUC decreased for 
lower APAP concentrations tested, which shows that at APAP concentrations lower 
than 1 mM UDP-glucuronyltransferase is not saturated. APAP-SULF formation was 
much greater than APAP-GLUC formation, and APAP-SULF generally decreased in 
the apical chamber and basolateral chamber/chip with decreasing APAP 
concentration. 
Figure 4.22. Results of HPLC analysis for a time course experiment with devices 
exposed to 10 mM digested APAP. (A) APAP, (B) APAP-GLUC, and (C) APAP-
SULF concentration at 2, 6, 12, and 24 hours (n = 1). 
Results from a time course experiment with 10 mM digested APAP are shown 
in Figure 4.22. The devices were disassembled at 2, 6, 12, and 24 hours to determine 
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APAP and metabolite concentration in the apical and basolateral chambers. The 
concentration of APAP in the basolateral/chip reservoir was very close to the 
concentration of APAP in the apical chamber by 12 hours, and equilibrium was 
reached by 24 hours. The formation of APAP-GLUC was relatively low and 
approximately the same in the apical chamber and basolateral chamber/chip. APAP-
SULF formation increased over the 24 hour period in the apical chamber and 
basolateral chamber/chip at about the same rate.  
Figure 4.23. HepG2/C3A viability (A) and glutathione levels (B) after 5.7% or 
1.9% ethanol was pumped through the apical chamber of the second generation 
GI tract μCCA for 24 hours. Controls had culture medium with no APAP 
circulated through the apical GI tract μCCA chamber for 24 hours. Values are 
expressed as mean ± SEM. Bars with a * are significant according to a one-way 
ANOVA with Tukey’s post test (p < 0.05, n = 3). 
APAP is not soluble in water and was dissolved at a concentration of 0.5 M in 
95% ethanol before dilution in MEM or digestion. At high concentrations of APAP, 
this resulted in a significant amount (5.7% at 30 mM and 1.9% at 10 mM) of ethanol 
in the culture medium. Control experiments were performed to determine the effects 
of ethanol on liver cell viability, and these results are shown in Figure 4.23. It was 
found that there was significant cell death caused by 5.7% (v/v) ethanol 
(approximately 17%), but liver cells exposed to 1.9% ethanol were not significantly 
affected.    
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4.5. Discussion 
Oral delivery is the preferred route of pharmaceutical administration due to the 
relatively low medical costs and relatively high patient comfort, compliance and 
convenience; but the intestinal wall acts as a biological barrier that both limits the 
uptake of and biotransforms drugs [35, 36]. Biotransformation occurs during 
transcellular absorption when pharmaceuticals come in contact with phase I and phase 
II enzymes [37]. The most notable phase I enzymes belong to the cytochrome P450 
superfamily which oxidize compounds, especially chemicals or drugs that are 
hydrophobic and relatively insoluble, to form a reactive intermediate [38]. The 
reactive intermediate is then susceptible to conjugation by a phase II enzyme such as 
UDP-glucuronyltransferase, sulfotransferase, or glutathione-S-transferase [37]. The 
resulting conjugate is usually pharmacologically inactive and less lipid soluble than its 
precursor, allowing the conjugate to be excreted in bile or urine [38]. 
The membrane lining the small intestine is composed of two main cell types: 
enterocyte and goblet. Absorptive enterocytes make up about 90% of the cell 
population in the upper intestine, display very tight intracellular junctions, and are 
covered with 1 μm long, tightly packed projections called microvilli [39]. Microvilli 
further increase the surface area of the intestine available for absorption. The 
absorptive cells allow the passage of small molecules by one or more of four different 
routes: passive transcellular (through the cell), passive paracellular (between cells), 
active (energy-dependent) carrier-mediated and transcytosis (transport across the 
epithelium with uptake into coated vesicles) [40]. Any material that is absorbed in the 
intestine must first diffuse across the mucus layer, the epithelial cells lining the 
intestine, the lamina propria, and the endothelial cells that line the capillaries, but the 
epithelial cell layer has been shown to be the rate-limiting step [41]. Caco-2 cells 
mimic absorptive enterocytes, which are the most populous cells in the intestinal 
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epithelium. Caco-2 cells also develop tight junctions, possess microvilli, can transport 
small molecules by all four major transport routes, and express many phase I and 
phase II enzymes [29, 31-33].  These qualities, along with the fact that epithelial cell 
layer has been shown to be the most significant barrier to oral absorption; make Caco-
2 cells an appropriate model for oral absorption studies. 
APAP is a weak organic acid (pKa = 9.7) that is not ionized at pH 7 [38]. 
Because APAP is a small molecule and non-ionized at a physiological pH, it is able to 
passively diffuse through the small intestinal cell membrane. Passive diffusion of a 
drug involves the movement of drug molecules down a concentration gradient without 
the expenditure of energy; the rate of penetration of a drug across a membrane is 
related to the concentration gradient by Fick’s Law [38]. 
APAP is also one of the most widely used analgesic and antipyretic drugs by 
children and adults worldwide, and the pharmacological side effects are thought to be 
based on the inhibition of prostaglandin synthesis [8, 42]. Therapeutic doses of 
immediate release APAP preparations are normally absorbed from the GI tract within 
one hour, while peak serum concentrations in acute overdose may be delayed for up to 
four hours [42]. A common tool that is used to predict potential hepatotoxic 
acetaminophen effects is the Rumack-Matthew scale [43]. The nomogram has a line 
from 200 mg/L serum APAP concentration at 4 hours to 50 mg/L at 12 hours after 
APAP overdose. Untreated patients with a serum APAP concentration above the line 
are considered at risk for hepatic damage. A 200 mg/L serum concentration is 
approximately 1 mM, which was the lowest APAP concentration tested with the 
μCCA devices.  
At therapeutic levels APAP is generally considered safe, but high doses cause 
liver cell necrosis [44]. The liver toxicity is due to CYP bioactivation of APAP to a 
reactive metabolite, NAPQI [10]. The lung is also one of the major targets for 
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exposure to xenobiotics because it receives 100% of cardiac output, and in humans 
lung injury is a common result of APAP overdose [45, 46]. Studies with rat type II 
pneumocytes and alveolar macrophages suggest that CYP and/or prostaglandin 
synthetase are involved in APAP lung toxicity [47].  
With the first generation GI tract μCCA we describe a prototype in vitro 
system that for the first time, although at a very basic level, mimics oral exposure to a 
drug, first pass metabolism, and the circulation of metabolites on a microscale. These 
results demonstrate that APAP can cross the Caco-2 cell monolayer and damage cells 
in the liver and lung compartments. The GI tract μCCA minimizes the toxicity of the 
APAP dose and acts as a barrier, however, as 30 mM APAP running through only the 
chip μCCA resulted in 100% cytotoxicity and the final concentration of APAP in the 
chip μCCA run together with the GI tract μCCA was approximately 10 mM. The GI 
tract μCCA could be minimizing the toxicity in one or a combination of the following 
ways: the concentration of the APAP could quickly reach near-equilibrium between 
the two μCCAs, and the extra medium flowing through the GI tract μCCA could 
dilute the concentration to a less toxic concentration; the Caco-2 cells could 
metabolize some of the drug into harmless compounds, preventing some of the APAP 
from reaching the liver and lung compartments; and/or the Caco-2 monolayer may 
truly act as a barrier and the drug may slowly diffuse into the basolateral chamber.  
The primary markers for cell toxicity in the first generation μCCA system 
experiments were glutathione depletion and cell viability. After a 6 hour exposure to 
APAP approximately half of the liver cells remained, while only about 20% of the 
lung cells remained viable (Figure 4.10A). The APAP dose was less toxic to the 
HepG2/C3A cells, which does not mimic in vivo results. The L2 cell line, however, 
expresses fewer phase II enzymes than the HepG2/C3A cell line. The viability results 
were most likely due to the increased phase II enzyme activity of HepG2/C3A cells 
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when compared with the L2 cell line. The HepG2 cells were presumably able to 
detoxify a larger amount of APAP via the glucuronide and sulfation pathways. The 
glutathione levels in each cell compartment correlated with the number of viable cells 
remaining after the 6 hour APAP dose (Figure 4.10B). Caco-2 cells remained viable 
and the monolayers remained intact after a 6-hour, 30 mM APAP exposure (data not 
shown).  
The first generation chip and GI tract μCCAs provide a framework for 
studying oral drug absorption and metabolism, but the system has several limitations. 
The chip was designed to mimic first pass metabolism in that all fluid circulating 
through the GI tract goes directly to the liver, but is diluted with fluid pumped directly 
to the liver. In order to achieve this effect two pump channels and two μCCA chip 
inlets were necessary. The peristaltic pump can only be run at a single flowrate, 
therefore the amount of medium pumped through the basolateral side of the GI tract 
μCCA was higher than desired and resulted in residence times that did not match 
physiological values. If the channel pumping to the basolateral chamber could have 
been run at 0.5 μL/min, for example, the residence times in the basolateral chamber 
and liver chamber would have been much closer to in vivo values. The two-inlet 
design of the chip and the addition of the GI tract μCCA made it very difficult to 
assemble and run the devices without letting air into the system. Air bubbles in the 
system often caused leakage and/or loss of cell viability [48], and experimental results 
from systems with an excessive amount of air bubbles had to be discarded. This issue 
with air bubbles necessitated the short experimental time frame (there were fewer 
problems with air bubbles during shorter experiments) and high drug concentrations 
(more physiologically relevant APAP concentrations did not have a noticeable effect 
on cells after only 6 hours). 
These problems led to several improvements that were incorporated into the 
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second generation μCCA system (Figures 4.4 and 4.5). The second generation chip 
μCCA was designed with one inlet and outlet to reduce the amount of air that enters 
the system, which allowed for longer experiments and more physiologically realistic 
APAP concentrations. Goblet-like, mucus secreting cells were incorporated into the 
GI tract μCCA membrane to better mimic the cell composition in vivo. HPLC was 
used to determine the APAP and metabolite concentrations at different time points 
throughout the experiment. Finally, in vitro digestion of APAP was performed and this 
chyme mimic was pumped through the apical chamber of the GI tract, which better re-
creates the absorption conditions in the upper small intestine. 
The results generated using the second generation GI tract and chip μCCAs 
demonstrate that liver and intestinal epithelial cells in the chip and GI tract μCCAs 
respond to APAP in a dose dependent manner for APAP in culture medium or chyme 
mimic (Figures 4.14, 4.15, 4.19, and 4.20). As the concentration of APAP in culture 
medium or chyme mimic circulated through the apical chamber of the GI tract μCCA 
increased, the viability of the liver cells and the glutathione levels of the liver and 
intestinal epithelial cells decreased. Some decrease in cell viability was due to ethanol, 
the APAP solvent, for the 30 mM concentration (Figure 4.23). The formation of 
APAP-GLUC appeared to be saturated even at the lowest APAP concentrations, but 
the formation of APAP-SULF increased with increasing APAP dose (Figures 4.17 and 
4.21). 
When APAP was circulated through the second generation apical GI μCCA 
chamber in MEM for 24 hours the concentrations of APAP in the apical chamber and 
basolateral/chip chamber reached near equilibrium after 24 hours for the 30 mM and 
10 mM concentrations (Figure 4.17). For the 3 mM and 1 mM concentrations the 
apical concentration was significantly higher than the basolateral chamber/chip 
concentration after 24 hours (Figure 4.17). The time course experiment with 10 mM 
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APAP showed that the APAP concentrations in the two chambers did not reach 
equilibrium until after the 12 hour time point (Figure 4.18). In this system absorption 
of APAP most likely occurs via passive diffusion down a concentration gradient, 
therefore complete absorption would mean that the concentration in the apical 
chamber and basolateral chamber/chip are equal. In vivo, APAP is completely 
absorbed within 1 hour at therapeutic doses. Peak serum concentrations in acute 
overdose, however, may be delayed for up to four hours, which means that complete 
absorption would be expected within 5-6 hours [42]. Passively diffused drugs diffuse 
through the intestinal epithelium at a constant rate, and the transport of passively 
diffused drugs through Caco-2 monolayers has been shown to correlate well with in 
vivo data [49]. Therefore one likely reason that APAP takes 2-3 times longer to reach 
equilibrium in the μCCA is the lower amount of surface area available for absorption 
in the device when compared with the small intestine in vivo. In future work, the 
surface area available for absorption could easily be increased in the devices.  
When APAP was circulated through the apical GI chamber in chyme mimic, 
the APAP concentration in the apical chamber and basolateral chamber/chip reached 
near equilibrium after 24 hours for all concentrations studied (Figure 4.21). The time 
course experiment with 10 mM APAP showed that the APAP concentrations in the 
two chambers reached equilibrium by approximately 12 hours (Figure 4.22). The most 
likely explanation for why the system reached equilibrium more quickly when 
digested APAP was used is that the chyme mimic slightly damaged the Caco-2/HT29-
MTX monolayer. This may have compromised the tight junctions and resulted in more 
drug passing through the monolayer. 
In conclusion, a prototype GI tract μCCA has been developed and used 
together with a chip μCCA to demonstrate digestion, absorption through the intestinal 
epithelium, and metabolism by the liver. The μCCA system can overcome many of the 
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drawbacks found in traditional drug testing methods. Multiple cell types and re-
circulating medium allow researchers to analyze the absorption and the systemic 
effects of the compound being studied and the effects of its metabolites in a way that 
mimics the dynamic, time dependent changes in drug concentration and metabolites 
after oral administration. Human cells can be used in the μCCAs, offering a superior 
method for predicting a potential drug’s effect on humans and sparing animals. The 
μCCAs are also inexpensive to produce and use very little of the compound of 
interest. The development and incorporation of a physiologically realistic GI tract 
μCCA may offer a new tool to help understand the kinetics of orally delivered drug 
ADMET, to aid in the development of oral delivery strategies, to help to find correct 
oral dosages for new pharmaceuticals, and to potentially better predict the systemic 
toxicity of orally delivered drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 141 
REFERENCES 
 
1. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: New 
estimates of drug development costs. Journal of Health Economics. 22(2):151. 
 
2. Agres T. 2005. Finding blockbusters a struggle. Drug Discovery & Development. 
8(3):16-19. 
 
3. Sankar U. 2005. The delicate toxicity balance in drug discovery. The Scientist. 
19(15):32-34. 
 
4. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. 1997. Physiological 
parameter values for physiologically based pharmacokinetic models. 
Toxicology and Industrial Health. 13(4):407-484. 
 
5. Sin A, Chin KC, Jamil MF, Kostov Y, Rao G, Shuler ML. 2004. The design and 
fabrication of three-chamber microscale cell culture analog devices with 
integrated dissolved oxygen sensors. Biotechnology Progress. 20(1):338-345. 
 
6. Viravaidya K, Sin A, Shuler ML. 2004. Development of a microscale cell culture 
analog to probe naphthalene toxicity. Biotechnology Progress. 20(1):316-323. 
 
7. Viravaidya K, Shuler ML. 2004. Incorporation of 3T3-L1 cells to mimic 
bioaccumulation in a microscale cell culture analog device for toxicity studies. 
Biotechnology Progress. 20(2):590-597. 
 
8. Bessems JGM, Vermeulen NPE. 2001. Paracetamol (acetaminophen)-induced 
toxicity: Molecular and biochemical mechanisms, analogues and protective 
approaches. Critical Reviews in Toxicology. 31(1):55-138. 
 
9. Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. 1980. Evidence that 
acetaminophen and n-hydroxyacetaminophen form a common arylating 
intermediate, n-acetyl-para-benzoquinoneimine. Molecular Pharmacology. 
18(3):536-542. 
 
10. Patten CJ, Thomas PE, Guy RL, Lee MJ, Gonzalez FJ, Guengerich FP, Yang CS. 
1993. Cytochrome-p450 enzymes involved in acetaminophen activation by rat 
and human liver-microsomes and their kinetics. Chemical Research in 
Toxicology. 6(4):511-518. 
 
11. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. 1973. Acetaminophen-
induced hepatic necrosis. 4. Protective role of glutathione. Journal of 
Pharmacology and Experimental Therapeutics. 187(1):211-217. 
 
12. Qiu YC, Benet LZ, Burlingame AL. 1998. Identification of the hepatic protein 
targets of reactive metabolites of acetaminophen in vivo in mice using two-
dimensional gel electrophoresis and mass spectrometry. Journal of Biological 
 142 
Chemistry. 273(28):17940-17953. 
 
13. Lee WM. 1995. Medical progress - drug-induced hepatotoxicity. New England 
Journal of Medicine. 333(17):1118-1127. 
 
14. Lesuffleur T, Barbat A, Dussaulx E, Zweibaum A. 1990. Growth adaptation to 
methotrexate of HT-29 human colon-carcinoma cells is associated with their 
ability to differentiate into columnar absorptive and mucus-secreting cells. 
Cancer Research. 50(19):6334-6343. 
 
15. Donato MT, Gomezlechon MJ, Castell JV. 1993. A microassay for measuring 
cytochrome-p450IA1 and cytochrome-p450IIB1 activities in intact human and 
rat hepatocytes cultured on 96-well plates. Analytical Biochemistry. 213(1):29-
33. 
 
16. Donato MT, Klocke R, Castell JV, Stenzel K, Paul D, Gomez-Lechon MJ. 2003. 
Constitutive and inducible expression of CYP enzymes in immortal 
hepatocytes derived from SV40 transgenic mice. Xenobiotica. 33(5):459-473. 
 
17. Dicker E, McHugh T, Cederbaum AI. 1990. Increased oxidation of para-
nitrophenol and aniline by intact hepatocytes isolated from pyrazole-treated 
rats. Biochimica et Biophysica Acta. 1035(3):249-256. 
 
18. Bradford MM. 1976. Rapid and sensitive method for quantitation of microgram 
quantities of protein utilizing principle of protein-dye binding. Analytical 
Biochemistry. 72(1-2):248-254. 
 
19. Kautzky F, Hartinger A, Kohler LD, Vogt H-J. 1996. In vitro cytotoxicity of 
antimicrobial agents to human keratinocytes. Journal of the European 
Academy of Dermatology and Venereology. 6(2):159-166. 
 
20. Chai JN, Lu FZ, Li BM, Kwok DY. 2004. Wettability interpretation of oxygen 
plasma modified poly(methyl methacrylate). Langmuir. 20(25):10919-10927. 
 
21. Glahn RP, Lee OA, Yeung A, Goldman MI, Miller DD. 1998. Caco-2 cell ferritin 
formation predicts nonradiolabeled food iron availability in an in vitro 
digestion/Caco-2 cell culture model. Journal of Nutrition. 128(9):1555-61. 
 
22. Wang EJ, Li Y, Lin M, Chen LS, Stein AP, Reuhl KR, Yang CS. 1996. Protective 
effects of garlic and related organosulfur compounds on acetaminophen-
induced hepatotoxicity in mice. Toxicology and Applied Pharmacology. 
136(1):146-154. 
 
23. Poulin P, Theil FP. 2002. Prediction of pharmacokinetics prior to in vivo studies. 
1. Mechanism-based prediction of volume of distribution. Journal of 
Pharmaceutical Sciences. 91(1):129-156. 
 
 143 
24. Watari N, Iwai M, Kaneniwa N. 1983. Pharmacokinetic study of the fate of 
acetaminophen and its conjugates in rats. Journal of Pharmacokinetics and 
Biopharmaceutics. 11(3):245-272. 
 
25. Hopkinson D, Bourne R, Barile FA. 1993. In vitro cytotoxicity testing - 24-hour 
and 72-hour studies with cultured lung cells. Atla-Alternatives To Laboratory 
Animals. 21(2):167-172. 
 
26. Shi MM, Kugelman A, Iwamoto T, Tian L, Forman HJ. 1994. Quinone-induced 
oxidative stress elevates glutathione and induces gamma-glutamylcysteine 
synthetase-activity in rat lung epithelial L2 cells. Journal of Biological 
Chemistry. 269(42):26512-26517. 
 
27. Hewitt NJ, Hewitt P. 2004. Phase I and II enzyme characterization of two sources 
of HEPG2 cell lines. Xenobiotica. 34(3):243-256. 
 
28. Hidalgo IJ, Raub TJ, Borchardt RT. 1989. Characterization of the human-colon 
carcinoma cell-line (Caco-2) as a model system for intestinal epithelial 
permeability. Gastroenterology. 96(3):736-749. 
 
29. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in 
humans and apparent drug permeability coefficients in human intestinal 
epithelial (Caco-2) cells. Biochemical and Biophysical Research 
Communications. 175(3):880-885. 
 
30. Basson MD, Turowski G, Emenaker NJ. 1996. Regulation of human (Caco-2) 
intestinal epithelial cell differentiation by extracellular matrix proteins. 
Experimental Cell Research. 225:301-305. 
 
31. Borlak J, Zwadlo C. 2003. Expression of drug-metabolizing enzymes, nuclear 
transcription factors, and abc transporters in Caco-2 cells. Xenobiotica. 
33(9):927-943. 
 
32. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. 1996. 
Comparative studies of drug-metabolizing enzymes in dog, monkey, and 
human small intestine cells, and in Caco-2 cells. Drug Metabolism and 
Disposition. 24(6):634-642. 
 
33. Baranczykkuzma A, Garren JA, Hidalgo IJ, Borchardt RT. 1991. Substrate-
specificity and some properties of phenol sulfotransferase from human 
intestinal Caco-2 cells. Life Sciences. 49(16):1197-1206. 
 
34. Nestorov IA, Aarons LJ, Arundel PA, Rowland M. 1998. Lumping of whole-body 
physiologically based pharmacokinetic models. Journal of Pharmacokinetics 
and Biopharmaceutics. 26(1):21-46. 
 
35. Lee HJ. 2002. Protein drug oral delivery: The recent progress. Archives of 
 144 
Pharmaceutical Research. 25(5):572-584. 
 
36. Lampen A, Bader A, Bestmann T, Winkler M, Witte L, Borlak JT. 1998. Catalytic 
activities, protein- and mRNA-expression of cytochrome p450 isoenzymes in 
intestinal cell lines. Xenobiotica. 28(5):429-441. 
 
37. Doherty MM, Charman WN. 2002. The mucosa of the small intestine: How 
clinically relevant as an organ of drug metabolism? Clinical Pharmacokinetics. 
41(4):235-253. 
 
38. Rang HP, Dale MM, Ritter JM. 1999. Pharmacology. 4th ed. Edinburgh: Churchill 
Livingston. 
 
39. Forstner JF, Forstner GG. 1994. Gastrointestinal mucus. Johnson LR, editor. 
Physiology of the gastrointestinal tract, 3rd ed. New York: Raven Press. 
 
40. Artursson P, Palm K, Luthman K. 2001. Caco-2 monolayers in experimental and 
theoretical predictions of drug transport. Advanced Drug Delivery Reviews. 
46(1-3):27-43. 
 
41. Audus KL, Bartel RL, Hidalgo IJ, Borchardt RT. 1990. The use of cultured 
epithelial cells for drug transport and metabolism studies. Pharmaceutical 
Research. 7(5):435-451. 
 
42. Kociancic T, Reed MD. 2003. Acetaminophen intoxication and length of 
treatment: How long is long enough? Pharmacotherapy. 23(8):1052-1059. 
 
43. Rumack BH, Matthew H. 1975. Acetaminophen poisoning and toxicity. 
Pediatrics. 55(6):871-876. 
 
44. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. 1973. 
Acetaminophen-induced hepatic necrosis.1. Role of drug-metabolism. Journal 
of Pharmacology and Experimental Therapeutics. 187(1):185-194. 
 
45. Dimova S, Hoet PHM, Nemery B. 2001. Xenobiotic-metabolizing enzyme 
activities in primary cultures of rat type II pneumocytes and alveolar 
macrophages. Drug Metabolism and Disposition. 29(10):1349-1354. 
 
46. Baudouin SV, Howdle P, Ogrady JG, Webster NR. 1995. Acute lung injury in 
fulminant hepatic-failure following paracetamol poisoning. Thorax. 50(4):399-
402. 
 
47. Dimova S, Hoet PHM, Nemery B. 2000. Paracetamol (acetaminophen) 
cytotoxicity in rat type II pneumocytes and alveolar macrophages in vitro. 
Biochemical Pharmacology. 59(11):1467-1475. 
 
48. Sin A, Reardon CF, Shuler ML. 2004. A self-priming microfluidic diaphragm 
 145 
pump capable of recirculation fabricated by combining soft lithography and 
traditional machining. Biotechnology and Bioengineering. 85(3):359-363. 
 
49. Lennernas H, Palm K, Fagerholm U, Artursson P. 1996. Comparison between 
active and passive drug transport in human intestinal epithelial (Caco-2) cells 
in vitro and human jejunum in vivo. International Journal of Pharmaceutics. 
127:103-107. 
 
 
 
 
 
 146 
CHAPTER 5 
 
CONCLUSIONS AND RECOMMENDATIONS 
  
5.1. Conclusions 
Our group has developed an in vitro cell culture model of the gastrointestinal 
tract that includes digestion, physiologically realistic cell populations, and a mucus 
layer. The applications of this model include predicting iron bioavailability, studying 
the effects of oral exposure to nanoparticles, and measuring the metabolism and 
toxicity of ingested chemicals or drugs. 
Co-cultures of Caco-2 and HT29-MTX represent the two major cell types 
found in the human intestinal epithelium. HT29-MTX cells form a physiologically 
realistic mucus layer that may interact with food digests and influence iron 
bioavailability predictions. In preliminary studies, increasing ratios of HT29-MTX 
cells decreased the amount of ferritin formation in high available iron digests such as 
those containing ferrous iron, heme iron, and whole ferritin molecules. For low 
available iron digests, which present iron to the cells in mostly ferric form, increasing 
the ratio of HT29-MTX cells had no effect on ferritin formation. The physiologically 
relevant ratios of 90:10 and 75:25 (Caco-2:HT29-MTX) offer the best compromise 
between model response and the presence of a mucus layer. 
 A physiologically realistic, cell culture model of the intestinal epithelium was 
used to study the sublethal effects of oral nanoparticle exposure. Iron, which is an 
essential nutrient that is transported across the intestinal epithelium via complex, 
highly regulated, protein-assisted vesicular and nonvesicular mechanisms, was chosen 
as a model compound. These preliminary results suggest that nanoparticle size, 
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concentration, and charge influence iron uptake and transport after oral exposure. Low 
doses (2x109 50 nm particles/mL or 1.25x108 200 nm particles/mL) of carboxylated, 
non-ionized, or aminated particles had no effect on iron uptake and transport. Mid 
doses of 50 nm carboxylated particles (2x1011 particles/mL) did not influence iron 
uptake, but significantly decreased iron transport in Caco-2/HT29-MTX monolayers. 
Mid doses of 200 nm carboxylated particles (1.25x1010 particles/mL) also did not 
affect iron uptake, but significantly decreased iron transport in +M cells monolayers. 
High doses of 50 nm carboxylated particles (2x1013 particles/mL) increased iron 
uptake and transport in Caco-2/HT29-MTX and +M cells monolayers. High doses of 
200 nm carboxylated particles (1.25x1012 particles/mL) significantly decreased iron 
uptake in Caco-2/HT29-MTX monolayers and increased iron transport in Caco-
2/HT29-MTX and +M cells monolayers. Mid doses of non-ionized 50 nm and 200 nm 
particles and 200 nm aminated particles had no effect on iron uptake or transport. 
Aminated, 50 nm particles at mid doses increased iron uptake in Caco-2/HT29-MTX 
and +M cells monolayers and increased iron transport in Caco-2/HT29-MTX 
monolayers.  
A GI tract μCCA has been developed and used together with a chip μCCA in 
proof of concept experiments to demonstrate digestion, absorption through the 
intestinal epithelium, and metabolism by the liver. With the GI tract and chip μCCA 
system we describe a prototype in vitro method that for the first time, although at a 
very basic level, mimics oral exposure to a drug, first pass metabolism, and the 
circulation of metabolites on a micron-sized scale. These results demonstrate that 
APAP crosses the Caco-2/HT29-MTX cell monolayer and is metabolized by HepG2 
liver cells, resulting in liver cell toxicity. 
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5.2. Recommendations 
5.2.1. Caco-2 and HT29-MTX co-cultures used for iron bioavailability studies 
For future studies with Caco-2 and HT29-MTX co-cultures in the in vitro 
digestion/cell culture model, it is recommended that the physiologically realistic ratios 
of 90:10 and 75:25 (Caco-2:HT29-MTX) are used. These ratios offer the best 
compromise between model response and the presence of a mucus layer. In digests 
with low available iron there was very little difference in cell ferritin formation 
between Caco-2 monolayers and co-cultures (Figure 2.9), and it is unclear if the minor 
differences between Caco-2 and co-cultures in low iron bioavailability conditions 
mean that the cells present absorb all available iron or that the mucus layer in the co-
cultures aids in iron absorption and helps to compensate for the lack of Caco-2 cells. 
Experiments in the future studying the effects of co-cultures in the presence of iron 
absorption inhibitors such as tannic acid could help to determine if the mucus layer 
aids in iron absorption from low available iron digests. 
Experiments characterizing the in vitro digestion/co-culture culture model 
without 15,000 MWCO dialysis membrane inserts were performed in an effort to 
make model conditions closer to those in vivo. The 15,000 MWCO dialysis 
membranes are used to protect the cell monolayers from digestive enzymes in 
samples, but also add an artificial barrier to iron absorption. In these experiments the 
cells were exposed to the chyme mimic for 24 hours, and it was hypothesized that the 
mucus layer would mimic its function in vivo and protect the cell monolayer from 
digestive enzymes. Dilution of the digests with culture medium by a factor of 5.5 
increased cell survival, but overall the changes in cell ferritin formation after direct 
exposure to digest were most likely due to cell damage. In the small intestine, there is 
a loosely adherent mucus layer and a layer that is firmly attached to the mucosa that is 
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approximately 15 μm thick in the human duodenum [1, 2]. The mucus layer formed by 
HT29-MTX cells is about 10 μm thick (Figure 2.1) and mimics the firmly adherent 
mucus layer in vivo. Co-cultures of Caco-2 and HT29-MTX and the addition of 
porcine mucin to the culture medium may better recreate in vivo conditions (i.e. the 
loosely and firmly adherent mucus layers) and allow for in vitro digestion/iron 
bioavailability experiments without the 15,000 MWCO inserts. 
The bacterial community in the gastrointestinal tract has been shown to play a 
major role in host health. Bacterial functions include metabolic activities that result in 
the recovery of energy and absorbable nutrients, important trophic effects on intestinal 
epithelial cells and on immune structure and function, and the protection of the host 
against pathogenic microbes [3]. Bacteria have also been shown to modulate gene 
expression related to nutrient absorption, mucosal barrier fortification, xenobiotic 
metabolism, angiogenesis, and postnatal intestinal maturation [4]. Future work with 
the in vitro digestion/co-culture model could benefit from including gut flora due to 
the role of bacteria in nutrient absorption gene expression and absorbable nutrient 
recovery.  
5.2.2. In vitro models for the evaluation of oral nanoparticle exposure toxicity 
This in vitro intestinal epithelial model used to study the effects of nanoparticle 
exposure provides a new tool to assess nanoparticle toxicity following ingestion, new 
metrics for measuring sublethal effects, and new data on the relationship between 
physicochemical properties of nanoparticles and their ability to disrupt cellular 
behavior. Similar disruptions in nutrient absorption could be possible with other 
inorganic elements such as calcium, copper, and zinc that require passive or active 
transport systems to be absorbed through the intestinal epithelium. Fat-soluble 
vitamins such as vitamins A, D, E, and K are absorbed only after micellization by 
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pancreatic lipase [5]. The micelles, due to their small size and hydrophilic surface, are 
able to gain proximity to the brush border and facilitate the diffusion of their contents 
into the phospholipid membrane of the epithelial layer. Hydrophobic, charged 
nanoparticles could potentially disrupt the formation of micelles, micelle interactions 
with the epithelial layer, and nutrient diffusion through the phospholipids layer. 
Interesting future studies would use the in vitro digestion/co-culture model for 
predicting iron bioavailability to study uptake of other inorganic elements (calcium, 
copper, or zinc) or fat soluble vitamins (A, D, E, and K) in the presence of 
nanoparticles. This work could help to determine if nanoparticle exposure affects the 
absorption of additional nutrients. The in vitro digestion/Caco-2 model has been used 
in the past to predict cartenoid, copper, calcium, and zinc bioavailability.  
Orally delivered nanoparticles have been shown to be taken up into the liver, 
spleen, blood, and bone marrow of rats [6]. Copper nanoparticles, but not copper 
microparticles, have also been shown to be toxic to mice after oral exposure; the 
kidney, liver, and spleen were found to be target organs of the copper nanoparticles 
[7]. These is very little data on the effects of oral exposure to nanoparticles, and the GI 
tract μCCA coupled with the chip μCCA offers an excellent tool to rapidly screen 
nanoparticles for toxic effects. The second generation chip μCCA was designed with a 
kidney, liver, fat, and bone marrow compartment to mimic the potential target toxicity 
and storage sites for nanoparticles.   
The in vitro intestinal epithelium model with mucus and M cells could also be 
used to study the mechanical effects (i.e. effects on tight junctions) of pathogenic 
bacteria exposure. Studies with pathogenic bacteria and specific virulence factors 
indicate four major mechanisms by which these pathogens may act on tight junctions: 
direct cleavage of tight junctional structural proteins, modification of the actin 
cytoskeleton, activation of cellular signal transduction, and triggering transmigration 
 151 
of polymorphonuclear cells across the epithelial cell barrier [8]. The intestinal 
epithelium model offers a physiologically realistic, high throughput method for 
evaluating the effects of pathogenic bacteria exposure, although the addition of a 
bacteriostatic antibiotic such as tetracycline to the culture medium would be necessary 
to inhibit the bacterial growth and prevent complete bacterial contamination of the 
mammalian/bacterial co-cultures. New therapeutics or better drug delivery methods 
could be developed from studies of these pathogens and the cellular processes and 
proteins they disrupt. 
5.2.3. GI tract μCCA for studying orally administered compound ADMET  
Experiments with APAP and the GI tract and chip μCCAs showed that the 
passively diffused drug took longer to completely absorb in the in vitro system when 
compared with in vivo data; the μCCA took approximately 12 hours to equilibrate, 
while complete absorption in acute overdose is expected within 5 hours [9]. It is likely 
that the reason APAP takes 2-3 times longer to reach equilibrium in the μCCA is the 
lower amount of surface area available for absorption in the device when compared 
with the small intestine in vivo. The Caco-2 cells express microvilli, which increase 
the absorptive surface area by about 20 times, but cannot form folds or villi [10]. In 
future work, the surface area available for absorption in the GI tract μCCA should be 
increased several fold to better mimic in vivo conditions. This can be done easily by 
modifying the size of the apical and basolateral chambers in the GI tract μCCA. If the 
entire Snapwell membrane holding Caco-2 and HT29-MTX cells were exposed to 
flow, for example, the surface area available for absorption would increase by a factor 
of  ~18 (0.062 cm2 to 1.12 cm2).  
 Future improvements to the GI tract μCCA could include the addition of 
peristalsis. The intestinal mucosa is repetitively subjected to physical forces that 
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induce deformation. These forces include villous motility, peristaltis, segmentation, 
and pressure and shear stress generated by the movement of the luminal contents [11].  
Previous studies have shown that cyclic strain with an amplitude (10% strain) and 
frequency (10 deformations per minute) similar to those seen in vivo induce Caco-2 
cell proliferation, differentiation, and intracellular signaling [11]. Laminar shear flow 
over HT29 colon carcinoma monolayers has been shown to influence cellular 
functions including cell morphology, cytoskeletal arrangements, and intracellular 
signaling [12]. To date, no in vitro permeability data has been published for devices 
that incorporate cyclic strain or both shear flow and cyclic strain.  
 
Figure 5.1. The GI tract μCCA that includes cyclic strain and shear flow and is 
based on the micropump developed by Sin et al. [13].  
A GI tract μCCA that includes cyclic strain and based on the micropump 
developed by Sin et al. has been fabricated (Figure 5.1) [13]. The top piece, which 
makes up the pump chamber, is machined poly-methylemethacrylate (PMMA). The 
next layer is a sheet of poly-dimethylsiloxane (PDMS). The center spacer is machined 
PMMA that will allow for shear flow to pass over a Caco-2 cell monolayer. The fourth 
layer is a microporous, PDMS membrane onto which Caco-2 cells are cultured. The 
bottom piece, which comprises the valve seats and connecting channels, is machined 
PMMA. Synthetic ruby balls sit in the valve seats to form one-way check valves. The 
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μCCA is actuated using oscillating air pressure controlled by a three-way solenoid 
valve. A syringe pump provides physiologically realistic shear flow over the Caco-2 
monolayer within the device, and the movement of the diaphragm will provide cyclic 
strain. The device will also pump at flow rates (~3.5 μL/min) compatible with the 
other μCCA devices being developed. When the GI tract μCCA is connected with a 
chip μCCA that mimics the other tissues and organs in the body, the GI tract μCCA 
will be capable of re-circulating culture medium through the system, eliminating the 
need for an external peristaltic pump. Preliminary experiments have been performed 
with this device, but more extensive characterization studies are necessary [14].   
Other improvements to the GI tract μCCA could include the addition of gut 
flora and variations in pH, which would better mimic in vivo conditions. After 
improvements have been made, the next recommended level of validation for the 
system would be a direct comparison between the μCCA system and animals for drug, 
chemical, or nanoparticle absorption, distribution, metabolism, elimination, and 
toxicity  (ADMET).  
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APPENDIX A 
 
DEVELOPMENT OF AN IN VITRO MODEL OF IRON TRANSPORT 
INCLUDING THE IRON REGULATING PROTEIN HEPCIDIN 
 
A.1. Introduction 
In some cases, absorption of compounds through the intestinal epithelium is 
regulated by feedback mechanisms. Iron is an essential nutrient in the body that is 
absorbed from food through the intestinal epithelium, but there is a delicate balance 
between iron absorption, utilization, and loss in the human body. An excess of 
systemic iron exceeds the capacity of the proteins that sequester it and catalyzes the 
formation of free radicals [1]. Free radicals go on to attack cell membranes, proteins, 
and DNA, causing tissue damage [2]. A lack of iron, on the other hand, results in 
anemia, which is characterized by not having enough hemoglobin to adequately 
oxygenate tissues [2]. Because the body has no significant mechanism for getting rid 
of excess iron, iron balance is dependent on tightly linking body iron requirements 
with intestinal iron absorption from food.  
Hepcidin, a recently discovered, liver-produced protein, has been shown to be 
the principle protein involved in iron regulation [3]. Intestinal iron absorption 
increases with decreased iron stores, increased erythropoietic activity in bone marrow, 
anemia, or hypoxia [3]. Iron absorption decreases in the presence of inflammation [3]. 
Each of these previously mentioned factors also regulate the expression of hepcidin. 
Intestinal iron absorption varies inversely with liver hepcidin expression and the 
protein also causes rapid sequestration of iron by reticuloendothelial cells and the liver 
[3].  
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In the small intestinal enterocyte, dietary iron is reduced to the ferrous state 
(Fe3+ to Fe2+) by duodenal ferric reductase (Dcytb), transported into the cell by 
divalent metal iron transporter 1 (DMT1), and stored within the cell as ferritin [3]. 
Iron is released by ferroportin into circulation and oxidized by hephaestin [3]. Iron is 
normally bound in the blood stream by the iron transport protein transferrin. 
Hepatocytes take up iron from the circulation as wither free iron or transferrin-bound 
iron through transferrin receptors 1 and 2. Transferrin receptor 2 (TFR2) may serve as 
a sensor of circulating transferrin-bound iron and influence the expression of hepcidin, 
as decreased hepcidin expression has been observed when the gene for TFR2 is 
mutated [4]. Hepcidin response is also controlled by HFE (a gene that when mutated is 
responsible for Type 1 hereditary hemochromatosis, an iron overload disease) and 
HJV (a gene that when mutated is responsible for Type 2 hereditary hemochromatosis) 
[5]. Hepcidin is secreted into circulation, where it down-regulates ferroportin iron 
release from enterocytes, macrophages, and hepatocytes [6]. IL-6, a mediator of 
inflammation, also induces hepcidin secretion, making hepcidin an acute-phase protein 
(any protein whose plasma concentration increases or decreases by 25% or more 
during certain inflammatory disorders) [7]. The sequestering of iron caused by 
hepcidin makes iron less available to microorganisms for use as a growth factor. 
Hepcidin has also been shown to have chemotherapeutic activity; the protein acts 
similarly to defensins and disrupts the bacterial membrane [8]. The hepcidin signaling 
pathway activated by IL-6 is not known, but Lee, et al. showed that mice homozygous 
for targeted HFE disruption and TFR2 mutation produced hepcidin in response to 
endotoxin injection [9]. The isolated hepatocytes of HFE and TFR2 knockout mice 
also produced hepcidin in response to IL-6 exposure. These results indicate that the 
IL-6-induced hepcidin signaling pathway does not require HFE or TFR2.  
A method for measuring iron transport through Caco-2 monolayers was 
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developed by Gangloff et al. [10]. The effects of the iron status (i.e. iron loaded or iron 
deficient) of the cells and of iron chelators were tested. Gangloff et al. designed their 
experiments based on in vivo data of intestinal iron absorption showing that iron 
transport increases in iron deficient patients, including those with iron deficiency 
anemia and hypoxia [2]. Chelators bind iron ions and keep iron in solution, and some 
chelators, such as ascorbic acid (AA), reduce iron from Fe3+ to Fe2+, the latter of 
which is the more absorbable form [10]. This reduction circumvents the need for 
Dcytb to reduce the iron before transport into the cell by DMT1 and aids in iron 
absorption. In the experiments, Caco-2 cells were plated onto Transwell® inserts and 
grown for a period of 15 days with normal culture medium containing fetal bovine 
serum. The cells were then given serum free medium with iron supplements varying in 
molarity and with varying chelators. It was expected that more iron would be taken up 
and transported in the iron-deficient cells and the cells exposed to iron absorption-
enhancing chelators. Gangloff et al. found that iron uptake followed physiological 
trends, but iron transport was not related to iron status or chelator. The lack of effect 
of iron status on iron transport, which does not agree with known physiological 
response, led the researchers to believe that the Caco-2 monolayers alone may be 
inadequate for iron transport studies [10].   
Munoz-Galarza compared iron transport and uptake in Transwell inserts to iron 
transport and uptake in a dynamic, laminar flow system [11]. In stagnant Transwell 
cultures, Munoz-Galarza found a significant difference between iron transport and 
uptake in iron loaded and iron deficient Caco-2 cells. In the laminar flow device, 
however, there was a significant difference between iron loaded and iron deficient 
cells only for iron uptake [11]. The iron regulatory protein hepcidin most likely 
accounts for the in vitro-in vivo discrepancies in the previous two in vitro iron 
transport models. 
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The role of hepcidin on in vitro iron absorption can be investigated by 
exposing Caco-2 and Hep3B co-cultures to iron loaded conditions, iron deficient 
conditions, IL-6, or hepcidin before performing iron transport studies. This could 
result in a more physiologically accurate model of iron absorption, and experiments of 
this type have never been reported. Caco-2 cells express the Dcytb, DMT1, 
ferroportin, and hephaestin proteins [12]. Caco-2 cells also store intracellular iron 
within the iron storage protein ferritin [12]. Hep3B cells have been shown to express 
the mRNA for hepcidin [13]. 
A.2. Material and Methods 
A.2.1. Chemicals, enzymes, and hormones 
All chemicals, enzymes, and hormones were purchased from Sigma Chemical 
Company (St. Louis, MO) unless otherwise stated. All glassware used in sample 
preparation and analysis was washed, soaked in 10% hydrochloric acid (HCl) and 10% 
nitric acid overnight, and rinsed with 18 MΩ water to avoid iron contamination. 
A.2.2. Cell culture 
Caco-2 and Hep3B (American Type Culture Collection, Manassas, VA) were 
routinely cultured as described for Caco-2 and HepG2/C3A in section 3.2.2. Caco-2 
cells were seeded into 8 μg/cm2 Type I collagen-coated (Becton Dickinson, Bedford, 
MA), 0.4 μm pore size, 24 mm polycarbonate Transwell inserts (Corning Life 
Sciences, Corning, NY) at a concentration of 100,000 cells/cm2. Hep3B cells were 
seeded onto the 8 μg/cm2 Type I collagen-coated bottom of a separate 6 well plate at a 
concentration of 20,000 cells/cm2. After 1 day, half of the Caco-2 Transwells were 
moved into the Hep3B plates. DMEM with FBS was used in the apical chamber and 
MEM with FBS was used in the basolateral chamber for 14 days. On day 14, very low 
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iron (<8 μg Fe/L) MEM (see section 3.2.2. for low iron medium description) was 
added to the top chamber of the inserts and low iron MEM was added to the lower 
compartment with one of the following treatments: unsupplemented (low iron MEM 
only), +66 uM iron as Fe-NTA (nitrilotriacetic acid disodium salt) in a 1:2 molar ratio, 
+66 uM iron as holo-transferrin (iron saturated transferrin), 20 ng/mL IL-6 (R&D 
Systems, Minneapolis, MN), or 10 μm hepcidin (Peptides International, Louisville, 
KY). The unsupplemented treatment provides an iron deficient condition, Fe-NTA 
provides an iron overload condition that mimics plasma iron exceeding the capacity of 
transferrin, holo-transferrin provides an additional iron overload condition and may 
also interact with TFR2, IL-6 treatment mimics inflammation, and hepcidin is the iron 
regulatory protein. Medium containing the same treatments was renewed on day 15 
and iron uptake and transport experiments were performed on day 16. Apical and 
basolateral culture medium was saved on days 14, 15 and 16 for later analysis with a 
Pro-hepcidin ELISA kit (DRG International, Inc., Mountainside, NJ) or mass 
spectrometry.  
A.2.3. TER measurement 
TER was measured as described in section 3.2.3 with an ENDOHM-24 SNAP 
chamber from World Precision Instruments (Sarasota, FL). Inserts with a TER of 450-
650 Ω/cm2 were used in experiments. 
A.2.4. 59Fe uptake and transport experiments 
 Iron uptake and transport experiments were performed as described in section 
3.2.5.  
A.3. Results  
Figure A.1 compares the results of iron transport through Caco-2 monolayers  
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Figure A.1. Caco-2 and Caco-2/Hep3B iron transport results. Differences 
between Caco-2 and co-culture transport that are significant are indicated with a 
*. Differences between unsupplemented and +IL-6 co-culture treatments that are 
significant are indicated with a **. Statistical significance between treatments 
was determined with Turkey’s pairwise comparison test with a family error rate 
of 0.05 (n = 6, n = 3 for hepcidin treatment). 
to Caco-2 monolayers co-cultured with Hep3B cells. The experiment was based on the 
hypothesis that Hep3B cells would upregulate hepcidin production in response to iron 
overload and inflammation conditions, which would then decrease iron transport. The 
IL-6 treatment was the only condition where the amount of iron transported by the 
Caco-2 and Caco-2/Hep3B co-culture treatments was statistically different. In 
addition, the unsupplemented co-culture transported a significantly higher amount of 
iron than the IL-6-treated co-culture and the IL-6 treatment iron transport was 
statistically the same as iron transport in wells treated with 10 μm hepcidin. The 
decrease in iron transport for co-cultures exposed to IL-6 could be caused by hepcidin 
binding to the ferroportin iron efflux protein and inhibiting iron transport. These 
results agree with data collected by Nemeth et al. and Lin et al., who showed that 
hepcidin mRNA transcription in Hep3B cells is up-regulated in response to IL-6 but 
not to Fe-NTA or holo-transferrin [13, 14]. Lin et al. concluded that up regulation of 
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hepcidin expression by iron loading requires intact hepatic architecture or extrahepatic 
signals [14].  
Figure A.2. Caco-2, Caco-2/Hep3B, and Hep3B iron uptake results. Differences 
between Caco-2 and Caco-2/Hep3B uptake that are significant according to 
Turkey’s pairwise comparison test with a family error rate of 0.05 are indicated 
with a * (n = 6, n = 3 for hepcidin treatment).   
Figure A.2 shows the iron uptake results. In all cases the co-cultures took up 
less iron than the Caco-2 monolayers. Figure A.3 shows the ferritin formation for all 
cell types at each treatment. In the Fe-NTA and holo-transferrin treatments the co-
cultured Caco-2 cells display more iron loading the Caco-2 cells cultured alone. The 
Hep3B cells show very high ferritin formation after the addition of Fe-NTA. This 
behavior is expected, as liver cells are a major iron storage site in vivo. The increased 
iron loading and decreased 59Fe uptake in the co-cultures is most likely the result of 
excess stored iron in the liver cells. This could indicate that the Hep3B cells are 
responding to the iron status of the medium by releasing iron stores when the medium 
becomes iron deficient.    
The uptake of iron by Caco-2 cultures is similar for all treatments. The co-
cultures show the same behavior. Uptake was high for both iron loaded and iron 
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deficient treatments because the 59FeCl3 delivered to the cells was chelated with 
ascorbic acid. AA is a reducing agent that enhances iron absorption. AA was used as a 
chelator to maximize iron uptake and the amount of iron available for transport, which 
would presumably make differences in transport more apparent.  
Figure A.3. Caco-2, Caco-2/Hep3B, and Hep3B ferritin formation results. 
Culture medium was assayed for hepcidin using a pro-hepcidin ELISA. All 
results were negative for the peptide. Medium samples were then analyzed with 
electrospray single quadrupole mass spectrometry, MALDI-TOF mass spectrometry, 
and Q trap electrospray ionization-based hybrid triple quadrupole/linear ion trap mass 
spectrometry, but hepcidin was not detected.  
A.4. Conclusions 
These results show that there are interesting differences in iron transport when 
Caco-2 and Hep3B cells are co-cultured and exposed to iron loaded conditions, iron 
deficient conditions, or IL-6. Hepcidin could not be detected in the culture medium 
(except for in the cultures treated with 10 μm hepcidin), however, even with one the 
most sensitive mass spectrometers available. Hepcidin may be produced by Hep3B 
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cells and hepcidin may be what is affecting the iron transport in Caco-2 cells, but 
proving the peptide is present would be necessary before making this claim.  
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length of chambersLch
8.25
114.9596
3.1
7.5
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
mm⋅:=width of chamberswch
8.25
0.5
3.1
7.5
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
mm⋅:=
liver
fat
kidney
marrow
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
chambers = Number of chambersNch 4:=
Area of cell assuming spherical geometry Acell 50.265 μm
2=Acell
π
4
dcl
2⋅:=
Volume of cell assuming spherical 
geometry
Vcell
201.062
201.062
201.062
201.062
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm3=Vcell
π
4
dcl
2⋅ hcl⋅:=
diameter of cellsdcl 8μm:=
height of cellshcl
4
4
4
4
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm⋅:=
μ 3.3 10 3−× Pa s⋅=μ ρ ν⋅:= dynamic viscosity of culture medium at 37o C.
ν 0.03 cm
2
s
⋅:= Kinematic viscosity of culture medium at 37 o C. Taken from Sun 
HB and H Yokota. Bone (2000) 
28(3): 303.
ρ 1.1 gm
mL
:= h2 100μm:=h1 30 μm⋅:=Density of culture medium at 37 o C. From Sun HB and H Yokota. Bone 
(2000) 28(3): 303.
cP
Poise
100
:=Poise Pa s⋅
10
:=μL 10 6− L:=μm 10 6− m:=
Definitions  
APPENDIX B 
 
DESIGN CALCULATIONS FOR THE SECOND GENERATION CHIP μCCA 
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Nc
1.354 106×
1.144 106×
1.912 105×
1.119 106×
⎛⎜⎜⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎟⎟⎠
= Number of cells in each chamber if 
confluent
Nc
Nci
4
wchi
Lchi
⋅
π dcl2⋅
⋅←
i 0 1, Nch 1−..∈for
Nc
:=
Shear stress per uni
area on cells
γ
1.005
0.229
2.293
0.459
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
dyne
cm2
=
γ
γ i
8
Qchi
wchi
hchi
⋅⋅ μ⋅
hchi
hcli
−←
i 0 1, Nch 1−..∈for
γ
:=
Residence time in 
each chamber
τch
1.204
22.072
0.198
2.398
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
min=Linear velocityuavch
98.99
83.333
225.806
45.185
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm
s
=
τch
τchi
wchi
Lchi
⋅ hchi hcli−⎛⎝ ⎞⎠⋅
Qchi
←
i 0 1, Nch 1−..∈for
τch
:=uavch
uavchi
Qchi
hchi
wchi
⋅←
i 0 1, Nch 1−..∈for
uavch
⎛⎜⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎟⎠
:=
Flow rate from pump @ 0.75 rpmQf 3.59
μL
min
=Qf
0
Nch 1−
i
Qchi∑=:=
flowrate through 
each chamber
Qch
1.47
0.25
1.26
0.61
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μL
min
⋅:=depth of chambershch
h1
h2
h1
h1
⎛⎜⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎟⎠
:=
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DH
DHi
4 wchi
⋅ hchi hcli−⎛⎝ ⎞⎠⋅
2 wchi
⋅ 2 hchi hcli−⎛⎝ ⎞⎠⋅+
←
i 0 1, Nch 1−..∈for
DH
:=
DH
51.837
161.074
51.567
51.82
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm= Hydraulic diameter
ReH
ReHi
DHi
Qchi
wchi
hchi
hcli
−⎛⎝ ⎞⎠⋅
⋅ ρ⋅
μ←
i 0 1, Nch 1−..∈for
ReH
:=
Reynolds number based on hydraulic diameter. 
Flow is laminar because Re < 2100ReH
1.974 10 3−×
4.661 10 3−×
4.479 10 3−×
9.006 10 4−×
⎛⎜⎜⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎟⎟⎠
=
fch
16
ReH
:= fch
8.107 103×
3.433 103×
3.573 103×
1.777 104×
⎛⎜⎜⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎟⎟⎠
= friction factor for each chamber
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B
1.75 Qch
2⋅ ρ⋅ 1 ε−( )⋅
ε 3 wbaf⋅ hbaf2⋅
:=A
150 Qch⋅ 1 ε−( )2⋅ μ⋅
ε 3 wbaf2⋅ hbaf⋅
:=
The distributor is not a straight channel, therefor there is a dependence of velocity on length. 
These equations are derived from the Ergun equation for a right triangular entrance.
Volume of 
distributors
Vdist
9.281 10 3−×
5.625 10 4−×
3.487 10 3−×
8.437 10 3−×
⎛⎜⎜⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎟⎟⎠
μL=Vdist ε Lbaf⋅ wbaf⋅ hbaf⋅:=
Length of distributorLbaf 0.5 wch⋅:=void fractionε 0.75:=
height of baffleshbaf 30 μm⋅:=
Width of 
distributor inlet
wbafin
342
63
263
139
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm⋅:=
wbaf 100 μm⋅:=
width of baffles. Left these
at 100 because the
 P drop is smaller and 
easier to balance
Pressure drop through the distributors is calculated with the Ergun equation (Treybal, Mass 
Transfer Ops, 3rd ed., pg 200; TP155.T81 @ Carpenter)
Pressure drop through chambersPdch
37.033
40.617
32.074
15.377
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa=
Pdch
Pdchi
2 Lchi
⋅
DHi
Qchi
wchi
hchi
hcli
−⎛⎝ ⎞⎠⋅
⎡⎢⎢⎣
⎤⎥⎥⎦
2
⋅ ρ⋅ fchi⋅←
i 0 1, Nch 1−..∈for
Pdch
:=
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e
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er
A
5.989
1.019
5.133
2.485
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
mg
μm s2⋅
= B
7.608
0.22
5.59
1.31
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
mg
s2
=
Pdbaf
Pdbafi
Ai ln
Lbafi
wbafini
+
wbafini
⎛⎜⎜⎝
⎞⎟⎟⎠
⋅ Bi 1Lbafi wbafini+
1
wbafini
−⎛⎜⎜⎝
⎞⎟⎟⎠
⋅−←
i 0 1, Nch 1−..∈for
Pdbaf
:=
Pdbaf
15.41
1.636
9.929
8.288
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa= Pressure drop through the distributors
The chamber exit has no baffles and is shorter (30/30/120 triangles with a trimmed top)
wchex wbafin:= width of chamber exit 
Lchin
wch
tan
π
3
⎛⎜⎝
⎞⎟⎠
:= beginning of trimmed top exit 
Lchex Lchin
wchex
2 tan
π
3
⎛⎜⎝
⎞⎟⎠⋅
−:= Lchex
4.664
0.27
1.714
4.29
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
mm= end of exit from chamb
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Pdchex
Pdchexi
32− μ⋅ Qchi⋅
hchi
Lchini
Lchexi
x
1
2 hchi
⋅
1
2 x⋅ tan π
3
⎛⎜⎝
⎞⎟⎠⋅
+⎛⎜⎜⎝
⎞⎟⎟⎠
3⌠⎮
⎮
⎮
⎮⌡
d⋅←
i 0 1, Nch 1−..∈for
Pdchex
:=
Pdchex
39.854
0.018
26.76
6.728
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa=
Pdchambers Pdch Pdbaf+ Pdchex+:=
Pdchambers
92.296
42.27
68.763
30.394
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa= Pressure drop for all chambers and their distributors and 
exits, fat is actually only Pdch because it is just connected 
channels
Channel (piping) dimensions
wp
342
63
263
139
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm⋅:= Lp
21.209
10.3378
22.6822
22.6568
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
mm⋅:= hp
100
100
100
100
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm⋅:=
Qp Qch:= Qp
1.47
0.25
1.26
0.61
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μL
min
= flowrate into each channel
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Nstreams 4:= 4 fluid pathways Nbendp
2
4
4
2
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
:= number of bends in 
pathways
Pp 2 wp⋅ 2 hp⋅+:= Pp
884
326
726
478
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm= Perimeter of pipes
uav
uavi
Qpi
wpi
hpi
⋅←
i 0 1, Nstreams 1−..∈for
uav
:=
uav
0.716
0.661
0.798
0.731
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
mm
s
= Average velocity in 
each pipe section
DHp
DHpi
4 wpi
hpi
⋅
Ppi
←
i 0 1, Nstreams 1−..∈for
DHp
:=
DHp
154.751
77.301
144.904
116.318
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm= Hydraulic diameter
ReHp
ReHpi
DHpi
uavi
⋅ ρ⋅
μ←
i 0 1, Nstreams 1−..∈for
ReHp
:=
ReHp
0.037
0.017
0.039
0.028
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
= Hydraulic Reynold's 
number for pipes, flow
is laminar because  
Re < 2100
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Pdfat
104.031
161.448
123.163
144.718
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa=Pdfat Pdch Pdp+ Pdf+:=
fat is 2nd value down
These values should be within ~5% of each otherPdstream
159.294
163.101
159.852
159.734
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa=
Pdstream Pdchambers Pdp+ Pdf+:=
Pressure drop for 
fittings
Pdf
8.468 10 4−×
1.443 10 3−×
2.104 10 3−×
8.827 10 4−×
⎛⎜⎜⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎟⎟⎠
Pa=
Pdf
Pdfi
K uavi
⎛⎝ ⎞⎠
2⋅ ρ⋅
2
Nbendpi
⋅←
i 0 1, Nstreams 1−..∈for
Pdf
:=
Pressure drop for 
channels
Pdp
66.997
120.83
91.087
129.34
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa=
Pdp
Pdpi
2 Lpi
⋅
DHpi
uavi
⎛⎝ ⎞⎠
2⋅ ρ⋅ fpi⋅←
i 0 1, Nstreams 1−..∈for
Pdp
:=
Pressure drop for fitting (T, side outlet), K~1.5 K 1.5:=
Friction factor for 
laminar flow in pipes
fp
432.98
938.88
414.857
564.197
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
=fp
16
ReHp
:=
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Summary 
Pdstream
159.294
163.101
159.852
159.734
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
Pa= Qch
1.47
0.25
1.26
0.61
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μL
min
=
wp
342
63
263
139
⎛⎜⎜⎜⎜⎝
⎞⎟⎟⎟⎟⎠
μm= Qf 3.59
μL
min
=
Vchip
0
Nstreams 1−
i
wpi
Lpi
⋅ hpi⋅∑= 0
Nch 1−
j
wchj
Lchj
⋅ hchj hclj−⎛⎝ ⎞⎠⋅ Vdistj+⎡⎣ ⎤⎦∑=
⎡⎢⎢⎣
⎤⎥⎥⎦
+:=
Vchip 10.724μL= Total volume of chip
τchip
Vchip
Qf
:=
τchip 179.227s= Total residence time on chip
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APPENDIX C 
 
SECOND GENERATION μCCA SYSTEM PBPK CODE 
 
%PBPK model for acetaminophen in human configuration  
%Acetaminophen (APAP) metabolized to NAPQI, APAP-GLUC, APAP-SULF 
  
function [t,x] = PBPK(APAP,timespan) 
  
%{ 
x(1): APAP in lumen 
x(2): APAP in GI 
x(3): APAP in liver 
x(4): APAP in kidney 
x(5): APAP in marrow 
x(6): APAP fat 
x(7): APAP in well perfused organs (lung) 
x(8): APAP in poorly perfused organs (muscle) 
x(9): APAP in blood plasma 
%} 
  
% concentration (nmol/ml or nmol/g) 
init_cond = zeros(9,1); 
  
init_cond(1) = APAP; 
init_cond(2) = 0; 
init_cond(3) = 0; 
init_cond(4) = 0; 
init_cond(5) = 0; 
init_cond(6) = 0; 
init_cond(7) = 0; 
init_cond(8) = 0; 
init_cond(9) = 0; 
  
% time span in hour 
time=[0 timespan*60]; 
[t,x] = ode45(@PBPK_ODE,time,init_cond); 
  
% function definition 
function dxdt=PBPK_ODE(t,x) 
  
dxdt = zeros(9,1); 
  
% parameters  
  
% organ size (ml); Tox. Ind. Health. 13(4):407 
V_LMN = 1000; 
V_G = 1190; 
V_L = 1820; 
V_K = 280; 
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V_M = 1400; 
V_F = 14980; 
V_W = 560; 
V_P = 28000; 
V_B = 5530; 
  
% flow rates (ml/min); Tox. Ind. Health. 13(4):407, Handbook of 
Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for 
Industrial Scientists. 
Q_G = 1100; 
Q_L = 1450; 
Q_K = 1240; 
Q_M = 120; 
Q_F = 260; 
Q_W = 1400; 
Q_P = 750; 
Q_B = 5600; 
  
% Partition coefficients; J. Pharm. Sci. (2002)91(1):129 
P_APAP_G = 0.795; 
P_APAP_L = 0.831; 
P_APAP_K = 0.85; 
P_APAP_M = 0.5; 
P_APAP_F = 0.513; 
P_APAP_W = 0.864; 
P_APAP_P = 0.819; 
  
% enzyme kinetic parameters 
Vm_CYP_L = 328;     % nmol/min/g; Chem. Res. Toxicol. (1993)6:511 
Km_CYP_L = 677;     % nmol/mL 
Vm_AG_L = 2.76;     % nmol/min/g; J. Pharmaco.  
  Biopharm.(1983)11(3):245  
Km_AG_L = 915;      % nmol/mL 
Vm_AS_L = 4.92;     % nmol/min/g; J. Pharmaco.  
  Biopharm.(1983)11(3):245 
Km_AS_L = 109;      % nmol/mL 
  
Kabs_APAP = 0.354;  % 1/hr, Kabs = 2*Peff/R, R = 1.75, Peff = 0.3096  
  cm/hr; Int. J. Pharm. (1999)20(2):119    
  
% Unbound fraction 
f_B_APAP = 1; 
  
% ODEs 
% APAP_LMN 
dxdt(1) = (-1*Kabs_APAP*x(1)*V_LMN)/V_LMN;     
% APAP_G 
dxdt(2) = (Kabs_APAP*x(1)*V_LMN + Q_G*x(9) - Q_G*x(2)/P_APAP_G)/V_G;     
% APAP_L 
dxdt(3) = (((Q_L-Q_G)*x(9) - Q_L*x(3)/P_APAP_L + Q_G*x(2)/P_APAP_G - 
Vm_CYP_L*f_B_APAP*x(3)/(Km_CYP_L+(f_B_APAP*x(3)))- 
Vm_AS_L*f_B_APAP*x(3)/(Km_AS_L+(f_B_APAP*x(3)))- 
Vm_AG_L*f_B_APAP*x(3)/(Km_AG_L+(f_B_APAP*x(3))))*V_L)/V_L;  
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% APAP_K 
dxdt(4) = (Q_K*x(9) - Q_K*x(4)/P_APAP_K)/V_K;  
% APAP_M 
dxdt(5) = (Q_M*x(9) - Q_M*x(5)/P_APAP_M)/V_M;  
% APAP_F 
dxdt(6) = (Q_F*x(9) - Q_F*x(6)/P_APAP_F)/V_F;  
% APAP_W 
dxdt(7) = (Q_W*x(9) - Q_W*x(7)/P_APAP_W)/V_W;  
% APAP_P 
dxdt(8) = (Q_P*x(9) - Q_P*x(5)/P_APAP_P)/V_P; 
% APAP_B 
dxdt(9) = (Q_L*x(3)/P_APAP_L + Q_K*x(4)/P_APAP_K + Q_M*x(5)/P_APAP_M 
+ Q_F*x(6)/P_APAP_F + Q_W*x(7)/P_APAP_W + Q_P*x(8)/P_APAP_P - 
Q_B*x(9))/V_B;  
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%PBPK model for acetaminophen in chip configuration  
%Acetaminophen (APAP) metabolized to NAPQI, APAP-GLUC, APAP-SULF 
  
function [t,x] = PBPK(APAP,timespan) 
  
%{ 
x(1): APAP in lumen 
x(2): APAP in GI 
x(3): APAP in liver 
x(4): APAP in kidney 
x(5): APAP in marrow 
x(6): APAP fat 
x(7): APAP in well perfused organs (lung) 
x(8): APAP in poorly perfused organs (muscle) 
x(9): APAP in blood plasma 
%} 
  
% concentration (nmol/ml or nmol/g) 
init_cond = zeros(9,1); 
  
init_cond(1) = APAP; 
init_cond(2) = 0; 
init_cond(3) = 0; 
init_cond(4) = 0; 
init_cond(5) = 0; 
init_cond(6) = 0; 
init_cond(7) = 0; 
init_cond(8) = 0; 
init_cond(9) = 0; 
  
% time span in hour 
time=[0 timespan*60]; 
[t,x] = ode45(@PBPK_ODE,time,init_cond); 
  
% function definition 
function dxdt=PBPK_ODE(t,x) 
  
dxdt = zeros(9,1); 
  
% parameters  
  
% organ size (ml); Tox. Ind. Health. 13(4):407 
V_LMN = 1000; 
V_G = 1190; 
V_L = 1820; 
V_K = 280; 
V_M = 1400; 
V_F = 14980; 
V_W = 560; 
V_P = 28000; 
V_B = 5530; 
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% flow rates (ml/min); Tox. Ind. Health. 13(4):407, Handbook of 
Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for 
Industrial Scientists. 
Q_G = 1100; 
Q_L = 1450; 
Q_K = 1240; 
Q_M = 120; 
Q_F = 260; 
Q_W = 1400; 
Q_P = 750; 
Q_B = 5600; 
  
% Partition coefficients; J. Pharm. Sci. (2002)91(1):129 
P_APAP_G = 0.795; 
P_APAP_L = 0.831; 
P_APAP_K = 0.85; 
P_APAP_M = 0.5; 
P_APAP_F = 0.513; 
P_APAP_W = 0.864; 
P_APAP_P = 0.819; 
  
% enzyme kinetic parameters 
Vm_CYP_L = 328;     % nmol/min/g; Chem. Res. Toxicol. (1993)6:511 
Km_CYP_L = 677;     % nmol/mL 
Vm_AG_L = 2.76;     % nmol/min/g; J. Pharmaco.  
  Biopharm.(1983)11(3):245  
Km_AG_L = 915;      % nmol/mL 
Vm_AS_L = 4.92;     % nmol/min/g; J. Pharmaco.  
  Biopharm.(1983)11(3):245 
Km_AS_L = 109;      % nmol/mL 
  
Kabs_APAP = 0.354;  % 1/hr, Kabs = 2*Peff/R, R = 1.75, Peff = 0.3096  
  cm/hr; Int. J. Pharm. (1999)20(2):119    
  
% Unbound fraction 
f_B_APAP = 1; 
 
% ODEs 
% APAP_LMN 
dxdt(1) = (-1*Kabs_APAP*x(1)*V_LMN)/V_LMN;     
% APAP_G 
dxdt(2) = (Kabs_APAP*x(1)*V_LMN + Q_G*x(9) - Q_G*x(2)/P_APAP_G)/V_G;     
% APAP_L 
dxdt(3) = 0.41*((((Q_L-Q_G)*x(9) - Q_L*x(3)/P_APAP_L + 
Q_G*x(2)/P_APAP_G - 
Vm_CYP_L*f_B_APAP*x(3)/(Km_CYP_L+(f_B_APAP*x(3)))- 
Vm_AS_L*f_B_APAP*x(3)/(Km_AS_L+(f_B_APAP*x(3)))- 
Vm_AG_L*f_B_APAP*x(3)/(Km_AG_L+(f_B_APAP*x(3))))*V_L)/V_L);  
% APAP_K 
dxdt(4) = 0.35*(((Q_K - Q_G)*x(9) - Q_K*x(4)/P_FT_K + 
Q_G*x(2)/P_FT_G)/V_K);  
% APAP_M 
dxdt(5) = 0.17*(((Q_M - Q_G)*x(9) - Q_M*x(5)/P_FT_P + 
Q_G*x(2)/P_FT_G)/V_M);  
 181 
% APAP_F 
dxdt(6) = 0.07*(((Q_F - Q_G)*x(9) - Q_F*x(6)/P_FT_F + 
Q_G*x(2)/P_FT_G)/V_F);  
% APAP_W 
dxdt(7) = (Q_W*x(9) - Q_W*x(7)/P_APAP_W)/V_W;  
% APAP_P 
dxdt(8) = (Q_P*x(9) - Q_P*x(8)/P_APAP_P)/V_P; 
% APAP_B 
dxdt(9) = (Q_L*x(3)/P_APAP_L + Q_K*x(4)/P_APAP_K + Q_M*x(5)/P_APAP_M 
+ Q_F*x(6)/P_APAP_F + Q_W*x(7)/P_APAP_W + Q_P*x(8)/P_APAP_P - 
Q_B*x(9))/V_B;  
 
